BioMedLib Search Engine
[ goto HOMEPAGE ]
Find more relevant answers, faster!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
adenocarcinoma of prostate 2005:2010[pubdate] *count=100
3352 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
adenocarcinoma of prostate
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 3352
1.
Tang Y, Hamburger AW, Wang L, Khan MA, Hussain A:
Androgen deprivation and stem cell markers in prostate cancers.
Int J Clin Exp Pathol
; 2009;3(2):128-38
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Androgen deprivation and stem cell markers in
prostate
cancers.
In our previous studies using human LNCaP xenografts and TRAMP (transgenic
adenocarcinoma of
mouse
prostate
) mice, androgen deprivation therapy (ADT) resulted in a temporary cessation
of prostate
cancer
(PCa) growth, but then tumors grew faster with more malignant behaviour.
To understand whether
cancer
stem cells might play a role in PCa progression in these animal models, we investigated the expressions of stem cell-related markers in tumors at different time points after ADT.
[MeSH-major]
Androgens / metabolism. Biomarkers, Tumor / metabolism.
Prostatic
Neoplasms / metabolism.
Prostatic
Neoplasms / pathology. Stem Cells / metabolism
[MeSH-minor]
Adenocarcinoma
/ pathology. Animals. Cell Line, Tumor. Disease Models, Animal. Humans. Immunohistochemistry. Male. Mice. Mice, SCID. Mice, Transgenic. Neoplasm Recurrence, Local / pathology. Neoplasm Transplantation. Orchiectomy. Time Factors
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
MedlinePlus Health Information.
consumer health - Stem Cells
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Natl Cancer Inst. 2008 May 7;100(9):672-9
[
18445819.001
]
[Cites]
Prostate. 2009 Dec 1;69(16):1763-73
[
19691128.001
]
[Cites]
Cell. 2008 May 16;133(4):704-15
[
18485877.001
]
[Cites]
Breast Cancer Res. 2008;10(2):R25
[
18366788.001
]
[Cites]
Curr Urol Rep. 2007 Jul;8(4):275-80
[
18519011.001
]
[Cites]
Nature. 2001 Nov 1;414(6859):105-11
[
11689955.001
]
[Cites]
Clin Cancer Res. 2002 Jan;8(1):22-8
[
11801536.001
]
[Cites]
Methods. 2001 Dec;25(4):402-8
[
11846609.001
]
[Cites]
Prostate. 2003 May 15;55(3):219-37
[
12692788.001
]
[Cites]
Blood. 2004 Mar 15;103(6):2332-6
[
14630803.001
]
[Cites]
Nat Immunol. 2004 Jul;5(7):738-43
[
15170211.001
]
[Cites]
Blood. 2004 Sep 15;104(6):1648-55
[
15178579.001
]
[Cites]
Development. 2004 Oct;131(20):4955-64
[
15371309.001
]
[Cites]
Eur J Surg Oncol. 2004 Nov;30(9):987-92
[
15498646.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43
[
7724580.001
]
[Cites]
Stem Cells. 2004;22(7):1142-51
[
15579635.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 May 10;102(19):6942-7
[
15860580.001
]
[Cites]
Clin Cancer Res. 2006 Jan 1;12(1):169-74
[
16397039.001
]
[Cites]
Dev Biol. 2006 Feb 1;290(1):66-80
[
16360140.001
]
[Cites]
Blood. 2006 Mar 1;107(5):2162-9
[
16269619.001
]
[Cites]
Mol Cell Biol. 2006 Aug;26(15):5688-97
[
16847323.001
]
[Cites]
Cold Spring Harb Symp Quant Biol. 2005;70:187-96
[
16869753.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11707-12
[
16857736.001
]
[Cites]
Cancer Res. 2006 Oct 1;66(19):9339-44
[
16990346.001
]
[Cites]
Nature. 2006 Dec 7;444(7120):756-60
[
17051156.001
]
[Cites]
J Clin Invest. 2007 Aug;117(8):2044-50
[
17671638.001
]
[Cites]
Eur Urol. 2008 Mar;53(3):524-31
[
18053634.001
]
[Cites]
Cell Stem Cell. 2007 Sep 13;1(3):313-23
[
18371365.001
]
[Cites]
Nat Genet. 2008 May;40(5):499-507
[
18443585.001
]
[Cites]
PLoS One. 2008;3(6):e2428
[
18560594.001
]
[Cites]
Mol Cancer Res. 2008 Jul;6(7):1146-53
[
18644979.001
]
[Cites]
Neoplasia. 2008 Sep;10(9):996-1003
[
18714401.001
]
[Cites]
Cell Stem Cell. 2007 Nov;1(5):555-67
[
18371393.001
]
[Cites]
Cancer Res. 2008 Dec 1;68(23):9703-11
[
19047148.001
]
[Cites]
Cytometry A. 2009 Jan;75(1):67-74
[
19051297.001
]
[Cites]
Clin Exp Metastasis. 2009;26(5):433-46
[
19221883.001
]
[Cites]
Cell. 2009 Aug 21;138(4):645-59
[
19682730.001
]
[Cites]
Clin Cancer Res. 2008 May 15;14(10):2936-43
[
18483360.001
]
(PMID = 20126580.001).
[ISSN]
1936-2625
[Journal-full-title]
International journal of clinical and experimental pathology
[ISO-abbreviation]
Int J Clin Exp Pathol
[Language]
eng
[Publication-type]
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Androgens; 0 / Biomarkers, Tumor
[Other-IDs]
NLM/ PMC2809992
[Keywords]
NOTNLM ; Prostate cancer / TRAMP mice / androgen deprivation / stem-like cells / xenograft tumor
2.
Walsh PC:
Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?
J Urol
; 2005 Sep;174(3):928-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Failure definition-dependent differences in outcome following radiation for localized
prostate
cancer
: can one size fit all?
[MeSH-major]
Adenocarcinoma
/ radiotherapy.
Prostatic
Neoplasms / radiotherapy
[MeSH-minor]
Biomarkers, Tumor / blood. Disease-Free Survival. Follow-Up Studies. Humans. Male. Multicenter Studies as Topic. Neoplasm Staging. Outcome Assessment (Health Care) / statistics & numerical data.
Prostate
-Specific Antigen / blood. Radioisotope Teletherapy / mortality. Treatment Failure
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16093990.001).
[ISSN]
0022-5347
[Journal-full-title]
The Journal of urology
[ISO-abbreviation]
J. Urol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
3.
Rioja Zuazu J, Zudaire Berbera JJ, Rincón Mayans A, Rosell Costa D, Robles Garcia JE, Berian Polo JM:
[Gleason score 8-10 prostatic adenocarcinoma: prognostic influence in the biochemical progression free survival].
Actas Urol Esp
; 2008 Sep;32(8):792-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Gleason score 8-10
prostatic
adenocarcinoma
: prognostic influence in the biochemical progression free survival].
[Transliterated title]
Adenocarcinoma
de
próstata gleason clínico 8-10: influencia pronóstica en
la
supervivencia libre
de
progresión bioquímica.
OBJECTIVE: Hereby, we analyze the characteristics of the clinical Gleason 8-10 group of patients with in our series diagnosed
of Prostate
Cancer
and treated by means of radical prostatectomy, and we try to ascertain which are the influence factors within this group upon progression and progression free survival.
MATERIAL AND METHODS: From the global series of 781 patients with T1-T2
prostate
cancer
treated by means of radical prostatectomy between 1990 and 2004, we study 108 with a Gleason score on the biopsy of 8-10.
RESULTS: Actual State: 62.7% (490/781) are alive and free of biochemical progression, 24.8% (194/781) are alive with biochemical progression, 2.9% (23/781) are dead by
cancer
and 1.9% (15/781) are dead by other cause and 7.6% (59/781) are lost.
[MeSH-major]
Adenocarcinoma
/ pathology.
Adenocarcinoma
/ surgery.
Prostatic
Neoplasms / pathology.
Prostatic
Neoplasms / surgery
[MeSH-minor]
Biopsy. Disease-Free Survival. Humans. Male. Prognosis.
Prostate
-Specific Antigen / blood. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19013977.001).
[ISSN]
0210-4806
[Journal-full-title]
Actas urologicas espanolas
[ISO-abbreviation]
Actas Urol Esp
[Language]
spa
[Publication-type]
Comparative Study; English Abstract; Journal Article
[Publication-country]
Spain
[Chemical-registry-number]
EC 3.4.21.77 / Prostate-Specific Antigen
Advertisement
4.
Sina B, Deng A:
Umbilical metastasis from prostate carcinoma (Sister Mary Joseph's nodule): a case report and review of literature.
J Cutan Pathol
; 2007 Jul;34(7):581-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Umbilical metastasis from
prostate
carcinoma (Sister Mary Joseph's nodule): a case report and review of literature.
We describe here an unusual case of a Sister Mary Joseph's nodule that was metastasized from
prostate
carcinoma 3 years after radiation therapy.
The lesion was the first sign of metastatic disease, and
the diagnosis
was made on skin biopsy.
The patient died of extensive metastases
of prostate
carcinoma 4 months later.
We report this case to extend the list of differential
diagnosis
for Sister Mary Joseph's nodule in male patients and emphasize the importance of Sister Mary Joseph's nodule as an ominous diagnostic sign.
[MeSH-major]
Adenocarcinoma
/ secondary.
Prostatic
Neoplasms / pathology. Skin Neoplasms / secondary. Umbilicus / pathology
[MeSH-minor]
Aged.
Diagnosis
, Differential. Fatal Outcome. Humans. Impetigo /
diagnosis
. Male. Urachal Cyst /
diagnosis
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17576339.001).
[ISSN]
0303-6987
[Journal-full-title]
Journal of cutaneous pathology
[ISO-abbreviation]
J. Cutan. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Denmark
5.
Gil-Bazo I, Ignacio Martínez-Salamanca J, Bianco Jr FJ:
[Update of the treatment of advanced prostate cancer and management of its complications].
Med Clin (Barc)
; 2005 Nov 12;125(17):671-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Update of the treatment of advanced
prostate
cancer
and management of its complications].
[Transliterated title]
Actualización del tratamiento del cáncer
de
próstata avanzado y
de
sus complicaciones.
Prostate adenocarcinoma
is the leading cause of
cancer
in Spain, among men older than 65.
1,200 new cases out of every 100,000 males are diagnosed with
prostate
cancer
on an annual basis.
In the United States, this illness represents the second leading cause of death due to
cancer
in males.
In those patients whose
prostate
tumors progress after surgery or radiotherapy, or have metastatic disease when diagnosed, a systemic approach in order to improve their quality of life and overall survival is mandatory.
However, most of these tumors becomes androgen-independent over time and behave as a more aggressive
cancer
type.
The accurate knowledge of the symptoms due to disease spreading as well as treatment's side effects is necessary to provide an appropriate palliative management that contributes to an improvement of the quality of life in advanced
prostate
cancer
patients.
[MeSH-major]
Adenocarcinoma
/ therapy.
Prostatic
Neoplasms / therapy
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16324498.001).
[ISSN]
0025-7753
[Journal-full-title]
Medicina clínica
[ISO-abbreviation]
Med Clin (Barc)
[Language]
spa
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Spain
[Number-of-references]
78
6.
Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL:
Metastatic patterns in adenocarcinoma.
Cancer
; 2006 Apr 1;106(7):1624-33
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Metastatic patterns in
adenocarcinoma
.
The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage
adenocarcinoma
to evaluate metastatic patterns.
RESULTS: Three primary tumors had single, dominant metastatic sites: ovary to abdominal cavity (91%),
prostate
to bone (90%), and pancreas to liver (85%).
In a study of combinations of liver, abdominal cavity, and bone metastases, 86%
of prostate
primary tumors had only bone metastases, 80% of ovarian primary tumors had only abdominal cavity metastases, and 74% of pancreas primary tumors had only liver metastases.
A single organ was the dominant source of metastases in 7 sites: axillary lymph node from the breast (97%), intestinal lymph node from the colon (84%), thoracic lymph node from the lung (66%), brain from the lung (64%), mediastinal lymph node from the lung (62%), supraclavicular lymph node from the breast (51%), and adrenal
gland
from the lung (51%).
[MeSH-major]
Adenocarcinoma
/ secondary. Algorithms. Neoplasm Metastasis. Registries / statistics & numerical data
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2006 American Cancer Society.
(PMID = 16518827.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
7.
Yasui Y, Tanaka T:
Protein expression analysis of inflammation-related colon carcinogenesis.
J Carcinog
; 2009;8:10
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Chronic inflammation is a risk factor for colorectal
cancer
(CRC) development.
Colonic
adenocarcinoma
developed after 20 weeks and a proteomics analysis based on two-dimensional gel electrophoresis and ultraflex TOF/TOF mass spectrometry was conducted in the cancerous and nontumorous tissue specimens.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 2001 Nov 1;61(21):7908-12
[
11691811.001
]
[Cites]
Science. 2001 Nov 30;294(5548):1866-70
[
11729302.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2688-93
[
11226300.001
]
[Cites]
Curr Opin Genet Dev. 2001 Feb;11(1):41-7
[
11163149.001
]
[Cites]
Electrophoresis. 2000 Nov;21(17):3673-83
[
11271486.001
]
[Cites]
J Hepatol. 2000 Oct;33(4):616-22
[
11059866.001
]
[Cites]
Arch Biochem Biophys. 2000 Feb 15;374(2):286-92
[
10666309.001
]
[Cites]
Adv Exp Med Biol. 2008;644:158-67
[
19209821.001
]
[Cites]
Chem Biol Interact. 2009 Jan 27;177(2):128-36
[
19028472.001
]
[Cites]
Int J Cancer. 2009 Jan 15;124(2):264-71
[
19003968.001
]
[Cites]
Nutr Cancer. 2008;60 Suppl 1:70-80
[
19003583.001
]
[Cites]
PPAR Res. 2008;2008:548919
[
18483618.001
]
[Cites]
World J Gastroenterol. 2008 May 7;14(17):2662-9
[
18461651.001
]
[Cites]
Mol Pharm. 2008 Jan-Feb;5(1):35-41
[
18159929.001
]
[Cites]
World J Gastroenterol. 2008 Jan 21;14(3):378-89
[
18200660.001
]
[Cites]
Annu Rev Pharmacol Toxicol. 2008;48:1-32
[
17608617.001
]
[Cites]
Curr Opin Mol Ther. 2007 Oct;9(5):467-76
[
17932810.001
]
[Cites]
Mol Cell Proteomics. 2007 Oct;6(10):1798-808
[
17627933.001
]
[Cites]
Int J Cancer. 2007 Nov 15;121(10):2331-9
[
17657716.001
]
[Cites]
J Pharm Sci. 2007 Aug;96(8):2145-53
[
17542013.001
]
[Cites]
BMC Cancer. 2007;7:84
[
17506908.001
]
[Cites]
Gastroenterology. 2006 Oct;131(4):1110-21
[
17030181.001
]
[Cites]
Proteomics. 2006 Feb;6(4):1158-65
[
16402363.001
]
[Cites]
BMC Cancer. 2005;5:46
[
15892897.001
]
[Cites]
Expert Rev Mol Diagn. 2005 May;5(3):353-75
[
15934813.001
]
[Cites]
Clin Cancer Res. 2005 May 15;11(10):3758-65
[
15897573.001
]
[Cites]
Arch Pharm Res. 2005 Mar;28(3):249-68
[
15832810.001
]
[Cites]
Clin Dev Immunol. 2004 Sep-Dec;11(3-4):195-204
[
15559364.001
]
[Cites]
J Biol Chem. 1998 Jan 16;273(3):1349-56
[
9430668.001
]
[Cites]
J Immunol. 1999 Jul 1;163(1):351-8
[
10384135.001
]
[Cites]
Biochimie. 1998 Oct;80(10):803-6
[
9893938.001
]
[Cites]
J Immunol. 1998 Nov 15;161(10):5733-44
[
9820555.001
]
[Cites]
Gastroenterology. 1998 May;114(5):912-22
[
9558279.001
]
[Cites]
Electrophoresis. 1997 Mar-Apr;18(3-4):324-7
[
9150909.001
]
[Cites]
Electrophoresis. 1994 Dec;15(12):1552-8
[
7536671.001
]
[Cites]
Am J Gastroenterol. 1995 Mar;90(3):377-80
[
7872273.001
]
[Cites]
J Biol Chem. 1994 Jul 22;269(29):18767-72
[
7913466.001
]
[Cites]
Genomics. 1993 Aug;17(2):519-21
[
8406508.001
]
[Cites]
Biochim Biophys Acta. 1988 Feb 24;947(1):101-12
[
3278736.001
]
[Cites]
Mol Biol Cell. 2004 Oct;15(10):4682-94
[
15317845.001
]
[Cites]
Gastroenterology. 2004 Jul;127(1):26-40
[
15236169.001
]
[Cites]
Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17
[
15194558.001
]
[Cites]
Clin Pharmacokinet. 2003;42(15):1331-57
[
14674787.001
]
[Cites]
Pharmacol Rev. 2003 Dec;55(4):649-73
[
14657421.001
]
[Cites]
Cancer Sci. 2003 Nov;94(11):965-73
[
14611673.001
]
[Cites]
Nat Rev Cancer. 2003 Apr;3(4):276-85
[
12671666.001
]
[Cites]
Mol Pharmacol. 2002 Sep;62(3):638-46
[
12181440.001
]
[Cites]
Curr Opin Mol Ther. 2001 Dec;3(6):538-45
[
11804268.001
]
[Cites]
Prostate. 2002 Jan 1;50(1):54-63
[
11757036.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15143-8
[
11742067.001
]
[Cites]
Proteomics. 2001 Oct;1(10):1303-19
[
11721642.001
]
[Cites]
Proteomics. 2001 Oct;1(10):1205-15
[
11721633.001
]
[Cites]
Annu Rev Biophys Biomol Struct. 2001;30:421-55
[
11441809.001
]
(PMID = 19491504.001).
[ISSN]
1477-3163
[Journal-full-title]
Journal of carcinogenesis
[ISO-abbreviation]
J Carcinog
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2699605
8.
Halvorson CR, Erickson CL, Gaspari AA:
A rare manifestation of nail changes with docetaxel therapy.
Skinmed
; 2010 May-Jun;8(3):179-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A 60-year-old African American man presented to the dermatology clinic for evaluation of skin and nail changes associated with docetaxel therapy for
adenocarcinoma of
the
prostate
.
[MeSH-minor]
Adenocarcinoma
/ drug therapy. Humans. Male. Middle Aged.
Prostatic
Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - Nail Diseases
.
Hazardous Substances Data Bank.
DOCETAXEL
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21137627.001).
[ISSN]
1540-9740
[Journal-full-title]
Skinmed
[ISO-abbreviation]
Skinmed
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
9.
Liauw SL, Stadler WM, Correa D, Weichselbaum RR, Jani AB:
Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
Int J Radiat Oncol Biol Phys
; 2010 May 1;77(1):125-30
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Dose-escalated radiotherapy for high-risk
prostate
cancer
: outcomes in modern era with short-term androgen deprivation therapy.
PURPOSE: Randomized data have supported the use of long-term androgen deprivation therapy (ADT) combined with radiotherapy (RT) for men with high-risk
prostate
cancer
.
MATERIALS AND METHODS: A total of 184 men with any single risk factor
of prostate
-specific antigen >or=10 ng/mL, clinical Stage T2b or greater, or Gleason score >or=7 were treated with primary external beam RT for nonmetastatic
adenocarcinoma of
the
prostate
.
Univariate and multivariable analyses were performed for risk factors, including T stage, Gleason score, radiation dose, and
prostate
-specific antigen level.
On a subset analysis of high-risk patients (National Comprehensive
Cancer
Network criteria), those with clinical Stage T3 disease (4-year FFBF rate, 46% vs. 80%; p = .0303) and a radiation dose <74 Gy (4-year FFBF rate, 64% vs. 80%) had a poorer outcome on univariate analysis.
CONCLUSION: Short-term ADT and RT might be acceptable for men with intermediate- and high-risk
prostate
cancer
, especially for clinically localized disease treated with doses of >or=74 Gy.
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lancet Oncol. 2005 Nov;6(11):841-50
[
16257791.001
]
[Cites]
N Engl J Med. 2009 Jan 15;360(3):e4
[
19144933.001
]
[Cites]
Lancet Oncol. 2006 Jun;7(6):472-9
[
16750497.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
[
16798415.001
]
[Cites]
Cancer. 2009 Apr 15;115(8):1784-90
[
19208426.001
]
[Cites]
J Urol. 2001 Sep;166(3):876-81
[
11490237.001
]
[Cites]
Lancet. 2002 Jul 13;360(9327):103-6
[
12126818.001
]
[Cites]
J Clin Oncol. 2003 Jun 1;21(11):2163-72
[
12775742.001
]
[Cites]
J Clin Oncol. 2003 Nov 1;21(21):3972-8
[
14581419.001
]
[Cites]
Urol Oncol. 2004 Jul-Aug;22(4):300-6
[
15283887.001
]
[Cites]
JAMA. 2004 Aug 18;292(7):821-7
[
15315996.001
]
[Cites]
JAMA. 1998 Sep 16;280(11):969-74
[
9749478.001
]
[Cites]
JAMA. 2005 Sep 14;294(10):1233-9
[
16160131.001
]
[Cites]
J Clin Oncol. 2006 Sep 20;24(27):4448-56
[
16983113.001
]
[Cites]
Urology. 2007 May;69(5):936-40
[
17482938.001
]
[Cites]
J Clin Oncol. 2007 Jun 10;25(17):2420-5
[
17557956.001
]
[Cites]
J Natl Compr Canc Netw. 2007 Aug;5(7):650-83
[
17692170.001
]
[Cites]
Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):247-54
[
17940447.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74
[
17765406.001
]
[Cites]
J Clin Oncol. 2008 Feb 1;26(4):585-91
[
18172188.001
]
[Cites]
J Urol. 2008 Apr;179(4):1368-73; discussion 1373
[
18289585.001
]
[Cites]
Eur Urol. 2008 Jun;53(6):1172-9
[
18222596.001
]
[Cites]
Am J Clin Oncol. 2008 Aug;31(4):375-8
[
18845997.001
]
[Cites]
J Clin Oncol. 2006 May 1;24(13):1990-6
[
16648499.001
]
(PMID = 19695789.001).
[ISSN]
1879-355X
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA090386-01; United States / NCI NIH HHS / CA / P50 CA090386; United States / NCI NIH HHS / CA / P50 CA090386-01
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Androgen Antagonists; EC 3.4.21.77 / Prostate-Specific Antigen
[Other-IDs]
NLM/ NIHMS273199; NLM/ PMC3049990
10.
Schmitz M, Grignard G, Margue C, Dippel W, Capesius C, Mossong J, Nathan M, Giacchi S, Scheiden R, Kieffer N:
Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis.
Int J Cancer
; 2007 Mar 15;120(6):1284-92
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Complete loss of PTEN expression as a possible early prognostic marker for
prostate
cancer
metastasis.
The EGF/IGF growth factors are potent mitogens that regulate cell proliferation and cell survival and are involved in
prostate
cancer
development.
Using laser microdissection technology and real-time PCR, together with immunohistochemistry, we have explored the growth factor and integrin dependent PI3-kinase/PTEN/Akt signalling pathway in
prostate
cell lines and tumour samples by analysing EGF-R, IGF1-R, ILK, beta3 integrin, PTEN and p-Akt protein expression.
We provide evidence that loss of PTEN expression rather than upregulated EGF/IGF1 receptor expression was responsible for increased p-Akt in neoplastic
prostate
cells.
We therefore compared PTEN expression in patient biopsies at first time
diagnosis
recruited prospectively (Study I, 112 patients) and patients with confirmed metastasis recruited retrospectively from the Luxembourg
cancer
registry (Study II, 42 patients).
In Study I, loss of PTEN expression at first time
diagnosis
was found in 26 of 112 patients (23%).
In Study II, 25 of the 42 patients (59%) with lymph node metastasis had complete loss of PTEN expression in both the neoplastic glands of the
prostate
and the invasive
prostate
cancer
cells in the lymph node, and of these 13 (52%) exhibited already loss of PTEN expression at first
diagnosis
.
These findings demonstrate that loss of PTEN expression is an important factor in progression towards metastatic disease and could potentially serve as an early prognostic marker for
prostate
cancer
metastasis.
[MeSH-major]
Adenocarcinoma
/ secondary. Biomarkers, Tumor / analysis. PTEN Phosphohydrolase / analysis.
Prostate
/ pathology.
Prostatic
Neoplasms / pathology
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2006 Wiley-Liss, Inc.
(PMID = 17163422.001).
[ISSN]
0020-7136
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Integrin beta3; 0 / RNA, Messenger; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
11.
Chen YC, Chiang CI, Lin RS, Pu YS, Lai MK, Sung FC:
Diet, vegetarian food and prostate carcinoma among men in Taiwan.
Br J Cancer
; 2005 Oct 31;93(9):1057-61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diet, vegetarian food and
prostate
carcinoma among men in Taiwan.
In a case-control study in a veterans hospital in Taiwan, we compared 237 histology-confirmed
prostate
carcinoma cases with 481 controls, frequency matched by age, for their consumption of vegetarian food, namely soybean products, rice, wheat protein and other vegetables.
The OR
of prostate
carcinoma for men with BMI < or =25 kg m(-2) was 1.74 (95% CI=1.21, 2.51), compared with men with higher BMI (>25 kg m(-2)).
This study suggests that the intake of the low fat local vegetarian food has a protective effect against
prostate
carcinoma for thin men in this study population.
[MeSH-major]
Adenocarcinoma
/ epidemiology. Diet, Vegetarian.
Prostatic
Neoplasms / epidemiology
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
MedlinePlus Health Information.
consumer health - Vegetarian Diet
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Natl Cancer Inst. 1974 Aug;53(2):341-6
[
4843267.001
]
[Cites]
Cancer. 2004 Nov 15;101(10 Suppl):2371-490
[
15495199.001
]
[Cites]
Am J Epidemiol. 1975 Jul;102(1):47-54
[
50734.001
]
[Cites]
Br J Cancer. 1981 Feb;43(2):233-5
[
7470386.001
]
[Cites]
J Natl Cancer Inst. 1981 Jun;66(6):1191-308
[
7017215.001
]
[Cites]
Am J Clin Nutr. 1985 Jul;42(1):127-34
[
4014062.001
]
[Cites]
Cancer Res. 1989 Apr 1;49(7):1857-60
[
2924323.001
]
[Cites]
Cancer. 1989 Aug 1;64(3):598-604
[
2743254.001
]
[Cites]
Am J Epidemiol. 1992 Jan 15;135(2):169-79
[
1536133.001
]
[Cites]
Ann Intern Med. 1993 May 15;118(10):793-803
[
8470854.001
]
[Cites]
J Natl Cancer Inst. 1993 Oct 6;85(19):1571-9
[
8105097.001
]
[Cites]
J Natl Cancer Inst. 1994 Feb 16;86(4):281-6
[
8158682.001
]
[Cites]
Int J Cancer. 1994 May 1;57(3):313-7
[
8168989.001
]
[Cites]
J Natl Cancer Inst. 1995 May 3;87(9):652-61
[
7752270.001
]
[Cites]
J Natl Cancer Inst. 1995 Dec 6;87(23):1767-76
[
7473833.001
]
[Cites]
Environ Health Perspect. 1995 Oct;103 Suppl 7:103-12
[
8593855.001
]
[Cites]
J Urol. 1996 Mar;155(3):969-74
[
8583620.001
]
[Cites]
Br J Cancer. 1996 Nov;74(10):1682-6
[
8932356.001
]
[Cites]
Eur J Cancer. 1997 Jan;33(1):101-7
[
9071908.001
]
[Cites]
Br J Cancer. 1997;76(5):678-87
[
9303371.001
]
[Cites]
Nutr Cancer. 1997;29(2):120-6
[
9427974.001
]
[Cites]
CA Cancer J Clin. 1998 Jan-Feb;48(1):31-48
[
9449932.001
]
[Cites]
CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1
[
10200776.001
]
[Cites]
Cancer. 1999 Aug 1;86(3):484-91
[
10430257.001
]
[Cites]
Br J Cancer. 1974 Apr;29(4):328-36
[
4851998.001
]
(PMID = 16205693.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Other-IDs]
NLM/ PMC2361673
12.
Gapter L, Wang Z, Glinski J, Ng KY:
Induction of apoptosis in prostate cancer cells by pachymic acid from Poria cocos.
Biochem Biophys Res Commun
; 2005 Jul 15;332(4):1153-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Induction of apoptosis in
prostate
cancer
cells by pachymic acid from Poria cocos.
PLA(2) is elevated in
prostatic
adenocarcinoma
and conversion of AA to prostaglandins leads to AKT pro-survival activity.
In this study, we investigated the effect of PA on the growth of human
prostate
cancer
cells.
PA significantly reduced cell proliferation and induced apoptosis in a dose- and time-dependent fashion, with androgen-insensitive DU145
prostate
cancer
cells showing greater growth inhibition relative to androgen-responsive LNCaP.
[MeSH-major]
Antineoplastic Agents / pharmacology. Apoptosis. Polyporales / metabolism.
Prostatic
Neoplasms / pathology. Triterpenes / metabolism
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Biochem Biophys Res Commun. 2006 Jan 6;339(1):457
(PMID = 15913545.001).
[ISSN]
0006-291X
[Journal-full-title]
Biochemical and biophysical research communications
[ISO-abbreviation]
Biochem. Biophys. Res. Commun.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / BAD protein, human; 0 / Carrier Proteins; 0 / Coloring Agents; 0 / Prostaglandins; 0 / Proto-Oncogene Proteins; 0 / Terpenes; 0 / Triterpenes; 0 / bcl-Associated Death Protein; 29070-92-6 / pachymic acid; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases
13.
Yoon GS, Wang W, Osunkoya AO, Lane Z, Partin AW, Epstein JI:
Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma.
J Urol
; 2008 Jun;179(6):2203-6; discussion 2206
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Residual tumor potentially left behind after local ablation therapy in
prostate adenocarcinoma
.
PURPOSE: We examined contralateral
prostate
cancer
potentially left behind by focal therapy.
There were 13 cases in which more than 0.5 cm(3)
cancer
was contralateral to the positive biopsy and 7 with predominantly anterior tumor.
CONCLUSIONS: In a highly selected population with limited unilateral biopsy
cancer
, tumor contralateral to the positive biopsy side at radical prostatectomy is typically small.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Technol Cancer Res Treat. 2004 Aug;3(4):365-70
[
15270587.001
]
[Cites]
Urology. 2004 Oct;64(4):733-7
[
15491711.001
]
[Cites]
Cancer. 1972 Jul;30(1):5-13
[
5064808.001
]
[Cites]
Cancer. 1992 Nov 1;70(9):2313-8
[
1382830.001
]
[Cites]
JAMA. 1994 Feb 2;271(5):368-74
[
7506797.001
]
[Cites]
Cancer. 2007 Aug 15;110(4):906-10
[
17587207.001
]
[Cites]
Am J Surg Pathol. 1997 Feb;21(2):174-8
[
9042283.001
]
[Cites]
Tech Urol. 1999 Sep;5(3):139-42
[
10527256.001
]
[Cites]
J Endourol. 2006 Sep;20(9):688-92
[
16999628.001
]
[Cites]
BJU Int. 2006 Nov;98(5):986-8
[
17034600.001
]
[Cites]
Urology. 2007 Jun;69(6):1117-20
[
17572198.001
]
[Cites]
J Urol. 1995 Mar;153(3 Pt 2):987-92
[
7853589.001
]
[CommentIn]
J Urol. 2008 Jun;179(6):2091
[
18423729.001
]
(PMID = 18423736.001).
[ISSN]
1527-3792
[Journal-full-title]
The Journal of urology
[ISO-abbreviation]
J. Urol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / CA 58236
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS374261; NLM/ PMC3353270
14.
Zhang H, Huang W:
Fusion proteins of Hsp70 with tumor-associated antigen acting as a potent tumor vaccine and the C-terminal peptide-binding domain of Hsp70 being essential in inducing antigen-independent anti-tumor response in vivo.
Cell Stress Chaperones
; 2006;11(3):216-26
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[MeSH-major]
Antigens, Neoplasm / immunology.
Cancer
Vaccines / immunology. HSP70 Heat-Shock Proteins / chemistry. HSP70 Heat-Shock Proteins / immunology. Vaccines, DNA / immunology
[MeSH-minor]
Adenocarcinoma
/ immunology.
Adenocarcinoma
/ therapy. Animals. Carcinoma, Lewis Lung / immunology. Carcinoma, Lewis Lung / therapy. Cell Culture Techniques. Cell Line, Transformed. Cell Line, Tumor. Cell Transformation, Viral. Colonic Neoplasms / immunology. Colonic Neoplasms / therapy. Escherichia coli / genetics. Lymphoma / immunology. Lymphoma / therapy. Melanoma, Experimental / immunology. Melanoma, Experimental / therapy. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Moloney murine leukemia virus / physiology. Neoplasm Transplantation / pathology. Protein Structure, Tertiary. RNA, Messenger / analysis. Recombinant Fusion Proteins / chemistry. Recombinant Fusion Proteins / immunology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13146-51
[
9371814.001
]
[Cites]
J Exp Med. 1997 Oct 20;186(8):1315-22
[
9334371.001
]
[Cites]
Pharmacol Ther. 1998 Nov;80(2):183-201
[
9839771.001
]
[Cites]
J Exp Med. 1999 May 3;189(9):1437-42
[
10224283.001
]
[Cites]
J Immunol. 2005 Jun 1;174(11):6566-9
[
15905492.001
]
[Cites]
Immunol Lett. 2006 Jun 15;105(2):167-73
[
16580737.001
]
[Cites]
J Exp Med. 2000 Jan 17;191(2):403-8
[
10637285.001
]
[Cites]
Immunol Today. 2000 Mar;21(3):129-32
[
10689300.001
]
[Cites]
Nat Med. 2000 Apr;6(4):435-42
[
10742151.001
]
[Cites]
J Immunol. 2001 Jan 1;166(1):490-7
[
11123328.001
]
[Cites]
Vaccine. 2001 Jan 8;19(11-12):1425-34
[
11163665.001
]
[Cites]
Vaccine. 2001 Mar 21;19(17-19):2590-7
[
11257397.001
]
[Cites]
Int Immunol. 2001 Oct;13(10):1233-42
[
11581168.001
]
[Cites]
Cancer Res. 2001 Nov 1;61(21):7920-4
[
11691813.001
]
[Cites]
Nat Rev Immunol. 2002 Mar;2(3):185-94
[
11913069.001
]
[Cites]
J Clin Oncol. 2002 Oct 15;20(20):4169-80
[
12377960.001
]
[Cites]
Int J Hyperthermia. 2002 Nov-Dec;18(6):576-85
[
12537756.001
]
[Cites]
Immunology. 2003 Sep;110(1):1-9
[
12941135.001
]
[Cites]
Clin Cancer Res. 2003 Aug 15;9(9):3235-45
[
12960108.001
]
[Cites]
Methods. 2004 Jan;32(1):7-12
[
14624870.001
]
[Cites]
J Immunol. 2003 Dec 15;171(12):6396-405
[
14662838.001
]
[Cites]
Prostate. 2004 Oct 1;61(2):161-70
[
15305339.001
]
[Cites]
Tissue Antigens. 2004 Oct;64(4):442-51
[
15361121.001
]
[Cites]
Int J Cancer. 1984 Mar 15;33(3):417-22
[
6698641.001
]
[Cites]
Proc Natl Acad Sci U S A. 1986 May;83(10):3121-5
[
3458168.001
]
[Cites]
Proc Natl Acad Sci U S A. 1986 May;83(10):3407-11
[
3458189.001
]
[Cites]
Annu Rev Biochem. 1986;55:1151-91
[
2427013.001
]
[Cites]
Cancer Res. 1987 Oct 1;47(19):5074-9
[
3497717.001
]
[Cites]
J Immunol. 1992 Aug 15;149(4):1223-9
[
1380036.001
]
[Cites]
Infect Immun. 1993 Jul;61(7):3012-6
[
8514408.001
]
[Cites]
J Exp Med. 1993 Oct 1;178(4):1391-6
[
8376942.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3077-81
[
7909157.001
]
[Cites]
J Immunol. 1994 Jun 1;152(11):5398-403
[
8189059.001
]
[Cites]
J Exp Med. 1994 Jul 1;180(1):347-52
[
7516411.001
]
[Cites]
Int J Cancer. 1995 Oct 9;63(2):310-4
[
7591222.001
]
[Cites]
J Exp Med. 1996 Dec 1;184(6):2207-16
[
8976176.001
]
[Cites]
J Exp Med. 1997 Feb 3;185(3):453-9
[
9053445.001
]
[Cites]
Science. 1997 Oct 3;278(5335):117-20
[
9311915.001
]
[Cites]
J Exp Med. 1998 Jul 20;188(2):277-86
[
9670040.001
]
(PMID = 17009594.001).
[ISSN]
1355-8145
[Journal-full-title]
Cell stress & chaperones
[ISO-abbreviation]
Cell Stress Chaperones
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HSP70 Heat-Shock Proteins; 0 / RNA, Messenger; 0 / Recombinant Fusion Proteins; 0 / Vaccines, DNA
[Other-IDs]
NLM/ PMC1576472
15.
Martina MS, Fortin JP, Fournier L, Ménager C, Gazeau F, Clément O, Lesieur S:
Magnetic targeting of rhodamine-labeled superparamagnetic liposomes to solid tumors: in vivo tracking by fibered confocal fluorescence microscopy.
Mol Imaging
; 2007 Mar-Apr;6(2):140-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Human
prostate adenocarcinoma
tumors implanted in mice were used as a system model.
[MeSH-major]
Adenocarcinoma
/
diagnosis
. Ferrosoferric Oxide / analysis. Fiber Optic Technology / methods. Fluorescent Dyes / analysis. Metal Nanoparticles / analysis. Microscopy, Confocal / methods. Microscopy, Fluorescence / methods.
Prostatic
Neoplasms /
diagnosis
. Rhodamines / analysis
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17445508.001).
[ISSN]
1535-3508
[Journal-full-title]
Molecular imaging
[ISO-abbreviation]
Mol Imaging
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Fluorescent Dyes; 0 / Liposomes; 0 / Rhodamines; 30IQX730WE / Polyethylene Glycols; XM0M87F357 / Ferrosoferric Oxide
16.
Furusato B, Koff S, McLeod DG, Sesterhenn IA:
Sarcoidosis of the prostate.
J Clin Pathol
; 2007 Mar;60(3):325-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Sarcoidosis of the
prostate
.
A 55-year-old African-American man with clinical stage T1c
prostate
cancer
underwent prostatectomy.
[MeSH-major]
Prostatic
Diseases / pathology. Sarcoidosis / pathology
[MeSH-minor]
Adenocarcinoma
/ complications. Humans. Incidental Findings. Male. Middle Aged.
Prostatic
Neoplasms / complications
Genetic Alliance.
consumer health - Sarcoidosis
.
MedlinePlus Health Information.
consumer health - Prostate Diseases
.
MedlinePlus Health Information.
consumer health - Sarcoidosis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Cancer. 1974 Mar;29(3):247-51
[
4830144.001
]
[Cites]
Am J Clin Pathol. 1949 Aug;19(8):725-49
[
18135500.001
]
[Cites]
Br J Urol. 1993 Oct;72(4):462-4
[
8261305.001
]
[Cites]
J Urol. 1980 Jan;123(1):133-4
[
7351709.001
]
(PMID = 17347286.001).
[ISSN]
0021-9746
[Journal-full-title]
Journal of clinical pathology
[ISO-abbreviation]
J. Clin. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
England
[Number-of-references]
5
[Other-IDs]
NLM/ PMC1860563
17.
Kotrikadze N, Alibegashvili M, Zibzibadze M, Abashidze N, Chigogidze T, Managadze L, Artsivadze K:
Activity and content of antioxidant enzymes in prostate tumors.
Exp Oncol
; 2008 Sep;30(3):244-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Activity and content of antioxidant enzymes in
prostate
tumors.
AIM: To investigate the antioxidant enzyme system in blood of men with benign hyperplasia
of prostate
(BHP) and with
prostate adenocarcinoma
(CaP).
Blood plasma and erythrocytes of men with
prostate
tumors served as the material for the studies; n = 15 for each group.
[MeSH-major]
Antioxidants / metabolism. Erythrocytes / enzymology. Oxidoreductases / metabolism.
Prostatic
Hyperplasia / enzymology.
Prostatic
Neoplasms / enzymology
[MeSH-minor]
Adenocarcinoma
/ blood.
Adenocarcinoma
/ enzymology.
Adenocarcinoma
/ pathology. Aged. Catalase / metabolism. Ceruloplasmin / metabolism. Glutathione / metabolism. Glutathione Peroxidase / metabolism. Glutathione Reductase / metabolism. Humans. Lipid Peroxidation. Male. Middle Aged. Superoxide Dismutase / metabolism. Thiobarbituric Acid Reactive Substances
MedlinePlus Health Information.
consumer health - Antioxidants
.
MedlinePlus Health Information.
consumer health - Enlarged Prostate (BPH)
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18806750.001).
[ISSN]
1812-9269
[Journal-full-title]
Experimental oncology
[ISO-abbreviation]
Exp. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Ukraine
[Chemical-registry-number]
0 / Antioxidants; 0 / Thiobarbituric Acid Reactive Substances; EC 1.- / Oxidoreductases; EC 1.11.1.6 / Catalase; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; EC 1.16.3.1 / Ceruloplasmin; EC 1.8.1.7 / Glutathione Reductase; GAN16C9B8O / Glutathione
18.
Brizuela L, Dayon A, Doumerc N, Ader I, Golzio M, Izard JC, Hara Y, Malavaud B, Cuvillier O:
The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer.
FASEB J
; 2010 Oct;24(10):3882-94
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in
prostate
cancer
.
The sphingosine kinase-1/sphingosine 1-phosphate (SphK1/S1P) pathway has been associated with
cancer
promotion and progression and resistance to treatments in a number of cancers, including
prostate adenocarcinoma
.
Here we provide the first evidence that dietary agents, namely, epigallocatechin gallate (EGCg, IC(50)≈75 μM), resveratrol (IC(50)≈40 μM), or a mixture of polyphenols from green tea [polyphenon E (PPE), IC(50)≈70 μM] or grapevine extract (vineatrol, IC(50)≈30 μM), impede
prostate
cancer
cell growth in vitro and in vivo by inhibiting the SphK1/S1P pathway.
These results provide the first demonstration that the prosurvival, antiapoptotic SphK1/S1P pathway represents a target of dietary green tea and wine polyphenols in
cancer
.
[MeSH-major]
Phosphotransferases (Alcohol Group Acceptor) / physiology.
Prostatic
Neoplasms / pathology. Tea / chemistry. Wine / analysis
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
Hazardous Substances Data Bank.
Green tea
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20522783.001).
[ISSN]
1530-6860
[Journal-full-title]
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
[ISO-abbreviation]
FASEB J.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Tea; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.- / sphingosine kinase
19.
Hemminki K, Granström C, Chen B:
The Swedish family-cancer database: update, application to colorectal cancer and clinical relevance.
Hered Cancer Clin Pract
; 2005;3(1):7-18
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The Swedish family-
cancer
database: update, application to colorectal
cancer
and clinical relevance.
The Swedish Family-
Cancer
Database has been used for almost 10 years in the study of familial risks at all common sites.
Cancer
cases were retrieved from the Swedish
Cancer
Registry from 1958-2002, including over 1.2 million first and multiple primary cancers and in situ tumours.
Compared to previous versions, only 6.0% of deceased offspring with a
cancer diagnosis
lack any parental information.
We show one application of the Database in the study of familial risks in colorectal
adenocarcinoma
, with defined age-group and anatomic site specific analyses.
Familial standardized incidence ratios (SIRs) were determined for offspring when parents or sibling were diagnosed with colon or rectal
cancer
.
The excess risk was limited to colon
cancer
and particularly to right-sided colon
cancer
.
The SIRs for colon
cancer
in age matched populations were 2.58 when parents were probands and 3.81 when siblings were probands; for right-sided colon
cancer the
SIRs were 3.66 and 7.53, respectively.
Thus the familial excess (SIR-1.00) was more than two fold higher for right-sided colon
cancer
.
Useful risk estimates have been developed for familial breast and
prostate
cancers.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Cancer. 2004 Jan 20;108(3):433-42
[
14648711.001
]
[Cites]
Br J Cancer. 2001 Apr 6;84(7):969-74
[
11286479.001
]
[Cites]
Int J Cancer. 2004 Jan 1;108(1):109-14
[
14618624.001
]
[Cites]
Fam Cancer. 2003;2(2):87-93
[
14574157.001
]
[Cites]
Am J Pathol. 2003 Sep;163(3):827-32
[
12937124.001
]
[Cites]
Lancet. 2003 Jul 5;362(9377):39-41
[
12853198.001
]
[Cites]
Cancer Res. 2003 Apr 15;63(8):1769-71
[
12702560.001
]
[Cites]
N Engl J Med. 2003 Mar 6;348(10):919-32
[
12621137.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1638-44
[
12496055.001
]
[Cites]
Cancer. 2003 Jan 1;97(1 Suppl):230-5
[
12491486.001
]
[Cites]
Eur J Cancer. 2002 Dec;38(18):2428-34
[
12460788.001
]
[Cites]
Int J Cancer. 2003 Jan 1;103(1):105-9
[
12455061.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1332-52
[
12433710.001
]
[Cites]
Science. 2002 Sep 20;297(5589):2013
[
12242432.001
]
[Cites]
Int J Cancer. 2002 May 10;99(2):229-37
[
11979438.001
]
[Cites]
Int J Cancer. 2002 May 10;99(2):218-28
[
11979437.001
]
[Cites]
CA Cancer J Clin. 2002 Jan-Feb;52(1):8-22
[
11814067.001
]
[Cites]
Nat Genet. 2002 Feb;30(2):227-32
[
11818965.001
]
[Cites]
Int J Cancer. 2001 Dec 1;94(5):743-8
[
11745471.001
]
[Cites]
Lancet. 2001 Oct 27;358(9291):1389-99
[
11705483.001
]
[Cites]
Am J Gastroenterol. 2001 Oct;96(10):2992-3003
[
11693338.001
]
[Cites]
Br J Cancer. 2001 Feb 2;84(3):388-91
[
11161404.001
]
[Cites]
N Engl J Med. 2000 Jul 13;343(2):78-85
[
10891514.001
]
[Cites]
J Clin Oncol. 2000 Jun;18(11):2193-200
[
10829038.001
]
[Cites]
Nat Genet. 2004 Dec;36(12):1312-8
[
15543147.001
]
[Cites]
J Med Genet. 2004 Nov;41(11):801-7
[
15520403.001
]
[Cites]
J Natl Cancer Inst. 1999 Jun 2;91(11):916-32
[
10359544.001
]
[Cites]
Int J Oncol. 1998 Mar;12(3):701-10
[
9472113.001
]
[Cites]
Nature. 1998 Jan 8;391(6663):184-7
[
9428765.001
]
[Cites]
Int J Cancer. 1996 Nov 15;68(4):428-35
[
8945611.001
]
[Cites]
Br Med Bull. 1994 Jul;50(3):527-35
[
7987639.001
]
[Cites]
Cancer Detect Prev. 1995;19(3):219-33
[
7750110.001
]
[Cites]
J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8
[
7932824.001
]
[Cites]
J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86
[
2593165.001
]
[Cites]
Am J Epidemiol. 1990 Jun;131(6):961-72
[
2188501.001
]
[Cites]
Int J Cancer. 2004 Jun 10;110(2):291-4
[
15069696.001
]
[Cites]
J Clin Oncol. 2003 Sep 1;21(17):3375-6
[
12947078.001
]
[Cites]
Int J Cancer. 2004 Sep 20;111(5):809-10
[
15252856.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1253-6
[
15247139.001
]
[Cites]
Stat Med. 2004 Apr 15;23(7):1111-30
[
15057881.001
]
[Cites]
Int J Cancer. 2004 Apr 20;109(4):554-8
[
14991577.001
]
[Cites]
J Med Genet. 2004 Feb;41(2):81-91
[
14757853.001
]
[Cites]
Gastroenterology. 2001 Oct;121(4):830-8
[
11606497.001
]
[Cites]
Gastroenterology. 2001 Aug;121(2):282-301
[
11487538.001
]
[Cites]
J Med Genet. 2003 Nov;40(11):807-14
[
14627668.001
]
(PMID = 20223029.001).
[ISSN]
1897-4287
[Journal-full-title]
Hereditary cancer in clinical practice
[ISO-abbreviation]
Hered Cancer Clin Pract
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Poland
[Other-IDs]
NLM/ PMC2837068
20.
Seo SI, Song SY, Kang MR, Kim MS, Oh JE, Kim YR, Lee JY, Yoo NJ, Lee SH:
Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
APMIS
; 2009 Aug;117(8):623-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in
prostate
cancers.
Activation of nuclear factor-kappa B (NF-kappaB) signaling is considered an important mechanism in the development
of prostate
cancers.
Expression of NF-kappaB members has been reported in
prostate
cancer
tissues, but expression of IKKepsilon has not yet been studied in
prostate
cancers.
In this study, we attempted to explore as to whether expressions of IKKepsilon and NF-kappaB members p50/105, p52/p100 and RelA are altered in
prostate
cancers.
We analyzed the expression of IKKepsilon, p50/105, p52/p100 and RelA in 107
prostate adenocarcinoma
tissues by immunohistochemistry using a tissue microarray (TMA) method.
In the TMA, IKKepsilon is expressed in basal cells, but not in alveolar cells in normal
prostate
glands.
IKKepsilon is expressed in 60.0%
of prostate
intraepithelial neoplasm (PIN) and 70.1% of the
prostate
cancers in the cytoplasm.
The increased cytoplasmic expression of IKKepsilon as well as the increased nuclear expressions of p50/105, p52/p100 and RelA in the
prostate
cancers compared to normal alveolar cells suggested that overexpression of these proteins may be related to activation of the NF-kappaB pathway and might play a role in tumorigenesis
of prostate
cancers.
[MeSH-major]
Adenocarcinoma
/ pathology. I-kappa B Kinase / biosynthesis. NF-kappa B p50 Subunit / biosynthesis. NF-kappa B p52 Subunit / biosynthesis.
Prostatic
Neoplasms / pathology. Transcription Factor RelA / biosynthesis
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19664134.001).
[ISSN]
1600-0463
[Journal-full-title]
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
[ISO-abbreviation]
APMIS
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Denmark
[Chemical-registry-number]
0 / NF-kappa B p50 Subunit; 0 / NF-kappa B p52 Subunit; 0 / Transcription Factor RelA; EC 2.7.11.10 / I-kappa B Kinase
21.
Nakata S, Nakano K, Takahashi H, Shimizu K, Higashi H, Ohki K:
[A case of prostate cancer diagnosed pathologically by bone metastatic site biopsy].
Nihon Hinyokika Gakkai Zasshi
; 2005 May;96(4):507-10
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[A case
of prostate
cancer
diagnosed pathologically by bone metastatic site biopsy].
A 61-year-old man consulted our hospital complaining of high
prostate
specific antigen (PSA) value and difficulty to urinate.
Prostate
biopsy had been performed at another hospital, but did not reveal
cancer
.
Transrectal ultrasound-guided
prostate
biopsy was performed, but
cancer
was not detected.
A repeat
prostate
biopsy was performed, but
cancer
was not detected from the
prostate
.
On right pubic bone biopsy, poorly to moderately differentiated
adenocarcinoma
was detected.
PSA immunohistochemical staining was positive, and
the diagnosis
was bone metastasis from
prostate
cancer
.
[MeSH-major]
Adenocarcinoma
/
diagnosis
. Bone Neoplasms / secondary. Bone and Bones / pathology.
Prostatic
Neoplasms /
diagnosis
. Pubic Bone
[MeSH-minor]
Biomarkers, Tumor / blood. Biopsy. Humans. Male. Middle Aged.
Prostate
-Specific Antigen / blood
Genetic Alliance.
consumer health - Bone Cancer
.
Genetic Alliance.
consumer health - Prostate cancer
.
Genetic Alliance.
consumer health - Metastatic cancer
.
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15948412.001).
[ISSN]
0021-5287
[Journal-full-title]
Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
[ISO-abbreviation]
Nippon Hinyokika Gakkai Zasshi
[Language]
jpn
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
22.
Cossu-Rocca P, Contini M, Brunelli M, Festa A, Pili F, Gobbo S, Eccher A, Mura A, Massarelli G, Martignoni G:
S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
Am J Surg Pathol
; 2009 Jul;33(7):1031-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from
prostatic
adenocarcinoma
.
In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from
prostatic
adenocarcinoma
, particularly with lesions arising in
the prostatic
urethra.
Alpha-methylacyl-CoA racemase (AMACR), a recently identified
prostate
cancer
marker, has also been found to be expressed in renal tubules and in some renal epithelial neoplasms.
In this study, we investigated the expression of S100A1 and AMACR in 18 nephrogenic adenomas and in 100
prostatic
adenocarcinomas.
A strong and distinct cytoplasmic or nucleocytoplasmic staining of S100A1 was found in 17 out of 18 cases of nephrogenic adenoma (94%), but never in
prostatic
adenocarcinoma
.
In contrast, AMACR expression was detected in 14 of 18 nephrogenic adenomas (78%) and in 96 of 100
prostatic
adenocarcinomas (96%).
We conclude that (1) S100A1 is a specific and sensitive immunohistochemical marker to differentiate nephrogenic adenoma from
prostatic
adenocarcinoma
;.
[MeSH-major]
Adenocarcinoma
/
diagnosis
. Adenoma /
diagnosis
.
Prostatic
Neoplasms /
diagnosis
. S100 Proteins / biosynthesis. Urogenital Neoplasms /
diagnosis
[MeSH-minor]
Biomarkers, Tumor / analysis.
Diagnosis
, Differential. Humans. Immunohistochemistry. Male. Racemases and Epimerases / biosynthesis. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19384190.001).
[ISSN]
1532-0979
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / S100A1 protein; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
23.
Wei H, Desouki MM, Lin S, Xiao D, Franklin RB, Feng P:
Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues.
Mol Cancer
; 2008 Jan 21;7:7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human
prostate
normal and malignant cells and tissues.
BACKGROUND: The disturbance of zinc homeostasis featured with a significant decrease of cellular zinc level was well documented to associate with the development and progression of human
prostate
malignancy.
We have previously reported that zinc treatment induces
prostate
malignant cell apoptosis through mitochondrial pathway.
However, the studies on the expression of MT in association with the
prostate
pathological and malignant status are very limited, and the zinc regulation of MT isoform expression in
prostate
cells remains elusive.
The goals of this study were to define the expression of endogenous MTs, the isoforms of MT 1, 2, 3 at both messenger ribonucleic acid (mRNA) and protein levels; and to investigate the zinc effect on MT expression in normal
prostate
, benign
prostatic
hyperplasia (BPH) and malignant PC-3 cells, and in relevant human tissues.
RESULTS: Our results demonstrated a significant suppression of endogenous levels of MT1/2 in malignant PC-3 cells (95% reduction compared to the normal
prostate
cells) and in human
adenocarcinoma
tissues (73% MT1/2 negative).
CONCLUSION: This study provided evidence of the association of attenuated MT1/2 with
prostate
tumor progression, and the zinc induction of MT1/2 expression resulting in cellular zinc restoration.
The results suggest the potential of MT1/2 as a candidate biomarker for
prostate
cancer
and the utilization of zinc in
prostate
cancer
prevention and treatment.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
Hazardous Substances Data Bank.
ZINC, ELEMENTAL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 2006 Aug 25;281(34):24085-9
[
16793761.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12347-52
[
16895980.001
]
[Cites]
J Clin Pathol. 2006 Nov;59(11):1171-4
[
16574721.001
]
[Cites]
J Environ Pathol Toxicol Oncol. 2006;25(3):597-610
[
17073562.001
]
[Cites]
Biochimie. 2006 Nov;88(11):1787-92
[
16935407.001
]
[Cites]
Cancer Res. 2007 Mar 15;67(6):2736-46
[
17363595.001
]
[Cites]
Prostate. 1999 Nov 1;41(3):196-202
[
10517878.001
]
[Cites]
Prostate. 2000 May 1;43(2):125-35
[
10754528.001
]
[Cites]
J Nutr. 2000 May;130(5S Suppl):1500S-8S
[
10801966.001
]
[Cites]
Mol Urol. 2000 Spring;4(1):31-6
[
10851304.001
]
[Cites]
Histopathology. 2002 Feb;40(2):143-51
[
11952858.001
]
[Cites]
Cell Mol Life Sci. 2002 Apr;59(4):627-47
[
12022471.001
]
[Cites]
Prostate. 2002 Jul 1;52(2):89-97
[
12111700.001
]
[Cites]
Prostate. 2002 Sep 1;52(4):311-8
[
12210492.001
]
[Cites]
Environ Health Perspect. 2002 Oct;110 Suppl 5:827-30
[
12426140.001
]
[Cites]
Eur J Biochem. 2002 Dec;269(24):6204-11
[
12473116.001
]
[Cites]
Cancer Lett. 2003 Oct 28;200(2):187-95
[
14568174.001
]
[Cites]
Saudi Med J. 2003 Nov;24(11):1246-9
[
14647563.001
]
[Cites]
Toxicol Sci. 2004 Aug;80(2):358-66
[
15129022.001
]
[Cites]
Histopathology. 2004 Aug;45(2):103-18
[
15279628.001
]
[Cites]
Cancer Res. 1980 Aug;40(8 Pt 1):2633-44
[
6992989.001
]
[Cites]
Neuron. 1991 Aug;7(2):337-47
[
1873033.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6333-7
[
1631128.001
]
[Cites]
Biochemistry. 1994 Jun 14;33(23):7250-9
[
8003488.001
]
[Cites]
Biochem Biophys Res Commun. 1995 Sep 14;214(2):639-45
[
7677777.001
]
[Cites]
J Urol. 1996 Nov;156(5):1679-81
[
8863569.001
]
[Cites]
Toxicol Lett. 1997 Jul 21;92(2):149-60
[
9295238.001
]
[Cites]
Clin Invest Med. 1997 Dec;20(6):371-80
[
9413634.001
]
[Cites]
Prostate. 1998 Jun 1;35(4):285-96
[
9609552.001
]
[Cites]
J Biol Chem. 1998 Jul 10;273(28):17425-32
[
9651329.001
]
[Cites]
Toxicol Lett. 1999 Apr 12;105(3):207-14
[
10355541.001
]
[Cites]
Prostate. 2005 Feb 15;62(3):209-16
[
15389791.001
]
[Cites]
Apoptosis. 2005 Jan;10(1):111-21
[
15711927.001
]
[Cites]
Biofactors. 2005;23(2):107-20
[
16179752.001
]
[Cites]
Mol Cancer. 2005;4:32
[
16153295.001
]
[Cites]
Toxicol Sci. 2006 Apr;90(2):369-76
[
16387743.001
]
[Cites]
Genes Dev. 2006 Jun 1;20(11):1458-69
[
16751183.001
]
[Cites]
Carcinogenesis. 2006 Jul;27(7):1489-96
[
16543248.001
]
[Cites]
Exp Biol Med (Maywood). 2006 Oct;231(9):1468-73
[
17018868.001
]
(PMID = 18208603.001).
[ISSN]
1476-4598
[Journal-full-title]
Molecular cancer
[ISO-abbreviation]
Mol. Cancer
[Language]
ENG
[Grant]
United States / PHS HHS / / R01-116815
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / RNA, Messenger; 9038-94-2 / Metallothionein; J41CSQ7QDS / Zinc
[Other-IDs]
NLM/ PMC2265743
24.
Sullivan LM, Smolkin ME, Frierson HF Jr, Galgano MT:
Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology.
Am J Surg Pathol
; 2008 Nov;32(11):1608-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In addition to staining adenocarcinomas of the alimentary system, studies have demonstrated CDX2 positivity in a percentage of ovarian mucinous and endometrioid tumors, carcinoids, and some adenocarcinomas of other sites such as the urinary bladder,
prostate
, lung, and pancreas.
The frequency and pattern of CDX2 staining in the more common histologic subtypes of cervical
adenocarcinoma
(endocervical usual-type and endometrioid) is parallel to that which is seen for adenocarcinomas of the upper gastrointestinal tract and pancreaticobiliary system.
[MeSH-major]
Adenocarcinoma
/ metabolism.
Adenocarcinoma
/ pathology. Intestine, Large / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Cervical Cancer
.
COS Scholar Universe.
author profiles
.
International Agency for Research on Cancer - Screening Group.
diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18753946.001).
[ISSN]
1532-0979
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
25.
Zhang L, Zhong K, Dai Y, Zhou H:
Genome-wide analysis of histone H3 lysine 27 trimethylation by ChIP-chip in gastric cancer patients.
J Gastroenterol
; 2009;44(4):305-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Genome-wide analysis of histone H3 lysine 27 trimethylation by ChIP-chip in gastric
cancer
patients.
In gastric
cancer
(GC), global and gene-specific DNA methylation changes have been demonstrated to occur.
[MeSH-major]
Adenocarcinoma
/ genetics. DNA Methylation. Genome. Stomach Neoplasms / genetics
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Science. 2000 Dec 22;290(5500):2306-9
[
11125145.001
]
[Cites]
Electrophoresis. 2001 Aug;22(14):2838-43
[
11565778.001
]
[Cites]
Nat Rev Cancer. 2006 Nov;6(11):846-56
[
17060944.001
]
[Cites]
Oncogene. 2006 Aug 28;25(38):5220-7
[
16936740.001
]
[Cites]
J Biol Chem. 2007 May 4;282(18):13854-63
[
17339327.001
]
[Cites]
Curr Opin Genet Dev. 2004 Apr;14 (2):155-64
[
15196462.001
]
[Cites]
Methods. 2001 Dec;25(4):402-8
[
11846609.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4173-8
[
12655055.001
]
[Cites]
World J Gastroenterol. 2007 Dec 14;13(46):6166-71
[
18069755.001
]
[Cites]
Methods Enzymol. 2004;376:269-88
[
14975312.001
]
[Cites]
BMC Genomics. 2007 May 24;8:131
[
17524140.001
]
[Cites]
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
[
15761078.001
]
[Cites]
Lab Invest. 2008 Feb;88(2):153-60
[
18059362.001
]
[Cites]
Genes Dev. 2002 Nov 15;16(22):2893-905
[
12435631.001
]
[Cites]
Genes Dev. 2002 Jan 15;16(2):235-44
[
11799066.001
]
[Cites]
Cell. 2007 May 18;129(4):823-37
[
17512414.001
]
[Cites]
Science. 2003 Apr 4;300(5616):131-5
[
12649488.001
]
[Cites]
Ann Surg Oncol. 2008 Jul;15(7):1968-76
[
18470569.001
]
[Cites]
Gastric Cancer. 2005;8(2):86-94
[
15864715.001
]
[Cites]
Nat Genet. 2008 Jun;40(6):741-50
[
18488029.001
]
[Cites]
Gene. 2001 Oct 31;278(1-2):25-31
[
11707319.001
]
[Cites]
EMBO J. 2005 Mar 23;24(6):1192-201
[
15729359.001
]
[Cites]
Nat Cell Biol. 2003 Mar;5(3):216-23
[
12598906.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 May 11;101(19):7398-403
[
15123805.001
]
[Cites]
Prostate. 2003 May 1;55(2):89-98
[
12661033.001
]
[Cites]
World J Gastroenterol. 2004 Apr 15;10(8):1125-31
[
15069711.001
]
[Cites]
Methods. 2006 Dec;40(4):365-9
[
17101450.001
]
[Cites]
Science. 2002 Nov 1;298(5595):1039-43
[
12351676.001
]
[Cites]
Zhonghua Zhong Liu Za Zhi. 2004 Jan;26(1):4-9
[
15059341.001
]
[Cites]
J Lab Clin Med. 1999 Oct;134(4):333-40
[
10521079.001
]
[Cites]
Carcinogenesis. 2008 Mar;29(3):629-37
[
18283041.001
]
[Cites]
Nat Rev Mol Cell Biol. 2007 Apr;8(4):307-18
[
17342184.001
]
[Cites]
Mol Cell Biol. 2007 Apr;27(7):2746-57
[
17242185.001
]
[Cites]
Science. 2001 Aug 10;293(5532):1074-80
[
11498575.001
]
[Cites]
Nat Rev Mol Cell Biol. 2005 Nov;6(11):838-49
[
16261189.001
]
[Cites]
Mol Cell Biol. 2005 Jun;25(11):4650-61
[
15899867.001
]
[Cites]
Oncol Rep. 2007 May;17(5):1051-5
[
17390043.001
]
[Cites]
Cancer Res. 2006 Jul 15;66(14):6899-902
[
16849531.001
]
[Cites]
Mol Cell. 2003 Jul;12(1):3-4
[
12887887.001
]
[Cites]
Mol Cell Biol. 2002 Oct;22(19):6689-96
[
12215526.001
]
[Cites]
Mol Cell Biol. 2003 Jan;23 (1):206-15
[
12482974.001
]
(PMID = 19267258.001).
[ISSN]
0944-1174
[Journal-full-title]
Journal of gastroenterology
[ISO-abbreviation]
J. Gastroenterol.
[Language]
eng
[Publication-type]
Journal Article; Validation Studies
[Publication-country]
Japan
[Chemical-registry-number]
0 / Histones
26.
Inahara M, Suzuki H, Kojima S, Komiya A, Fukasawa S, Imamoto T, Naya Y, Ichikawa T:
Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings.
Urology
; 2006 Oct;68(4):815-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Improved
prostate
cancer
detection using systematic 14-core biopsy for large
prostate
glands with normal digital rectal examination findings.
OBJECTIVES: To evaluate in a retrospective study the improvements in
prostate
cancer
detection rates for patients with a
prostate
gland
larger than 30 cm3 using a systematic 14-core biopsy strategy compared with a systematic 8-core biopsy.
METHODS: We retrospectively assessed 273 patients with screened
prostate
-specific antigen (PSA) levels of 3.0 to 50.0 ng/mL.
A total of 204 patients with a
prostate
volume of 30 cm3 or larger and with normal digital rectal examination findings were enrolled in this study.
Of the 204 patients, 110 underwent 8-core biopsy and 94 underwent 14-core biopsy of the
prostate
.
We compared
the cancer
detection rates
of prostate
biopsy between the 8 and 14-core groups using total PSA, free/total PSA ratio, PSA density, and PSA density adjusted by transition zone volume.
RESULTS: Of the 204 patients, 40 (19.5%) were identified as having
prostate adenocarcinoma
.
The cancer
detection rate for the 8 and 14-core groups was 14.5% (16 of 110 patients) and 24.5% (23 of 94 patients), respectively.
The 14-core biopsy had a statistically significant greater
cancer
detection rate than did the 8-core group in patients with a
prostate
volume of 30 to 40 cm3 (36.7% versus 11.8%, respectively, P<0.05) and a PSA density adjusted by transition zone volume of 0.38 ng/mL/cm3 or greater (47.8% versus 20.0%, respectively, P <0.05).
CONCLUSIONS: The 14-core
prostate
needle biopsy is a recommended method for detecting
prostate
cancer
in a large-volume
prostate
gland
without increasing the risk of complications.
[MeSH-major]
Adenocarcinoma
/ pathology.
Prostate
/ pathology.
Prostatic
Neoplasms / pathology
[MeSH-minor]
Adult. Biomarkers, Tumor / blood. Biopsy, Needle. Digital Rectal Examination. Humans. Male. Neoplasm Staging. Organ Size.
Prostate
-Specific Antigen / blood. Retrospective Studies
Genetic Alliance.
consumer health - Rectal Cancer
.
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17070359.001).
[ISSN]
1527-9995
[Journal-full-title]
Urology
[ISO-abbreviation]
Urology
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
27.
Colloca G, Venturino A, Vitucci P:
Re: Hara et al.: Decline of the red cell blood count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor 1 and erythropoesis. (Urology 2010;75:1441-1445).
Urology
; 2010 Oct;76(4):1020
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Re: Hara et al.: Decline of the red cell blood count in patients receiving androgen deprivation therapy for localized
prostate
cancer
: impact of ADT on insulin-like growth factor 1 and erythropoesis. (Urology 2010;75:1441-1445).
[MeSH-major]
Adenocarcinoma
/ drug therapy. Androgen Antagonists / adverse effects. Anemia / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Erythrocyte Count. Erythropoiesis / drug effects. Insulin-Like Growth Factor I / physiology.
Prostatic
Neoplasms / drug therapy. Receptor, IGF Type 1 / physiology
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Anemia
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
Hazardous Substances Data Bank.
TESTOSTERONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Urology. 2010 Jun;75(6):1441-5
[
20110105.001
]
(PMID = 20932425.001).
[ISSN]
1527-9995
[Journal-full-title]
Urology
[ISO-abbreviation]
Urology
[Language]
eng
[Publication-type]
Comment; Letter
[Publication-country]
United States
[Chemical-registry-number]
0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 3XMK78S47O / Testosterone; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.10.1 / Receptor, IGF Type 1
28.
Li M, Zhang Y, Feurino LW, Wang H, Fisher WE, Brunicardi FC, Chen C, Yao Q:
Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer.
Cancer Sci
; 2008 Apr;99(4):733-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic
cancer
.
Although up-regulation of IL-8 is indicated in many cancers, its function in pancreatic
cancer
has not been well characterized.
In this study we examined the expression of IL-8 on pancreatic
cancer
cells and clinical tissue specimens, and investigated the effect of exogenous IL-8 on gene expression, and signaling in human pancreatic
cancer
cells.
We found that pancreatic
cancer
cells expressed higher amount of IL-8 mRNA than normal human pancreatic ductal epithelium cells.
IL-8 mRNA was also substantially overexpressed in 11 of 14 (79%) clinical pancreatic-
adenocarcinoma
samples compared with that in their surrounding normal tissues.
Exogenous IL-8 up-regulated the expression of vascular endothelial growth factor(165), and neuropilin (NRP)-2 in BxPC-3 cells, one of human pancreatic
cancer
cell lines.
Our studies suggest that IL-8 might be a malignant factor in human pancreatic
cancer
by induction of vascular endothelial growth factor and NRP-2 expression and ERK activation.
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
Hazardous Substances Data Bank.
COBALT, ELEMENTAL
.
Hazardous Substances Data Bank.
COBALTOUS CHLORIDE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Cancer Res. 1999 Nov;5(11):3711-21
[
10589791.001
]
[Cites]
Cancer Biol Ther. 2007 Jul;6(7):1096-100
[
17568185.001
]
[Cites]
Pancreas. 2000 Jul;21(1):52-6
[
10881932.001
]
[Cites]
Am J Pathol. 2000 Nov;157(5):1623-31
[
11073822.001
]
[Cites]
J Interferon Cytokine Res. 2000 Nov;20(11):935-46
[
11096450.001
]
[Cites]
J Interferon Cytokine Res. 2000 Nov;20(11):1023-8
[
11096460.001
]
[Cites]
J Interferon Cytokine Res. 2001 Jul;21(7):529-37
[
11506748.001
]
[Cites]
Cytokine Growth Factor Rev. 2001 Dec;12(4):375-91
[
11544106.001
]
[Cites]
Cancer. 2002 Sep 15;95(6):1206-14
[
12216086.001
]
[Cites]
Int J Oncol. 2003 Apr;22(4):765-71
[
12632066.001
]
[Cites]
Pancreas. 2004 Apr;28(3):344-52
[
15084984.001
]
[Cites]
Ann Surg. 2004 Jun;239(6):763-9; discussion 769-71
[
15166955.001
]
[Cites]
J Biol Chem. 1992 Nov 5;267(31):22506-11
[
1331059.001
]
[Cites]
Eur Cytokine Netw. 1993 Sep-Oct;4(5):351-8
[
8117936.001
]
[Cites]
J Exp Med. 1994 May 1;179(5):1409-15
[
7513008.001
]
[Cites]
Am J Pathol. 1996 Jun;148(6):1763-70
[
8669463.001
]
[Cites]
Am J Pathol. 1997 Oct;151(4):1105-13
[
9327744.001
]
[Cites]
Int J Cancer. 1997 Sep 17;72(6):937-41
[
9378554.001
]
[Cites]
Cancer Immunol Immunother. 1998 Sep;47(1):47-57
[
9755878.001
]
[Cites]
Prostate. 1999 Oct 1;41(2):78-88
[
10477904.001
]
[Cites]
Cancer. 2004 Nov 15;101(10):2341-50
[
15476280.001
]
[Cites]
Cancer. 2004 Dec 15;101(12):2727-36
[
15526319.001
]
[Cites]
Cytokine. 2005 Feb 21;29(4):159-68
[
15652448.001
]
[Cites]
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):440-9
[
15701826.001
]
[Cites]
Int J Cancer. 2005 Aug 20;116(2):275-81
[
15800914.001
]
[Cites]
Cancer Res. 2005 Aug 15;65(16):7214-22
[
16103072.001
]
[Cites]
Nat Med. 2005 Sep;11(9):992-7
[
16127434.001
]
[Cites]
Am J Surg. 2005 Nov;190(5):739-45
[
16226951.001
]
[Cites]
Arch Immunol Ther Exp (Warsz). 2005 Sep-Oct;53(5):381-7
[
16314822.001
]
[Cites]
Int J Oncol. 2006 Apr;28(4):939-46
[
16525644.001
]
[Cites]
Cancer. 2006 May 15;106(10):2284-94
[
16604531.001
]
[Cites]
Cancer Lett. 2006 Sep 28;241(2):221-7
[
16458421.001
]
[Cites]
J Biol Chem. 2007 Mar 2;282(9):6906-15
[
17204468.001
]
[Cites]
Cancer Lett. 2007 Apr 8;248(1):58-67
[
16828224.001
]
[Cites]
J Interferon Cytokine Res. 1999 Dec;19(12):1363-71
[
10638705.001
]
(PMID = 18307536.001).
[ISSN]
1349-7006
[Journal-full-title]
Cancer science
[ISO-abbreviation]
Cancer Sci.
[Language]
ENG
[Grant]
United States / NHLBI NIH HHS / HL / R01 HL083471; United States / NIBIB NIH HHS / EB / R01 EB002436; United States / NHLBI NIH HHS / HL / HL083471-02; United States / NIBIB NIH HHS / EB / EB002436-02; United States / NCCIH NIH HHS / AT / R21 AT003094-01; United States / NHLBI NIH HHS / HL / HL08347; United States / NIDCR NIH HHS / DE / DE015543-02; United States / NIDCR NIH HHS / DE / R01 DE015543; United States / NIDCR NIH HHS / DE / R01 DE015543-02; United States / NIBIB NIH HHS / EB / R01 EB002436-02; United States / NHLBI NIH HHS / HL / R01 HL083471-02; United States / NCCIH NIH HHS / AT / R21 AT003094; United States / NIBIB NIH HHS / EB / EB002436; United States / NCCIH NIH HHS / AT / AT003094-01; United States / NIDCR NIH HHS / DE / R01 DE15543
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Interleukin-8; 0 / Neuropilin-2; 0 / Vascular Endothelial Growth Factor A; 3G0H8C9362 / Cobalt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EVS87XF13W / cobaltous chloride
[Other-IDs]
NLM/ NIHMS228014; NLM/ PMC2930017
29.
Weidle UH, Evtimova V, Alberti S, Guerra E, Fersis N, Kaul S:
Cell growth stimulation by CRASH, an asparaginase-like protein overexpressed in human tumors and metastatic breast cancers.
Anticancer Res
; 2009 Apr;29(4):951-63
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In non-transformed tissues CRASH was only detected in testis, brain, esophagus,
prostate
and proliferating endometrium.
Twenty-eight out of 42 endometrium tumors expressed CRASH at high levels as did 5/41
prostate
carcinomas, as well as ovary and breast cancers, indicating a regulation of CRASH expression by sex hormones.
[MeSH-minor]
Adenocarcinoma
/ metabolism.
Adenocarcinoma
/ secondary. Amino Acid Sequence. Animals. Antibodies, Monoclonal / immunology. Blotting, Western. Carcinoma, Transitional Cell / metabolism. Carcinoma, Transitional Cell / secondary. Cell Line, Tumor. Cystadenocarcinoma / metabolism. Cystadenocarcinoma / secondary. Female. Humans. Immunoenzyme Techniques. Mice. Mice, Inbred BALB C. Molecular Sequence Data. Prognosis. RNA, Small Interfering / pharmacology. Sequence Homology, Amino Acid
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19414332.001).
[ISSN]
0250-7005
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Autoantigens; 0 / RNA, Small Interfering; EC 3.5.1.- / ASRGL1 protein, human; EC 3.5.1.1 / Asparaginase
30.
Jungwirth N, Haeberle L, Schrott KM, Wullich B, Krause FS:
Serotonin used as prognostic marker of urological tumors.
World J Urol
; 2008 Oct;26(5):499-504
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Our study examines the relevance of serum serotonin levels to urinary bladder,
prostate
, renal, and testicular carcinoma when it comes to prognosis and occurrence of these oncological conditions.
MATERIALS AND METHODS: Serotonin levels were obtained in 109 patients presenting with urothelial carcinoma to the urinary bladder,
adenocarcinoma of
the
prostate
and renal cell carcinoma, as well as presenting with seminomatous and non-seminomatous testicular tumors.
In
prostate
carcinoma, serotonin levels showed a tendency with organ exceeding growth, Grading/Gleason Score, PSA values >100 ng/ml, and the presence of distant metastases.
CONCLUSION: Serotonin levels are suitable for prognostic evaluation of urothelial carcinoma in the urinary bladder,
adenocarcinoma of
the
prostate
, and renal cell carcinoma, especially taking into account the lab cost of 25<euro> per test.
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Carcinoma, Renal Cell / blood. Female. Humans. Male. Middle Aged. Prognosis.
Prostatic
Neoplasms / blood. Testicular Neoplasms / blood. Urinary Bladder Neoplasms / blood. Young Adult
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Immunopathol Pharmacol. 2007 Oct-Dec;20(4):765-70
[
18179749.001
]
[Cites]
Urologe A. 2005 Sep;44(9):991-6
[
16049723.001
]
[Cites]
Prostate. 2004 May 15;59(3):328-36
[
15042609.001
]
[Cites]
Nature. 1951 Jun 23;167(4260):1033
[
14843163.001
]
[Cites]
Zentralbl Chir. 1992;117(2):77-80
[
1315472.001
]
[Cites]
Thromb Res. 2000 Jun 1;98(5):367-74
[
10828476.001
]
[Cites]
World J Urol. 2008 Jun;26(3):243-50
[
18392627.001
]
[Cites]
Am J Physiol. 1953 Oct;175(1):157-61
[
13114371.001
]
[Cites]
Int J Urol. 2008 May;15(5):423-8
[
18452460.001
]
[Cites]
J Urol. 2001 Sep;166(3):871-5
[
11490236.001
]
[Cites]
Blood. 1981 Mar;57(3):505-9
[
6161649.001
]
[Cites]
Oncol Rep. 2005 Dec;14(6):1593-7
[
16273262.001
]
[Cites]
J Urol. 2002 Sep;168(3):1204-11
[
12187268.001
]
[Cites]
J Clin Gastroenterol. 2006 Aug;40(7):592-5
[
16917399.001
]
[Cites]
Pathol Res Pract. 2003;199(8):559-63
[
14533941.001
]
[Cites]
J Neurol Sci. 2007 Mar 15;254(1-2):3-8
[
17258772.001
]
[Cites]
Int Urol Nephrol. 2002;34(3):357-60
[
12899227.001
]
[Cites]
J Urol. 2006 Oct;176(4 Pt 1):1648-53
[
16952708.001
]
[Cites]
Prostate. 2006 Aug 1;66(11):1136-43
[
16652383.001
]
[Cites]
Arch Esp Urol. 2007 Apr;60(3):306-9
[
17601310.001
]
[Cites]
Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):33-41
[
17382264.001
]
[Cites]
Urologe A. 2006 Mar;45(3):295-6
[
16482464.001
]
[Cites]
Acta Oncol. 2007;46(6):747-56
[
17653896.001
]
[Cites]
Regul Pept. 2007 Oct 4;143(1-3):39-46
[
17391782.001
]
[Cites]
Urologe A. 2005 Sep;44(9):1024-30
[
16075198.001
]
[Cites]
BJU Int. 2006 Mar;97(3):634-9
[
16469039.001
]
(PMID = 18581119.001).
[ISSN]
0724-4983
[Journal-full-title]
World journal of urology
[ISO-abbreviation]
World J Urol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 333DO1RDJY / Serotonin
31.
Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, Kelly WK:
Second-line chemotherapy for prostate cancer: patient characteristics and survival.
Clin Prostate Cancer
; 2005 Sep;4(2):86-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Second-line chemotherapy for
prostate
cancer
: patient characteristics and survival.
PURPOSE: First-line chemotherapy with docetaxel in patients with progressive castrate metastatic
prostate
cancer
has been shown to improve overall survival compared with mitoxantrone-based therapies.
PATIENTS AND METHODS: Patients with progressive castrate metastatic
prostate
cancer
enrolled on an antimicrotubule-based protocol for treatment were followed to determine their baseline characteristics and outcomes with second- or third-line systemic therapy.
Corresponding
prostate
-specific antigen (PSA) decreases > or = 50% were observed in 72%, 15%, and 22% of patients.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Prostatic
Neoplasms / drug therapy
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16197608.001).
[ISSN]
1540-0352
[Journal-full-title]
Clinical prostate cancer
[ISO-abbreviation]
Clin Prostate Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / K30 CA05826
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / LSM4 protein, S cerevisiae; 0 / Ribonucleoprotein, U4-U6 Small Nuclear; 0 / Saccharomyces cerevisiae Proteins
32.
Tani Y, Suttie A, Flake GP, Nyska A, Maronpot RR:
Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model.
Vet Pathol
; 2005 May;42(3):306-14
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epithelial-stromal tumor of the seminal vesicles in the transgenic
adenocarcinoma
mouse
prostate
model.
The transgenic
adenocarcinoma
mouse
prostate
(TRAMP) model, designed for researching human
prostatic cancer
, was genetically engineered to harbor a transgene composed of the simian virus 40 Large-T/small-t antigen promoted by the rat probasin gene.
In addition to
prostatic
neoplasms, the TRAMP mouse develops tumors in the seminal vesicles.
Some of the larger papillary, polypoid lesions exhibited a phyllodes pattern resembling that seen in mixed epithelial-stromal tumors of the breast,
prostate
, and seminal vesicles of humans.
Our recommended
diagnosis
of this lesion in the seminal vesicles is epithelial-stromal tumor.
Hazardous Substances Data Bank.
BROMODEOXYURIDINE
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15872376.001).
[ISSN]
0300-9858
[Journal-full-title]
Veterinary pathology
[ISO-abbreviation]
Vet. Pathol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Polyomavirus Transforming; 0 / Desmin; G34N38R2N1 / Bromodeoxyuridine
33.
Yamamoto S, Ito T, Aizawa T, Miki M, Furusato M:
The possibility of 'de novo' cancer in the prostate.
Int J Urol
; 2005 Apr;12(4):361-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The possibility of '
de
novo'
cancer
in the
prostate
.
BACKGROUND: To investigate the possibility of '
de
novo'
prostate
cancer
by analyzing the relationship between high grade
prostatic
intraepithelial neoplasia (HGPIN) and latent
prostate
cancer
.
MATERIALS AND METHODS: Latent
prostate
cancers found at autopsy were examined and 55
cancer
foci with a poorly (Gleason grade 4 and 5) or moderately (Gleason grade 3) differentiated component were selected.
High grade intraepithelial neoplasia was defined as positive if it was observed within 2 mm from the edge of
the cancer
focus and the relationship between HGPIN and the two groups was investigated.
RESULTS: The MDG had 39
cancer
foci (71.0%) and there were 16 in the SDG (29.0%).
In the MDG, 13 small-volume
cancer
foci were HGPIN positive, but in the SDG, none of the small-volume cancers were HGPIN positive.
CONCLUSIONS: Small-volume
cancer
foci without HGPIN in the SDG may be candidates for
de
novo
prostate
cancers.
[MeSH-major]
Adenocarcinoma
/ pathology.
Prostatic
Intraepithelial Neoplasia / pathology.
Prostatic
Neoplasms / pathology
[MeSH-minor]
Aged. Aged, 80 and over. Autopsy.
Diagnosis
, Differential. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Severity of Illness Index
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15948722.001).
[ISSN]
0919-8172
[Journal-full-title]
International journal of urology : official journal of the Japanese Urological Association
[ISO-abbreviation]
Int. J. Urol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Australia
34.
Bauduceau O, Vedrine L, Chargari C, Ceccaldi B, Le Moulec S, Houlgatte A:
[Testicular metastasis of prostatic adenocarcinoma: a case report].
Prog Urol
; 2007 Apr;17(2):251-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Testicular metastasis of
prostatic
adenocarcinoma
: a case report].
Metastasis
of prostate adenocarcinoma
to testis is an extremely rare occurrence.
Orchiectomy is necessary to confirm histopathological
diagnosis
.
Metastatic carcinoma of the
prostate
to the testis is a commonly accepted as a sign of disseminated disease.
We report a case of a 62-year-old patient who presented a
prostatic
carcinoma with a testicular metastasis.
[MeSH-major]
Adenocarcinoma
/ secondary.
Prostatic
Neoplasms / pathology. Testicular Neoplasms / secondary
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
MedlinePlus Health Information.
consumer health - Testicular Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17489329.001).
[ISSN]
1166-7087
[Journal-full-title]
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
[ISO-abbreviation]
Prog. Urol.
[Language]
fre
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
France
35.
Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F, Thalman G:
Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer.
Prostate
; 2010 Jun 01;70(8):875-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Evaluation of the frequency of putative
prostate
cancer
stem cells in primary and metastatic
prostate
cancer
.
BACKGROUND: Tumour cells with a stem cell-like phenotype have recently been identified in
prostate
tumors and it has been suggested that this population may be responsible for the diversity of cell types within tumors and also for the initiation of metastases.
In this study we have, for the first time, assessed matched primary and bone marrow biopsies from
prostate
cancer
patients for the distribution of cells carrying these and a number of other putative stem cell markers.
METHODS: Eleven matched (primary and bone metastasis) specimens from
prostate
cancer
patients were assessed for the presence of cd133, cd44, alpha2beta1 integrin, CXCR4, c-met, alpha6 integrin, and nestin using immunohistochemistry and stain intensity and distribution scored.
[MeSH-major]
Adenocarcinoma
/ secondary. Bone Neoplasms / secondary. Neoplastic Stem Cells / cytology.
Prostatic
Neoplasms / pathology
[MeSH-minor]
Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Bone and Bones / metabolism. Bone and Bones / pathology. Cell Count. Humans. Immunohistochemistry. Integrins / metabolism. Intermediate Filament Proteins / metabolism. Male. Nerve Tissue Proteins / metabolism. Nestin.
Prostate
/ metabolism.
Prostate
/ pathology
Genetic Alliance.
consumer health - Prostate cancer
.
Genetic Alliance.
consumer health - Metastatic cancer
.
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20127735.001).
[ISSN]
1097-0045
[Journal-full-title]
The Prostate
[ISO-abbreviation]
Prostate
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / G0900871
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Integrins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
36.
Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O:
Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Virchows Arch
; 2006 Feb;448(2):127-34
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Endoglin (CD105) expression in angiogenesis of colon
cancer
: analysis using tissue microarrays and comparison with other endothelial markers.
Some markers of angiogenic endothelial cells are emerging as targets of
cancer
therapy.
The present study compares the expression of CD105 with that of other endothelial markers in all tissue layers during the development of colon
cancer
.
We examined sections from endoscopic mucosal resection and surgical resection of tubular adenoma (n=31), carcinoma in adenoma (n=11), and
adenocarcinoma
(n=34).
In contrast,
cancer
-associated blood vessels (up to 80%) and
cancer
cells themselves expressed high levels of CD105.
In normal mucosa, CD105 was weakly expressed in endothelial cells of capillaries (< or =21%), and significant differences in its expression in endothelial cells between the normal mucosa and adenoma, carcinoma in adenoma, and
adenocarcinoma
were found.
Flt-1, Flk-1, transforming growth factor-beta1, transforming growth factor-beta receptor II, and CD44 were strongly expressed in
the cancer
cells but were not expressed in the blood vessels.
The present study shows that
de
novo blood vessels of colon
cancer
specifically express CD105.
These findings provide the basis for novel antiangiogenic
cancer
therapies.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Natl Cancer Inst. 1999 Aug 4;91(15):1267-9
[
10433607.001
]
[Cites]
FASEB J. 2003 Jun;17 (9):984-92
[
12773481.001
]
[Cites]
Cancer Res. 1995 Sep 15;55(18):3964-8
[
7664263.001
]
[Cites]
Prostate. 2002 Jun 1;51(4):268-75
[
11987155.001
]
[Cites]
Gastroenterology. 2000 Nov;119(5):1358-72
[
11054395.001
]
[Cites]
J Pathol. 1996 Apr;178(4):363-6
[
8691311.001
]
[Cites]
Oncol Rep. 2002 May-Jun;9(3):617-20
[
11956638.001
]
[Cites]
Cancer. 2004 Jun 15;100(12):2491-9
[
15197790.001
]
[Cites]
Int J Cancer. 1996 Feb 8;65(4):513-8
[
8621236.001
]
[Cites]
Lab Invest. 2002 Sep;82(9):1255-7
[
12218087.001
]
[Cites]
Virchows Arch. 2003 Aug;443(2):115-21
[
12802583.001
]
[Cites]
Hum Pathol. 2004 May;35(5):604-11
[
15138936.001
]
[Cites]
Pathol Int. 2004 Jul;54(7):490-7
[
15189502.001
]
[Cites]
Cancer Biol Ther. 2002 Sep-Oct;1(5):548-53
[
12496487.001
]
[Cites]
Obstet Gynecol. 2000 Aug;96(2):224-8
[
10908767.001
]
[Cites]
Curr Cancer Drug Targets. 2003 Dec;3(6):427-32
[
14683500.001
]
[Cites]
Curr Drug Targets. 2003 May;4(4):291-6
[
12699349.001
]
[Cites]
Hum Pathol. 2004 Feb;35(2):176-83
[
14991534.001
]
[Cites]
Endocrinology. 2004 Jun;145(6):2896-905
[
14988387.001
]
[Cites]
N Engl J Med. 1988 Sep 1;319(9):525-32
[
2841597.001
]
[Cites]
Clin Cancer Res. 1995 Dec;1(12 ):1623-34
[
9815965.001
]
[Cites]
World J Gastroenterol. 2003 Dec;9(12 ):2866-9
[
14669355.001
]
[Cites]
J Histochem Cytochem. 2004 Jan;52(1):87-101
[
14688220.001
]
[Cites]
Int J Cancer. 1993 May 28;54(3):363-70
[
8509210.001
]
[Cites]
Br J Cancer. 2003 May 6;88(9):1424-31
[
12778073.001
]
[Cites]
Anticancer Res. 1997 Sep-Oct;17(5B):3743-6
[
9427772.001
]
[Cites]
Oncogene. 2003 Sep 29;22(42):6557-63
[
14528280.001
]
[Cites]
Surgery. 2002 Jan;131(1 Suppl):S109-13
[
11821796.001
]
[Cites]
Microsc Res Tech. 2001 Feb 15;52(4):437-49
[
11170303.001
]
(PMID = 16177881.001).
[ISSN]
0945-6317
[Journal-full-title]
Virchows Archiv : an international journal of pathology
[ISO-abbreviation]
Virchows Arch.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antigens, CD; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Endoglin; 0 / Receptors, Cell Surface
37.
Kim SY, Song SY, Kim MS, Lee JY, Lee HM, Choi HY, Yoo NJ, Lee SH:
Immunohistochemical analysis of Fas and FLIP in prostate cancers.
APMIS
; 2009 Jan;117(1):28-33
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunohistochemical analysis of Fas and FLIP in
prostate
cancers.
Fas-mediated apoptosis is considered a principal pathway for apoptosis induction in normal and
cancer
cells.
Expression of Fas has been reported in
prostate
tissues several times, but the data were not consistent.
Expression of FLICE-like inhibitory protein (FLIP), an inhibitor of Fas-mediated apoptosis, has not been studied by immunohistochemistry in
prostate
tissues.
The aim of this study is to explore whether alterations of Fas and FLIP expression occur in
prostate
cancer
tissues.
We analyzed the expression of Fas and FLIP in 107
prostate adenocarcinoma
tissues by immunohistochemistry using a tissue microarray approach.
Prostate
intraepithelial neoplasm also showed a strong Fas immunoreactivity.
The decreased expression of Fas in a large fraction
of prostate
cancers compared with their normal cells suggested that loss of Fas expression might play a role in tumorigenesis in some
prostate
cancers possibly by inhibiting apoptosis mediated by Fas.
[MeSH-major]
Adenocarcinoma
/ metabolism. Antigens, CD95 / metabolism. CASP8 and FADD-Like Apoptosis Regulating Protein / metabolism.
Prostate
/ metabolism.
Prostatic
Neoplasms / metabolism
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19161534.001).
[ISSN]
1600-0463
[Journal-full-title]
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
[ISO-abbreviation]
APMIS
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Antigens, CD95; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein
38.
Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF, Mineva ND, Kaplan-Lefko PJ, Foster BA, Cook BP, Dufault MR, Cao X, Wang CJ, Teicher BA, Klinger KW, Greenberg NM, Madden SL:
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
Prostate
; 2007 Jan 1;67(1):83-106
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse
prostate
cancer
model.
BACKGROUND: A major focus
of prostate
cancer
research has been to identify genes that are deregulated during tumor progression, potentially providing diagnostic markers and therapeutic targets.
METHODS: We have employed serial analysis of gene expression (SAGE) and microarray hybridization to identify alterations that occur during malignant transformation in the Transgenic
Adenocarcinoma of
the Mouse
Prostate
(TRAMP) model.
CONCLUSIONS: Our analyses identified well-characterized genes that were previously known to be involved in
prostate
cancer
, validating our study, and also uncovered transcripts that had not previously been implicated in
prostate
cancer
progression.
[MeSH-major]
Adenocarcinoma
/ genetics. Androgens / genetics. Disease Models, Animal. Gene Expression Profiling. Genes, Neoplasm / physiology. Genetic Engineering / methods. Oligonucleotide Array Sequence Analysis.
Prostatic
Neoplasms / genetics
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2006 Wiley-Liss, Inc.
(PMID = 17013881.001).
[ISSN]
1097-0045
[Journal-full-title]
The Prostate
[ISO-abbreviation]
Prostate
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA73747; United States / NCI NIH HHS / CA / CA84296
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Validation Studies
[Publication-country]
United States
[Chemical-registry-number]
0 / Androgens
39.
Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD:
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
PLoS Med
; 2006 Dec;3(12):e486
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A genome-wide screen for promoter methylation in lung
cancer
identifies novel methylation markers for multiple malignancies.
However, DNA methylation markers that are highly specific and sensitive for common tumors would be useful for the early detection of
cancer
, and those required for the malignant phenotype would identify pathways important as therapeutic targets.
METHODS AND FINDINGS: In an effort to identify new
cancer
-specific methylation markers, we employed a high-throughput global expression profiling approach in lung
cancer
cells.
We identified 132 genes that have 5' CpG islands, are induced from undetectable levels by 5-aza-2'-deoxycytidine in multiple non-small cell lung
cancer
cell lines, and are expressed in immortalized human bronchial epithelial cells.
Methylation analysis of a subset (45/132) of these promoter regions in primary lung
cancer
(n = 20) and adjacent nonmalignant tissue (n = 20) showed that 31 genes had acquired methylation in the tumors, but did not show methylation in normal lung or peripheral blood cells.
We studied the eight most frequently and specifically methylated genes from our lung
cancer
dataset in breast
cancer
(n = 37), colon
cancer
(n = 24), and
prostate
cancer
(n = 24) along with counterpart nonmalignant tissues.
CONCLUSIONS: By using a systematic biological screen we identified multiple genes that are methylated with high penetrance in primary lung, breast, colon, and
prostate
cancers.
Genetic Alliance.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
AZACITIDINE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 1995 Jan 15;55(2):220-3
[
7812947.001
]
[Cites]
Cancer. 1995 May 1;75(9):2400-1
[
7712451.001
]
[Cites]
Cancer Res. 1995 Oct 1;55(19):4268-72
[
7671234.001
]
[Cites]
Int J Cancer. 2006 Feb 15;118(4):924-31
[
16108009.001
]
[Cites]
Cancer Res. 2006 Feb 15;66(4):2116-28
[
16489012.001
]
[Cites]
Nat Rev Cancer. 2006 Feb;6(2):107-16
[
16491070.001
]
[Cites]
Cell. 2006 Apr 21;125(2):315-26
[
16630819.001
]
[Cites]
Cancer Lett. 2007 Mar 8;247(1):56-71
[
16644104.001
]
[Cites]
Nat Med. 1995 Jul;1(7):686-92
[
7585152.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6
[
8790415.001
]
[Cites]
J Cell Biochem Suppl. 1996;24:32-91
[
8806092.001
]
[Cites]
Nat Genet. 2000 Feb;24(2):132-8
[
10655057.001
]
[Cites]
J Natl Cancer Inst. 2000 Apr 5;92(7):564-9
[
10749912.001
]
[Cites]
Nature. 2000 Aug 17;406(6797):747-52
[
10963602.001
]
[Cites]
Cancer Res. 2001 Jan 1;61(1):249-55
[
11196170.001
]
[Cites]
Int J Cancer. 1998 Dec 9;78(6):766-74
[
9833771.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
[
9843981.001
]
[Cites]
Nat Genet. 1999 Sep;23(1):41-6
[
10471496.001
]
[Cites]
Cancer Res. 2004 Dec 15;64(24):9027-34
[
15604268.001
]
[Cites]
Clin Cancer Res. 2004 Dec 15;10(24):8472-8
[
15623627.001
]
[Cites]
Clin Cancer Res. 2005 Jan 1;11(1):166-72
[
15671542.001
]
[Cites]
J Natl Cancer Inst. 2005 Feb 16;97(4):273-82
[
15713962.001
]
[Cites]
Clin Cancer Res. 2005 May 15;11(10):3654-60
[
15897561.001
]
[Cites]
Nat Rev Cancer. 2005 Aug;5(8):615-25
[
16034368.001
]
[Cites]
Cancer Cell. 2005 Oct;8(4):275-85
[
16226703.001
]
[Cites]
Int J Cancer. 2005 Dec 10;117(5):738-45
[
15981206.001
]
[Cites]
Bioinformatics. 2005 Nov 1;21(21):4067-8
[
16141249.001
]
[Cites]
Nat Rev Genet. 2006 Jan;7(1):21-33
[
16369569.001
]
[Cites]
Nat Chem Biol. 2005 Sep;1(4):216-22
[
16408038.001
]
[Cites]
Cancer Res. 2006 Jan 15;66(2):653-8
[
16423993.001
]
[Cites]
Cancer Res. 2006 Jan 15;66(2):1208-17
[
16424060.001
]
[Cites]
Nat Genet. 2006 Feb;38(2):149-53
[
16444255.001
]
[Cites]
Cancer Res. 2001 Apr 1;61(7):3105-9
[
11306494.001
]
[Cites]
Cancer Res. 2001 Apr 15;61(8):3225-9
[
11309270.001
]
[Cites]
J Natl Cancer Inst. 2001 May 2;93(9):691-9
[
11333291.001
]
[Cites]
Hum Mol Genet. 2001 Dec 15;10(26):3001-7
[
11751682.001
]
[Cites]
Clin Cancer Res. 2002 Feb;8(2):514-9
[
11839671.001
]
[Cites]
Nat Genet. 2002 Jun;31(2):141-9
[
11992124.001
]
[Cites]
Nat Rev Genet. 2002 Jun;3(6):415-28
[
12042769.001
]
[Cites]
Oncogene. 2002 Jul 18;21(31):4822-9
[
12101420.001
]
[Cites]
Genet Epidemiol. 2002 Jun;23(1):70-86
[
12112249.001
]
[Cites]
Bioinformatics. 2002 Nov;18(11):1427-31
[
12424112.001
]
[Cites]
Bioinformatics. 2003 Jan 22;19(2):185-93
[
12538238.001
]
[Cites]
Nucleic Acids Res. 2003 Feb 15;31(4):e15
[
12582260.001
]
[Cites]
Nat Genet. 2003 Mar;33 Suppl:245-54
[
12610534.001
]
[Cites]
Cancer Res. 2003 Mar 1;63(5):1114-21
[
12615730.001
]
[Cites]
Cancer Res. 2003 Apr 1;63(7):1596-601
[
12670910.001
]
[Cites]
Ann N Y Acad Sci. 2003 Mar;983:22-7
[
12724209.001
]
[Cites]
Genome Biol. 2003;4(5):P3
[
12734009.001
]
[Cites]
Cancer Res. 2003 Jul 1;63(13):3735-42
[
12839967.001
]
[Cites]
Nat Rev Cancer. 2004 Feb;4(2):143-53
[
14732866.001
]
[Cites]
Clin Cancer Res. 2004 May 1;10(9):3104-9
[
15131050.001
]
[Cites]
Cancer Res. 2004 May 15;64(10):3465-73
[
15150099.001
]
[Cites]
Cell. 2004 Jun 25;117(7):927-39
[
15210113.001
]
[Cites]
Hum Mol Genet. 2004 Sep 1;13(17):1969-78
[
15254011.001
]
[Cites]
J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19
[
15316056.001
]
[Cites]
Cancer Res. 2004 Sep 1;64(17):5982-7
[
15342377.001
]
[Cites]
Nat Rev Cancer. 2004 Sep;4(9):707-17
[
15343277.001
]
[Cites]
Cancer Res. 2004 Sep 15;64(18):6410-5
[
15374948.001
]
[Cites]
Oncogene. 2004 Oct 7;23(46):7669-78
[
15361840.001
]
[Cites]
Science. 1991 Jul 5;253(5015):49-53
[
1905840.001
]
[Cites]
Oncogene. 1992 Jan;7(1):171-80
[
1311061.001
]
[Cites]
Nucleic Acids Res. 1994 Aug 11;22(15):2990-7
[
8065911.001
]
[Cites]
Genes Chromosomes Cancer. 1994 Jul;10(3):183-9
[
7522041.001
]
[Cites]
Science. 1994 Dec 23;266(5193):2011-5
[
7605428.001
]
[Cites]
Cancer Res. 1995 Jan 1;55(1):28-30
[
7805035.001
]
[CommentIn]
PLoS Med. 2006 Dec;3(12):e479
[
17194184.001
]
(PMID = 17194187.001).
[ISSN]
1549-1676
[Journal-full-title]
PLoS medicine
[ISO-abbreviation]
PLoS Med.
[Language]
ENG
[Databank-accession-numbers]
GEO/ GSE5816
[Grant]
United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / U01 CA084971; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / U01CA84971
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / CCNA1 protein, human; 0 / Cyclin A; 0 / Cyclin A1; 0 / DNA-Binding Proteins; 0 / MSX1 Transcription Factor; 0 / MSX1 protein, human; 0 / Transcription Factors; 148814-46-4 / BNC1 protein, human; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K; M801H13NRU / Azacitidine
[Other-IDs]
NLM/ PMC1716188
40.
Krambeck AE, DiMarco DS, Rangel LJ, Bergstralh EJ, Myers RP, Blute ML, Gettman MT:
Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques.
BJU Int
; 2009 Feb;103(4):448-53
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Radical prostatectomy for
prostatic
adenocarcinoma
: a matched comparison of open retropubic and robot-assisted techniques.
PATIENTS AND METHODS: From August 2002 to December 2005 we identified 294 patients undergoing RARP for clinically localized
prostate
cancer
.
A comparison RRP group of 588 patients from the same period was matched 2:1 for surgical year, age, preoperative
prostate
-specific antigen level, clinical stage and biopsy Gleason grade.
[MeSH-major]
Adenocarcinoma
/ surgery. Intraoperative Complications / etiology. Postoperative Complications / etiology. Prostatectomy / methods.
Prostatic
Neoplasms / surgery. Robotics
MedlinePlus Health Information.
consumer health - After Surgery
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18778350.001).
[ISSN]
1464-410X
[Journal-full-title]
BJU international
[ISO-abbreviation]
BJU Int.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
41.
Bono AV, Pannellini T, Liberatore M, Montironi R, Cunico SC, Cheng L, Sasso F, Musiani P, Iezzi M:
Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
Anal Quant Cytol Histol
; 2010 Jun;32(3):136-45
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Sorafenib's inhibition
of prostate
cancer
growth in transgenic
adenocarcinoma
mouse
prostate
mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
OBJECTIVE: To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade
prostate
intraepithelial neoplasia (HGPIN) into
adenocarcinoma
(ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic
adenocarcinoma
mouse
prostate
(TRAMP) mice.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
Hazardous Substances Data Bank.
NICOTINAMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20701066.001).
[ISSN]
0884-6812
[Journal-full-title]
Analytical and quantitative cytology and histology
[ISO-abbreviation]
Anal. Quant. Cytol. Histol.
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
42.
Hill R, Song Y, Cardiff RD, Van Dyke T:
Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis.
Cell
; 2005 Dec 16;123(6):1001-11
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Our understanding of
cancer
has largely come from the analysis of aberrations within the tumor cell population.
We demonstrate that this indeed occurs in a mouse model
of prostate
cancer
where epithelial cell cycle disruption via cell-specific inhibition of pRb function induces a paracrine p53 response that suppresses fibroblast proliferation in associated stroma.
[MeSH-minor]
Actins / analysis.
Adenocarcinoma
/ genetics.
Adenocarcinoma
/ metabolism.
Adenocarcinoma
/ pathology. Animals. Antigens, Polyomavirus Transforming / genetics. Cell Proliferation. Connective Tissue / pathology. Disease Models, Animal. Gene Deletion. Genotype. Keratin-8. Keratins / analysis. Loss of Heterozygosity / genetics. Male. Mice. Mice, Knockout. Mice, Transgenic. Models, Biological. Paracrine Communication.
Prostate
/ metabolism.
Prostate
/ pathology.
Prostatic
Neoplasms / genetics.
Prostatic
Neoplasms / metabolism.
Prostatic
Neoplasms / pathology. Retinoblastoma Protein / metabolism. S100 Proteins / analysis
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Cell. 2005 Dec 16;123(6):985-7
[
16360028.001
]
(PMID = 16360031.001).
[ISSN]
0092-8674
[Journal-full-title]
Cell
[ISO-abbreviation]
Cell
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01-CA046283; United States / NCI NIH HHS / CA / U01-CA84294
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Actins; 0 / Antigens, Polyomavirus Transforming; 0 / Keratin-8; 0 / Krt8 protein, mouse; 0 / Retinoblastoma Protein; 0 / S100 Proteins; 0 / S100a4 protein, mouse; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins
43.
Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, Hayward SW, Wills ML, Logan SK, Zhang P, Matusik RJ:
Down-regulation of p57Kip2 induces prostate cancer in the mouse.
Cancer Res
; 2008 May 15;68(10):3601-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Down-regulation of p57Kip2 induces
prostate
cancer
in the mouse.
However, little is known about the role of p57(Kip2) in tumorigenesis and
cancer
progression.
Here, we show that the expression of p57(Kip2) is significantly decreased in human
prostate
cancer
, and the overexpression of p57(Kip2) in
prostate
cancer
cells significantly suppressed cell proliferation and reduced invasive ability.
In addition, overexpression of p57(Kip2) in LNCaP cells inhibited tumor formation in nude mice, resulting in well-differentiated squamous tumors rather than
adenocarcinoma
.
Furthermore, the prostates of p57(Kip2) knockout mice developed
prostatic
intraepithelial neoplasia and
adenocarcinoma
.
Remarkably, this mouse
prostate
cancer
is pathologically identical to human
prostate adenocarcinoma
.
Therefore, these results strongly suggest that p57(Kip2) is an important gene in
prostate
cancer
tumorigenesis, and the p57(Kip2) pathway may be a potential target for
prostate
cancer
prevention and therapy.
[MeSH-major]
Cyclin-Dependent Kinase Inhibitor p57 / biosynthesis. Down-Regulation. Gene Expression Regulation, Neoplastic.
Prostatic
Neoplasms / metabolism
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18483241.001).
[ISSN]
1538-7445
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01-CA116097; United States / NCI NIH HHS / CA / R01-CA76142
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cdkn1c protein, mouse; 0 / Cyclin D; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / Cyclins; 0 / Retinoblastoma Protein; EC 2.7.11.22 / Cdk2 protein, mouse; EC 2.7.11.22 / Cdk4 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
44.
Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, Bostwick DG:
The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Urology
; 2005 Jan;65(1):76-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative
cancer
volume in human
prostate
.
OBJECTIVES: To perform the first evaluation of the effects of the 5-alpha-reductase inhibitor class of drugs on
cancer
histopathologic features at radical prostatectomy in a placebo-controlled multicenter trial.
The histopathologic features of benign epithelium, high-grade
prostatic
intraepithelial neoplasia, and
cancer
were recorded, and the treatment effect was scored.
Digital imaging analysis was used to measure the stroma/epithelium ratio and epithelial height, as well as the nuclear area in
cancer
.
In
cancer
tissue, the tumor volume was significantly lower in the dutasteride-treated men than in the placebo-treated men (mean 15% versus 24%, respectively, P = 0.025), the percentage of atrophic epithelium was increased (P = 0.041), and the stroma/
gland
ratio was doubled (P = 0.046).
CONCLUSIONS: After short-term dutasteride treatment, benign epithelium showed involution and epithelial shrinkage, and
prostate
cancer
tissue demonstrated a decrease in epithelium relative to stroma.
These findings indicate that dutasteride induces significant phenotypic alterations in both the benign and the neoplastic
prostate
, supportive of a chemopreventive or chemoactive role.
[MeSH-major]
5-alpha Reductase Inhibitors.
Adenocarcinoma
/ drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Azasteroids / therapeutic use. Neoplasm Proteins / antagonists & inhibitors.
Prostate
/ drug effects.
Prostatic
Neoplasms / drug therapy
[MeSH-minor]
Aged. Atrophy. Combined Modality Therapy. Double-Blind Method. Dutasteride. Epithelial Cells / drug effects. Epithelial Cells / pathology. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Neoadjuvant Therapy. Pilot Projects. Prostatectomy.
Prostatic
Intraepithelial Neoplasia / drug therapy.
Prostatic
Intraepithelial Neoplasia / enzymology.
Prostatic
Intraepithelial Neoplasia / pathology.
Prostatic
Intraepithelial Neoplasia / surgery. Stromal Cells / drug effects. Stromal Cells / pathology
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15667867.001).
[ISSN]
1527-9995
[Journal-full-title]
Urology
[ISO-abbreviation]
Urology
[Language]
eng
[Publication-type]
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
[Publication-country]
United States
[Chemical-registry-number]
0 / 5-alpha Reductase Inhibitors; 0 / Antineoplastic Agents, Hormonal; 0 / Azasteroids; 0 / Neoplasm Proteins; O0J6XJN02I / Dutasteride
45.
Kirschner-Hermanns R, Borchers H, Reineke T, Willis S, Jakse G:
Fecal incontinence after radical perineal prostatectomy: a prospective study.
Urology
; 2005 Feb;65(2):337-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
All patients had undergone extrafascial perineal prostatectomy for Stage cT1-cT3N0M0
prostate
cancer
.
[MeSH-minor]
Adenocarcinoma
/ complications.
Adenocarcinoma
/ radiotherapy.
Adenocarcinoma
/ surgery. Aged. Anal Canal / innervation. Anal Canal / physiopathology. Humans. Incidence. Male. Middle Aged. Perineum / surgery. Prospective Studies.
Prostatic
Neoplasms / complications.
Prostatic
Neoplasms / radiotherapy.
Prostatic
Neoplasms / surgery. Radiotherapy, Adjuvant. Surveys and Questionnaires
Genetic Alliance.
consumer health - Incontinence
.
MedlinePlus Health Information.
consumer health - After Surgery
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15708049.001).
[ISSN]
1527-9995
[Journal-full-title]
Urology
[ISO-abbreviation]
Urology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
46.
Tappel A:
Lysosomal and prostasomal hydrolytic enzymes and redox processes and initiation of prostate cancer.
Med Hypotheses
; 2005;64(6):1170-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lysosomal and prostasomal hydrolytic enzymes and redox processes and initiation
of prostate
cancer
.
Lysosomes, lysosomal enzymes and oxidant processes are known to be involved in
cancer
processes.
However, integrated biochemical and cell biology studies are necessary to understand how lysosomal enzymes and prostasomal enzymes combined with oxidant processes could initiate
cancer
.
Most
prostate
cancer
is likely to be initiated in the
prostate
duct system.
The lysosomal enzymes acid phosphatase and glucosidase and prostasomal proteins and enzymes are found in human semen and therefore have come through
prostate
ducts.
The hypothesis presented here is that the lysosomal enzymes and prostasomes are exocytosed from
prostate
cells into the duct system of the
prostate
where their hydrolytic enzymes and oxidative processes, for example, the iron from the iron-sulfur clusters of the prostasomal dehydrogenases, damage proteins and other components of cells leading to the initiation of
cancer
.
Risk factors for
prostate
cancer
are known to initiate activity of lysosomal enzymes and could initiate activity of prostasomal enzymes.
Other dietary components in fruits and vegetables protect against
prostate
cancer
and can be hypothesized as decreasing cellular output of lysosomal or protasomal enzymes or inhibiting lysosomal and prostasomal enzymes in the duct system.
Measurements of multiple lysosomal and prostasomal enzyme activities and their biochemical pathways are vital to the understanding of protectors to inhibit lysosomal or prostasomal enzyme activities that might be leading to
prostate
cancer
.
Lysosomal enzyme activities may be precursors to the onset of other kinds of
cancer
with other similar non-invasive screening techniques possible.
This overall hypothesis suggests protection against
prostate
cancer
by inhibitors of lipid peroxidation including the dietary antioxidants selenium, vitamin E and lycopene and also cysteine glutathione.
[MeSH-major]
Adenocarcinoma
/ etiology. Cell Transformation, Neoplastic / metabolism. Lysosomes / enzymology. Models, Biological.
Prostatic
Neoplasms / etiology
[MeSH-minor]
Animals. Anticarcinogenic Agents / therapeutic use. Antioxidants / therapeutic use. Cocarcinogenesis. Diet. Enzyme Activation. Enzyme Inhibitors / therapeutic use. Exocytosis. Humans. Hydrolysis. Lipid Peroxidation. Male. Organelles / enzymology. Oxidation-Reduction.
Prostate
/ ultrastructure. Risk Factors
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15823710.001).
[ISSN]
0306-9877
[Journal-full-title]
Medical hypotheses
[ISO-abbreviation]
Med. Hypotheses
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Scotland
[Chemical-registry-number]
0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Enzyme Inhibitors
47.
Cibull TL, Jones TD, Li L, Eble JN, Ann Baldridge L, Malott SR, Luo Y, Cheng L:
Overexpression of Pim-1 during progression of prostatic adenocarcinoma.
J Clin Pathol
; 2006 Mar;59(3):285-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Overexpression of Pim-1 during progression of
prostatic
adenocarcinoma
.
Recently, evidence has shown Pim-1 to be important in
prostatic
carcinogenesis.
In order to further our understanding of its role in
prostate
cancer
, we investigated Pim-1 expression in normal, premalignant, and malignant
prostate
tissue.
METHODS: Using immunohistochemistry, Pim-1 expression was analysed in
prostate
tissue from 120 radical prostatectomy specimens.
In each case, Pim-1 staining was evaluated in benign
prostatic
epithelium, high grade
prostatic
intraepithelial neoplasia (PIN), and
prostatic
adenocarcinoma
.
RESULTS: Pim-1 immunoreactivity was identified in 120 cases (100%)
of adenocarcinoma
, 120 cases (100%) of high grade PIN, and 62 cases (52%) of benign glands.
The number of cells staining in benign epithelium (mean 34%) was much lower than that in high grade PIN (mean 80%; p<0.0001) or
adenocarcinoma
(mean, 84%; p<0.0001).
There was no significant difference between high grade PIN and
adenocarcinoma
in the percentage of cells staining positively for Pim-1 (p = 0.34).
The staining intensity for Pim-1 was significantly lower in benign
prostatic
epithelium than in PIN and
adenocarcinoma
(p<0.001).
CONCLUSIONS: Pim-1 expression is elevated in PIN and
prostatic
adenocarcinoma
compared with benign
prostatic
epithelium.
This finding suggests that upregulation of Pim-1 may play a role in
prostatic
neoplasia.
[MeSH-major]
Adenocarcinoma
/ chemistry. Biomarkers, Tumor / analysis.
Prostatic
Neoplasms / chemistry. Proto-Oncogene Proteins c-pim-1 / analysis
[MeSH-minor]
Aged. Analysis of Variance. Disease Progression. Humans. Male. Middle Aged. Neoplasm Staging. Prostatectomy.
Prostatic
Hyperplasia / metabolism.
Prostatic
Hyperplasia / surgery.
Prostatic
Intraepithelial Neoplasia / chemistry.
Prostatic
Intraepithelial Neoplasia / surgery. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Cell. 2003 Sep;4(3):223-38
[
14522256.001
]
[Cites]
Lab Invest. 2003 Sep;83(9):1301-9
[
13679438.001
]
[Cites]
Cancer Res. 2003 Dec 1;63(23):8079-84
[
14678956.001
]
[Cites]
Blood. 2004 May 15;103(10):3744-50
[
14764533.001
]
[Cites]
Clin Cancer Res. 2004 May 1;10(9):3064-8
[
15131044.001
]
[Cites]
Cancer. 2004 Jun 1;100(11):2362-6
[
15160339.001
]
[Cites]
J Urol. 1974 Jan;111(1):58-64
[
4813554.001
]
[Cites]
J Biol Chem. 1999 Jun 25;274(26):18659-66
[
10373478.001
]
[Cites]
Oncogene. 1999 Jul 8;18(27):4022-31
[
10435626.001
]
[Cites]
J Urol. 2000 Jun;163(6):1751-5
[
10799175.001
]
[Cites]
Int Immunol. 2000 Oct;12(10):1389-96
[
11007756.001
]
[Cites]
Nature. 2001 Aug 23;412(6849):822-6
[
11518967.001
]
[Cites]
J Immunol. 2002 Feb 15;168(4):1524-7
[
11823475.001
]
[Cites]
Am J Pathol. 2002 Feb;160(2):667-71
[
11839587.001
]
[Cites]
Nat Genet. 2002 Sep;32(1):153-9
[
12185366.001
]
[Cites]
Oncogene Res. 1987 Jun;1(1):87-101
[
3329711.001
]
[Cites]
Mol Cell Biol. 1988 Apr;8(4):1498-503
[
2837645.001
]
[Cites]
J Urol. 1991 Feb;145(2):324-8; discussion 328-9
[
1988723.001
]
[Cites]
EMBO J. 1991 Mar;10(3):655-64
[
1825810.001
]
[Cites]
Cancer Res. 1991 May 1;51(9):2486-9
[
1826633.001
]
[Cites]
Am J Pathol. 1996 May;148(5):1375-80
[
8623909.001
]
[Cites]
Arch Biochem Biophys. 1996 Jun 15;330(2):259-65
[
8660654.001
]
[Cites]
Oncogene. 1997 Sep 18;15(12):1471-80
[
9333023.001
]
[Cites]
Cell Growth Differ. 1997 Dec;8(12):1371-80
[
9419425.001
]
[Cites]
J Natl Cancer Inst. 1998 Feb 4;90(3):233-7
[
9462681.001
]
[Cites]
EMBO J. 1998 Sep 15;17(18):5349-59
[
9736613.001
]
[Cites]
Mol Cell. 1998 Oct;2(4):417-25
[
9809063.001
]
[Cites]
J Vet Sci. 2001 Dec;2(3):167-79
[
12441685.001
]
[Cites]
Am J Pathol. 2003 Dec;163(6):2271-6
[
14633601.001
]
(PMID = 16505280.001).
[ISSN]
0021-9746
[Journal-full-title]
Journal of clinical pathology
[ISO-abbreviation]
J. Clin. Pathol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 2.7.11.1 / Proto-Oncogene Proteins c-pim-1
[Other-IDs]
NLM/ PMC1860332
48.
Ghadjar P, Keller T, Rentsch CA, Isaak B, Behrensmeier F, Stroux A, Thalmann GN, Aebersold DM:
Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.
Brachytherapy
; 2009 Jan-Mar;8(1):45-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Toxicity and early treatment outcomes in low- and intermediate-risk
prostate
cancer
managed by high-dose-rate brachytherapy as a monotherapy.
METHODS AND MATERIALS: Between October 2003 and June 2006, 36 patients with low (28) and intermediate (8) risk
prostate
cancer
(PCA) were treated by HDR-B monotherapy.
[MeSH-major]
Adenocarcinoma
/ radiotherapy. Brachytherapy / adverse effects. Iridium Radioisotopes / adverse effects.
Prostatic
Neoplasms / radiotherapy. Urethra / radiation effects
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19038584.001).
[ISSN]
1538-4721
[Journal-full-title]
Brachytherapy
[ISO-abbreviation]
Brachytherapy
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Iridium Radioisotopes
49.
Ogawa K, Nakamura K, Onishi H, Koizumi M, Sasaki T, Araya M, Miyabe Y, Otani Y, Teshima T, Japanese Patterns of Care Study Working Subgroup of Prostate Cancer:
Influence of age on the pattern and outcome of external beam radiotherapy for clinically localized prostate cancer.
Anticancer Res
; 2006 Mar-Apr;26(2B):1319-25
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Influence of age on the pattern and outcome of external beam radiotherapy for clinically localized
prostate
cancer
.
BACKGROUND: The influence of age on the patterns and outcomes of external beam radiotherapy for clinically localized
prostate
cancer
patients was examined.
CONCLUSION: Age did not influence the disease characteristics, patterns of external beam radiotherapy, survival and late toxicities for clinically localized
prostate
cancer
patients.
[MeSH-major]
Adenocarcinoma
/ radiotherapy.
Prostatic
Neoplasms / radiotherapy
[MeSH-minor]
Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Combined Modality Therapy. Dose-Response Relationship, Radiation. Humans. Male. Middle Aged. Neoplasm Staging.
Prostate
-Specific Antigen / blood. Radiotherapy, Conformal / adverse effects. Retrospective Studies. Treatment Outcome
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16619540.001).
[ISSN]
0250-7005
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Antineoplastic Agents, Hormonal; EC 3.4.21.77 / Prostate-Specific Antigen
50.
Patel AR, Jones JS, Zhou M, Schoenfield L, Magi-Galluzzi C:
Parasagittal biopsies are more important as part of an initial biopsy strategy than as part of a repeat biopsy strategy: observations from a unique population.
Prostate Cancer Prostatic Dis
; 2007;10(4):352-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Comparing the yield of parasagittal biopsies during initial saturation biopsy to the yield during repeat saturation biopsy for detection
of prostate
cancer
.
Office-based saturation biopsy (24 cores) with periprostatic lidocaine block was performed in 139 consecutive men who had never previously undergone
prostate
biopsy.
Indication for biopsy was elevated
prostate
-specific antigen >2.5 ng/dl.
Subanalysis of patients from this unique study was performed to compare the location of saturation biopsy
cancer
detection in these patients to a cohort of 100 patients who had previously undergone biopsy with nonmalignant findings.
In the initial biopsy group,
cancer
was detected in 62/139 patients (44.6%).
Breakdown of
cancer
location demonstrated unique parasagittal cancers in 9/62 patients (14.5%).
Laterally base
cancer
was found exclusively in 22/62 patients (35.5%).
For the repeat biopsy population,
cancer
was found in 25 patients (25%); no patients (0%) had exclusive parasagittal
cancer
.
The exclusive parasagittal
cancer
detection rate decreases significantly in the repeat biopsy population when using the same biopsy method.
Our findings support including traditional template parasagittal sampling of the
prostate
on first-time biopsy in addition to lateral cores typical of extended field biopsies for a total of 10-12 cores.
[MeSH-major]
Adenocarcinoma
/ pathology.
Prostate
/ pathology.
Prostatic
Neoplasms / pathology
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Biopsy. Cohort Studies. Early
Diagnosis
. Humans. Male. Middle Aged. Prospective Studies
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17420763.001).
[ISSN]
1476-5608
[Journal-full-title]
Prostate cancer and prostatic diseases
[ISO-abbreviation]
Prostate Cancer Prostatic Dis.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
51.
Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Church T, Yurgalevitch S, Austin JH, Prorok PC, Gohagan JK, PLCO Project Team:
Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial.
J Natl Cancer Inst
; 2005 Jul 6;97(13):989-97
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Flexible sigmoidoscopy in the PLCO
cancer
screening trial: results from the baseline screening examination of a randomized trial.
BACKGROUND: The
Prostate
, Lung, Colorectal and Ovarian (PLCO)
cancer
screening trial is a randomized clinical trial to test the effectiveness of
cancer
screening, including the effect of flexible sigmoidoscopy screening on colorectal
cancer
mortality.
The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal
cancer
, 1.1-2.5 in women and 2.4-5.6 in men; for advanced adenoma, 18.0-30.4 in women and 36.1-49.1 in men; and for colorectal
cancer
or any adenoma, 50.6-79.6 in women and 101.9-128.6 in men.
Approximately 77% (130/169) of the colorectal
adenocarcinoma
patients were stage I or II at
diagnosis
.
Diagnostic follow-up varied according to polyp size, yet
cancer
or adenoma detection rates met expectations.
[MeSH-major]
Colorectal Neoplasms /
diagnosis
. Colorectal Neoplasms / mortality. Mass Screening / methods. Sigmoidoscopy
[MeSH-minor]
Adenoma /
diagnosis
. Adenoma / mortality. Age Distribution. Aged. Carcinoma /
diagnosis
. Carcinoma / mortality. Colonic Polyps /
diagnosis
. Colonic Polyps / mortality. Female. Humans. Male. Middle Aged. Sex Distribution. Surveys and Questionnaires. United States / epidemiology
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15998952.001).
[ISSN]
1460-2105
[Journal-full-title]
Journal of the National Cancer Institute
[ISO-abbreviation]
J. Natl. Cancer Inst.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
52.
Destombe C, Botton E, Le Gal G, Roudaut A, Jousse-Joulin S, Devauchelle-Pensec V, Saraux A:
Investigations for bone metastasis from an unknown primary.
Joint Bone Spine
; 2007 Jan;74(1):85-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Using the final
diagnosis
as the reference standard, we evaluated the diagnostic usefulness of each investigation.
The primary was located in the lung in 37 patients,
prostate
in 26, breast or female genital tract in 24, urinary system in 11, gastrointestinal tract in 11, head and neck in 6, and other organs in 4.
The histological biopsy findings indicated
adenocarcinoma
in 58 cases, epidermoid carcinoma in 28 cases, undifferentiated carcinoma in 2 cases, and other histological patterns in 9 cases.
Tumor marker assays were of limited value for determining the site of the primary, with the exception
of prostate
-specific antigen.
[MeSH-major]
Bone Neoplasms /
diagnosis
. Bone Neoplasms / secondary. Neoplasms, Unknown Primary /
diagnosis
[MeSH-minor]
Adenocarcinoma
/
diagnosis
.
Adenocarcinoma
/ pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Biopsy. Bone and Bones / pathology. Breast Neoplasms /
diagnosis
. Breast Neoplasms / pathology. Cohort Studies. Diagnostic Imaging. Female. Humans. Lung Neoplasms /
diagnosis
. Lung Neoplasms / pathology. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Urogenital Neoplasms /
diagnosis
. Urogenital Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Bone Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Joint Bone Spine. 2008 Jan;75(1):100; author reply 100-1
[
18083617.001
]
(PMID = 17218141.001).
[ISSN]
1778-7254
[Journal-full-title]
Joint, bone, spine : revue du rhumatisme
[ISO-abbreviation]
Joint Bone Spine
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
France
[Chemical-registry-number]
0 / Biomarkers, Tumor
53.
Koutrouvelis PG, Theodorescu D, Katz S, Lailas N, Hendricks F:
Brachytherapy of prostate cancer after colectomy for colorectal cancer: pilot experience.
J Urol
; 2005 Jan;173(1):82-5; discussion 85-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Brachytherapy
of prostate
cancer
after colectomy for colorectal
cancer
: pilot experience.
PURPOSE: We present a method of brachytherapy for
prostate
cancer
using a 3-dimensional stereotactic system and computerized tomography guidance in patients without a rectum due to previous treatment for colorectal
cancer
.
MATERIALS AND METHODS: From June 1994 to November 2003 a cohort of 800 patients were treated with brachytherapy for
prostate
cancer
.
Four patients had previously been treated for colorectal
cancer
with 4,500 cGy external beam radiation therapy, abdominoperineal resection and chemotherapy, while 1 underwent abdominoperineal resection alone for ulcerative colitis.
Patient followup included clinical examination and serum
prostate
specific antigen measurement.
CONCLUSIONS: Three-dimensional computerized tomography guided brachytherapy for
prostate
cancer
in patients with a history of colorectal
cancer
who have no rectum is a feasible method of treatment.
[MeSH-major]
Adenocarcinoma
/ radiotherapy. Brachytherapy / methods. Colectomy. Colorectal Neoplasms / surgery. Neoplasms, Second Primary / radiotherapy.
Prostatic
Neoplasms / radiotherapy
Genetic Alliance.
consumer health - Colorectal Cancer
.
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15592034.001).
[ISSN]
0022-5347
[Journal-full-title]
The Journal of urology
[ISO-abbreviation]
J. Urol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
54.
Roobol MJ, Roobol DW, Schröder FH:
Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Urology
; 2005 Feb;65(2):343-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Is additional testing necessary in men with
prostate
-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
OBJECTIVES: Currently, several
prostate
cancer
rescreening intervals are in use in different countries worldwide, varying from 1 to 4 years.
Recently, it has been proposed to determine the rescreening interval relative to the initial
prostate
-specific antigen (PSA) level and possibly to extend the rescreening interval up to 5 years.
Of these men, 13 (0.98%) had a PSA level of 3.0 ng/mL or greater, and three cancers were detected (
cancer
detection rate 0.23%).
At the third screening visit, 1017 men (76.8%) attended, 34 men (3.3%) had a PSA level of 3.0 ng/mL or greater, and five cancers were detected (
cancer
detection rate 0.49%).
The 2344 subsequent PSA determinations in an 8-year period after the initial screening resulted in eight cancers detected, for an overall
cancer
detection rate of 0.47%.
Through linkage of all men with
the cancer
registry, no additional cancers were found.
CONCLUSIONS: A strategy of PSA screening every 8 years for men with a PSA level of 1.0 ng/mL or less will lead to a considerable decrease in the number of screening visits (with the associated costs and stress), with a minimal risk of missing aggressive
cancer
at a curable stage.
[MeSH-major]
Adenocarcinoma
/ epidemiology. Early
Diagnosis
. Mass Screening / methods.
Prostatic
Neoplasms / epidemiology
[MeSH-minor]
Aged. Biomarkers, Tumor / blood. Cohort Studies. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Proteins / blood.
Prostate
-Specific Antigen / blood. Time Factors. Unnecessary Procedures
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15708050.001).
[ISSN]
1527-9995
[Journal-full-title]
Urology
[ISO-abbreviation]
Urology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 3.4.21.77 / Prostate-Specific Antigen
55.
Fritzsche FR, Stephan C, Gerhardt J, Lein M, Hofmann I, Jung K, Dietel M, Kristiansen G:
Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer.
Histol Histopathol
; 2010 06;25(6):733-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in
prostate
cancer
.
T-cell receptor gamma chain alternative reading frame protein (TARP) has recently been proposed as being up-regulated in
prostate
cancer
(PCA).
Additionally, TARP has been proposed as a potential therapeutic target for
cancer
therapy.
We analysed the protein expression of TARP in a large well characterised
prostate
cancer
cohort to assess its diagnostic and prognostic value.
Methodologically, we constructed a tissue microarray comprising more than 600 PCA cases including matching benign
prostate
tissue.
Our results show that TARP is significantly over-expressed in the vast majority (approximately 85%) of PCA in comparison to non neoplastic
prostate
tissue.
[MeSH-major]
Adenocarcinoma
/
diagnosis
. Nuclear Proteins / metabolism.
Prostatic
Neoplasms /
diagnosis
[MeSH-minor]
Adult. Aged. Biomarkers, Tumor / metabolism. Blotting, Western. Cohort Studies. Disease-Free Survival. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis.
Prostate
-Specific Antigen / blood
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20376779.001).
[ISSN]
1699-5848
[Journal-full-title]
Histology and histopathology
[ISO-abbreviation]
Histol. Histopathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Spain
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / TARP; EC 3.4.21.77 / Prostate-Specific Antigen
56.
Xie W, Nakabayashi M, Regan MM, Oh WK:
Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Cancer
; 2007 Dec 15;110(12):2709-15
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Higher
prostate
-specific antigen levels predict improved survival in patients with hormone-refractory
prostate
cancer
who have skeletal metastases and normal serum alkaline phosphatase.
BACKGROUND: Higher
prostate
-specific antigen (PSA) and alkaline phosphatase (ALK-P) levels predicted worse survival in men with metastatic hormone-refractory
prostate
cancer
(HRPC).
[MeSH-major]
Adenocarcinoma
/ blood.
Adenocarcinoma
/ mortality. Alkaline Phosphatase / blood. Androgen Antagonists / therapeutic use. Bone Neoplasms / secondary.
Prostate
-Specific Antigen / blood.
Prostatic
Neoplasms / blood
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer Screening
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2007 American Cancer Society
(PMID = 17960608.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Androgen Antagonists; EC 3.1.3.1 / Alkaline Phosphatase; EC 3.4.21.77 / Prostate-Specific Antigen
57.
Mizukami H, Yoshizawa Y, Sasaya S, Nemoto H, Maezawa K, Sanada Y:
[A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery].
Gan To Kagaku Ryoho
; 2007 Jun;34(6):953-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[A case of advanced colon
cancer
invading the rectum effectively treated with chemoradiation therapy before surgery].
He was diagnosed as advanced sigmoid colon
cancer
which invaded the rectal colon (Ra) and
prostate
(SI, N 0, P 0, H 0, M (-), cStage IIIa).
Postoperative histopathological examination of the resected sigmoid colon and rectum revealed no remnant
cancer
tissue.
[MeSH-major]
Adenocarcinoma
/ radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Prostatic
Neoplasms / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / radiotherapy
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17565265.001).
[ISSN]
0385-0684
[Journal-full-title]
Gan to kagaku ryoho. Cancer & chemotherapy
[ISO-abbreviation]
Gan To Kagaku Ryoho
[Language]
jpn
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
58.
Singh SV, Powolny AA, Stan SD, Xiao D, Arlotti JA, Warin R, Hahm ER, Marynowski SW, Bommareddy A, Potter DM, Dhir R:
Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice.
Cancer Res
; 2008 Nov 15;68(22):9503-11
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Garlic constituent diallyl trisulfide prevents development of poorly differentiated
prostate
cancer
and pulmonary metastasis multiplicity in TRAMP mice.
Identification of agents that are nontoxic but can delay onset and/or progression
of prostate
cancer
, which is the second leading cause of
cancer
-related deaths among men in the United States, is highly desirable.
We now show that p.o. gavage of garlic constituent diallyl trisulfide (DATS; 1 and 2 mg/day, thrice/week for 13 weeks beginning at age 8 weeks) significantly inhibits progression to poorly differentiated
prostate
carcinoma and pulmonary metastasis multiplicity in transgenic
adenocarcinoma of
mouse
prostate
(TRAMP) mice without any side effects.
There was a trend of a decrease in average wet weights of the urogenital tract and
prostate
gland
in 1 and 2 mg DATS-treated mice compared with controls ( approximately 25-46% decrease in DATS-treated mice compared with controls).
The incidence and the area of the dorsolateral
prostate
occupied by the poorly differentiated carcinoma were significantly lower in both 1 and 2 mg DATS-treated mice compared with control mice.
The dorsolateral
prostate
from DATS-treated TRAMP mice exhibited decreased cellular proliferation in association with induction of cyclinB1 and securin protein levels, and suppression of the expression of neuroendocrine marker synaptophysin.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Carcinogenesis. 1988 Jan;9(1):131-4
[
3335037.001
]
[Cites]
Carcinogenesis. 2006 Mar;27(3):533-40
[
16169930.001
]
[Cites]
J Natl Cancer Inst. 1989 Jan 18;81(2):162-4
[
2909758.001
]
[Cites]
Mol Biother. 1991 Jun;3(2):103-7
[
1910619.001
]
[Cites]
Chem Res Toxicol. 1991 Nov-Dec;4(6):642-7
[
1807447.001
]
[Cites]
Cancer Res. 2006 May 15;66(10):5379-86
[
16707465.001
]
[Cites]
Nutr Cancer. 2006;55(1):94-107
[
16965246.001
]
[Cites]
Clin Cancer Res. 2006 Nov 15;12(22):6836-43
[
17121905.001
]
[Cites]
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
[
17237035.001
]
[Cites]
Cancer Lett. 2007 Mar 18;247(2):167-81
[
16793203.001
]
[Cites]
Mol Cancer Ther. 2007 Apr;6(4):1249-61
[
17406033.001
]
[Cites]
Nat Rev Immunol. 2007 May;7(5):329-39
[
17438573.001
]
[Cites]
Mol Cancer Ther. 2007 May;6(5):1599-609
[
17513609.001
]
[Cites]
Cancer Res. 2007 Jun 15;67(12):5976-82
[
17575168.001
]
[Cites]
J Cell Biochem. 2007 Jul 1;101(4):927-36
[
17177290.001
]
[Cites]
Cancer Res. 2007 Jul 15;67(14):6925-35
[
17638904.001
]
[Cites]
Trends Immunol. 2007 Nov;28(11):491-6
[
17964217.001
]
[Cites]
Neoplasia. 2007 Nov;9(11):938-50
[
18030362.001
]
[Cites]
Am J Pathol. 2008 Jan;172(1):236-46
[
18156212.001
]
[Cites]
J Cell Physiol. 2000 Mar;182(3):311-22
[
10653597.001
]
[Cites]
Prostate. 2000 Mar 1;42(4):274-9
[
10679756.001
]
[Cites]
Cancer Res. 2000 May 1;60(9):2449-57
[
10811123.001
]
[Cites]
Carcinogenesis. 2000 Jun;21(6):1129-34
[
10837000.001
]
[Cites]
Cancer Res. 2000 Sep 15;60(18):5125-33
[
11016639.001
]
[Cites]
Pathol Int. 2001 Jun;51(6):452-9
[
11422807.001
]
[Cites]
J Leukoc Biol. 2002 Jun;71(6):941-9
[
12050178.001
]
[Cites]
J Natl Cancer Inst. 2002 Nov 6;94(21):1648-51
[
12419792.001
]
[Cites]
Prostate. 2003 May 15;55(3):219-37
[
12692788.001
]
[Cites]
N Engl J Med. 2003 Jul 24;349(4):366-81
[
12878745.001
]
[Cites]
J Nat Prod. 2003 Jul;66(7):1022-37
[
12880330.001
]
[Cites]
Cancer Res. 2003 Sep 15;63(18):5940-9
[
14522920.001
]
[Cites]
Annu Rev Cell Dev Biol. 2003;19:207-35
[
14570569.001
]
[Cites]
Oncogene. 2004 Jul 22;23(33):5594-606
[
15184882.001
]
[Cites]
Chin Med J (Engl). 2004 Aug;117(8):1155-60
[
15361287.001
]
[Cites]
Cancer Res. 1993 Aug 1;53(15):3493-8
[
8339252.001
]
[Cites]
J Urol. 1994 Apr;151(4):914-9
[
8126824.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43
[
7724580.001
]
[Cites]
Carcinogenesis. 1996 Apr;17(4):669-73
[
8625476.001
]
[Cites]
Arch Biochem Biophys. 1996 Dec 15;336(2):199-214
[
8954567.001
]
[Cites]
Int J Cancer. 1997 Dec 10;73(6):897-902
[
9399673.001
]
[Cites]
Biochem Biophys Res Commun. 1998 Mar 27;244(3):917-20
[
9535768.001
]
[Cites]
Jpn J Cancer Res. 1999 Jun;90(6):614-21
[
10429652.001
]
[Cites]
Clin Cancer Res. 2005 Apr 1;11(7):2670-9
[
15814648.001
]
[Cites]
Mutat Res. 2005 Aug 25;576(1-2):111-9
[
15885713.001
]
[Cites]
J Biol Chem. 2005 Aug 5;280(31):28519-28
[
15961392.001
]
[Cites]
Oncogene. 2005 Sep 15;24(41):6256-68
[
15940258.001
]
[Cites]
J Biol Chem. 2005 Oct 21;280(42):35299-309
[
16118211.001
]
[Cites]
J Biol Chem. 2005 Dec 16;280(50):41487-93
[
16219763.001
]
[Cites]
Cancer Res. 1988 Dec 1;48(23):6872-5
[
3180095.001
]
(PMID = 19010926.001).
[ISSN]
1538-7445
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA113363-04; United States / NCI NIH HHS / CA / R01 CA113363; United States / NCI NIH HHS / CA / CA113363; United States / NCI NIH HHS / CA / R01 CA113363-04
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Allyl Compounds; 0 / Antigens, Viral, Tumor; 0 / Cadherins; 0 / Proliferating Cell Nuclear Antigen; 0 / Sulfides; 0 / Synaptophysin; 0ZO1U5A3XX / diallyl trisulfide
[Other-IDs]
NLM/ NIHMS70762; NLM/ PMC2597366
59.
Tan WW:
Novel agents and targets in managing patients with metastatic prostate cancer.
Cancer Control
; 2006 Jul;13(3):194-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Novel agents and targets in managing patients with metastatic
prostate
cancer
.
BACKGROUND: Docetaxel has recently been found to improve survival in patients with metastatic androgen-independent
prostate
cancer
(AIPC).
METHODS: Clinically relevant articles focusing on chemotherapy drugs for metastatic
prostate
cancer
and their mechanism of action and efficacy were reviewed from January 2004 through April 2006.
[MeSH-major]
Adenocarcinoma
/ therapy. Bone Neoplasms / therapy.
Prostatic
Neoplasms / therapy
Genetic Alliance.
consumer health - Prostate cancer
.
Genetic Alliance.
consumer health - Metastatic cancer
.
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16885915.001).
[ISSN]
1073-2748
[Journal-full-title]
Cancer control : journal of the Moffitt Cancer Center
[ISO-abbreviation]
Cancer Control
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
33
60.
Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS:
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
J Clin Oncol
; 2008 Oct 01;26(28):4563-71
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant
prostate
cancer
commonly remains hormone driven.
PURPOSE: Studies indicate that castration-resistant
prostate
cancer
(CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling.
PATIENTS AND METHODS: Chemotherapy-naïve men (n = 21) who had
prostate
cancer
that was resistant to multiple hormonal therapies were treated in this phase I study of once-daily, continuous abiraterone acetate, which escalated through five doses (250 to 2,000 mg) in three-patient cohorts.
Declines in
prostate
-specific antigen >or= 30%, 50%, and 90% were observed in 14 (66%), 12 (57%), and 6 (29%) patients, respectively, and lasted between 69 to >or= 578 days.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Androstenols / therapeutic use. Neoplasms, Hormone-Dependent / drug therapy.
Prostatic
Neoplasms / drug therapy
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Nat Clin Pract Oncol. 2009 Jan;6(1):12-3
[
18957947.001
]
[CommentIn]
J Clin Oncol. 2008 Oct 1;26(28):4535-6
[
18626003.001
]
[CommentIn]
Eur Urol. 2008 Dec;54(6):1438-9
[
19189435.001
]
[CommentIn]
Eur Urol. 2009 Jan;55(1):248
[
20050017.001
]
[CommentIn]
Eur Urol. 2009 Jul;56(1):220
[
19995520.001
]
[ErratumIn]
J Clin Oncol. 2012 May 20;30(15):1896
(PMID = 18645193.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / G0501019; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
[Publication-type]
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Androstenes; 0 / Androstenols; G819A456D0 / abiraterone
61.
Kanno H, Umemoto S, Izumi K, Hasumi H, Osada Y, Ohta J, Mikata K, Tuchiya F:
[Prostate cancer development after transurethral resection of the prostate--histopathological studies of radical prostatectomy specimens].
Nihon Hinyokika Gakkai Zasshi
; 2006 May;97(4):649-59
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Prostate
cancer
development after transurethral resection of the
prostate
--histopathological studies of radical prostatectomy specimens].
PURPOSE: We investigated
prostate
cancer
(ca.) development after transurethral resection of the
prostate
(TURP).
In 13 (3.2%) of 407 Non-Stage A pts. (who had no ca. initially),
prostate
ca. developed after 1 to 7 yrs.
Stage A pts. received regular needle biopsy
of prostate
(Pbx).
Long term (5 or 10 years) MAB therapy changed moderately-differentiated
adenocarcinoma
(AC) to poorly-differentiated AC in 2 pts. during follow-up.
Pbx before TURP was done to reveal that there was no
cancer
in 11 pts.
PSA (8.6 +/- 4.0 ng/ml) decreased after TURP but was kept in high level (4.8 +/- 2.2 ng/ml) after 1 year and increased (8.7 +/- 4.5) when
cancer
was diagnosed in all 13 pts.
Interval between TURP and
diagnosis
was short in pts. who had
cancer
of high Gleason Score (GS) or large
prostate
.
CONCLUSIONS: As significant
cancer
developed in 22% of Stage A pts. (1.2% of TURP) in long term follow-up, regular Pbx (to get TZ tissue) is mandatory regardless of PSA value or DRE.
Aggressive
cancer
developed in 3.2% of Non-Stage A pts. (3.0% of TURP). Pts. with high PSA or abnormal DRE after TURP must receive needle biopsy actively.
[MeSH-major]
Neoplasm Recurrence, Local / pathology.
Prostate
/ pathology.
Prostatic
Neoplasms / pathology. Transurethral Resection
of Prostate
[MeSH-minor]
Aged. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period.
Prostate
-Specific Antigen / blood. Prostatectomy. Time Factors
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16768146.001).
[ISSN]
0021-5287
[Journal-full-title]
Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
[ISO-abbreviation]
Nippon Hinyokika Gakkai Zasshi
[Language]
jpn
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
EC 3.4.21.77 / Prostate-Specific Antigen
62.
Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR:
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.
Cancer Epidemiol Biomarkers Prev
; 2006 Oct;15(10):1977-83
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Obesity, diabetes, and risk
of prostate
cancer
: results from the
prostate
cancer
prevention trial.
Studies on the relationship between obesity and
prostate
cancer
incidence are inconsistent.
In part, this inconsistency may be due to a differential effect of obesity on low-grade and high-grade
cancer
or confounding of the association of obesity with
prostate
cancer
risk by diabetes.
We investigated the associations of obesity and diabetes with low-grade and high-grade
prostate
cancer
risk.
Data were from 10,258 participants (1,936
prostate
cancers) in the
Prostate
Cancer
Prevention Trial who all had
cancer
presence or absence determined by
prostate
biopsy.
Multiple logistic regression was used to model the risk of total
prostate
cancer
, and polytomous logistic regression was used to model the risk of low-grade and high-grade
prostate
cancer
.
Compared with men with body mass index < 25, obese men (body mass index > or =30) had an 18% [odds ratio (OR), 0.82; 95% confidence interval (95% CI), 0.69-0.98] decreased risk of low-grade
prostate
cancer
(Gleason <7) and a 29% (OR, 1.29; 95% CI, 1.01-1.67) increased risk of high-grade
prostate
cancer
(Gleason > or =7) or, alternatively, a 78% (OR, 1.78; 95% CI, 1.10-2.87) increased risk defining high-grade
cancer
as Gleason sum 8 to 10.
Diabetes was associated with a 47% (OR, 0.53; 95% CI, 0.34-0.83) reduced risk of low-grade
prostate
cancer
and a 28% (OR, 0.72; 95% CI, 0.55-0.94) reduced risk of high-grade
prostate
cancer
.
Associations of obesity or diabetes with
cancer
risk were not substantially changed by mutually statistical controlling for each other.
Obesity increases the risk of high-grade but decreases the risk of low-grade
prostate
cancer
, and this relationship is independent of the lower risk for
prostate
cancer
among men with diabetes.
[MeSH-major]
Adenocarcinoma
/ epidemiology.
Adenocarcinoma
/ prevention & control. Diabetes Mellitus / epidemiology. Obesity / epidemiology.
Prostatic
Neoplasms / epidemiology.
Prostatic
Neoplasms / prevention & control
Genetic Alliance.
consumer health - Diabetes
.
Genetic Alliance.
consumer health - Obesity
.
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Diabetes
.
MedlinePlus Health Information.
consumer health - Obesity
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
FINASTERIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):182-3
[
17220351.001
]
(PMID = 17035408.001).
[ISSN]
1055-9965
[Journal-full-title]
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
[ISO-abbreviation]
Cancer Epidemiol. Biomarkers Prev.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / 1 P01 CA108964-01A1; United States / NCI NIH HHS / CA / 5 R01 CA63164; United States / NCI NIH HHS / CA / 5 U10 CA37429
[Publication-type]
Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride
63.
Yeh IT, Reddick RL, Kumar AP:
Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Prostate
; 2009 May 15;69(7):755-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Malignancy arising in seminal vesicles in the transgenic
adenocarcinoma of
mouse
prostate
(TRAMP) model.
BACKGROUND: Transgenic
adenocarcinoma of
mouse
prostate
(TRAMP) mice, derived by
prostate
specific expression of SV40 large T antigen using the rat probasin promoter, all develop
prostate
tumors akin to human
prostate
cancers.
In some cases, the stromal cells become large mass lesions that overgrow the
prostate
.
(1) A definite
adenocarcinoma
pattern metastatic from the
prostate
;.
[MeSH-major]
Adenocarcinoma
/ pathology.
Prostatic
Neoplasms / pathology. Seminal Vesicles / pathology
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2009 Wiley-Liss, Inc.
(PMID = 19170049.001).
[ISSN]
1097-0045
[Journal-full-title]
The Prostate
[ISO-abbreviation]
Prostate
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
64.
Zhao Z, Liu J, Li S, Shen W:
Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Prostate
; 2009 Sep 1;69(12):1292-302
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prostate
stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent
cancer
after transurethral resection of the
prostate
for benign
prostatic
hyperplasia.
BACKGROUND: Recent data showed that
prostate
stem cell antigen (PSCA) mRNA expression in transurethral resection of the
prostate
(TURP)-resected tissues predicted the subsequent
prostate
cancer
after TURP in benign
prostatic
hyperplasia (BPH) patients with both PSA < 4.0 ng/ml and normal DRE findings.
This study was to determine whether PSCA mRNA positivity in preoperatively negative
prostatic
biopsy samples from BPH men with PSA > 4.0 ng/ml and/or suspicious DRE findings had predictive performance following TURP.
MATERIALS AND METHODS: PSCA in situ hybridization was performed on negative
prostatic
biopsies taken before TURP from 166 enrolled symptomatic BPH patients, who were continuously followed for 5 years postoperatively.
Predictive performance of PSCA mRNA for subsequent
cancer
onset was evaluated by univariate and multivariate Cox proportional hazards models with bootstrapping and concordance indices.
A final multivariate Cox proportional hazards model demonstrated that only PSCA mRNA expression in negative
prostatic
biopsies was predictive of the subsequent
cancer
development after TURP (hazard ratio = 3.49; 95% CI: 2.02-4.75; P < 0.001), with the concordance index of 0.893.
CONCLUSIONS: This prospective study identifies PSCA mRNA in preoperatively negative
prostatic
biopsies as a significant predictor of subsequent
cancer
after TURP.
[MeSH-major]
Adenocarcinoma
/ genetics. Gene Expression. Membrane Glycoproteins / genetics. Neoplasm Proteins / genetics.
Prostatic
Hyperplasia / genetics.
Prostatic
Neoplasms / genetics. RNA, Messenger / metabolism. Transurethral Resection
of Prostate
[MeSH-minor]
Aged. Aged, 80 and over. Antigens, Neoplasm. Biopsy. Cell Count. Disease Progression. Follow-Up Studies. GPI-Linked Proteins. Humans. In Situ Hybridization. Male. Middle Aged. Predictive Value of Tests. Prospective Studies.
Prostate
-Specific Antigen / blood
Genetic Alliance.
consumer health - Prostate cancer
.
Genetic Alliance.
consumer health - Benign Prostatic Hyperplasia
.
MedlinePlus Health Information.
consumer health - Enlarged Prostate (BPH)
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19462463.001).
[ISSN]
1097-0045
[Journal-full-title]
The Prostate
[ISO-abbreviation]
Prostate
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PSCA protein, human; 0 / RNA, Messenger; EC 3.4.21.77 / Prostate-Specific Antigen
65.
Jantscheff P, Esser N, Graeser R, Ziroli V, Kluth J, Unger C, Massing U:
Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts.
Prostate
; 2009 Aug 1;69(11):1151-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3
prostate
cancer
xenografts.
BACKGROUND: Gemcitabine (Gemc) is an efficient chemotherapeutic drug in various
cancer
types (e.g., pancreas) but has only limited effects on hormone-refractory
prostate
cancer
(HRPCa).
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives.
Prostatic
Neoplasms / drug therapy. Transplantation, Heterologous
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19399788.001).
[ISSN]
1097-0045
[Journal-full-title]
The Prostate
[ISO-abbreviation]
Prostate
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0 / Liposomes; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.13.12.- / Luciferases
66.
Krupka TM, Dremann D, Exner AA:
Time and dose dependence of pluronic bioactivity in hyperthermia-induced tumor cell death.
Exp Biol Med (Maywood)
; 2009 Jan;234(1):95-104
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Pluronic block copolymers have been shown to sensitize
cancer
cells resulting in an increased activity of antineoplastic agents.
In the current study we examined a new application of Pluronic bioactivity in potentiating hyperthermia-induced
cancer
cell injury.
DHD/K12/TRb rat
adenocarcinoma
cells were exposed to low-grade hyperthermia at 43 degrees C with or without Pluronic P85 or Pluronic L61.
Based on these results, we conclude that Pluronic is effective in improving hyperthermic
cancer
treatment in vitro by potentiating heat-induced cytotoxicity in a concentration and time dependent manner.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
POLOXALENE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lancet. 2000 Apr 1;355(9210):1119-25
[
10791373.001
]
[Cites]
J Control Release. 2008 Sep 10;130(2):98-106
[
18534704.001
]
[Cites]
Radiology. 2000 Oct;217(1):119-26
[
11012432.001
]
[Cites]
Int J Hyperthermia. 2001 Mar-Apr;17(2):97-105
[
11252361.001
]
[Cites]
Eur J Ultrasound. 2001 Jun;13(2):129-47
[
11369525.001
]
[Cites]
J Vasc Interv Radiol. 2001 Jul;12(7):823-33
[
11435538.001
]
[Cites]
Radiology. 2001 Aug;220(2):420-7
[
11477246.001
]
[Cites]
Radiology. 2001 Oct;221(1):159-66
[
11568334.001
]
[Cites]
J Pharmacol Exp Ther. 2001 Nov;299(2):483-93
[
11602658.001
]
[Cites]
Br J Cancer. 2001 Dec 14;85(12):1987-97
[
11747344.001
]
[Cites]
J Pharm Sci. 2002 Jan;91(1):157-70
[
11782905.001
]
[Cites]
Front Radiat Ther Oncol. 2002;36:171-6
[
11842749.001
]
[Cites]
Radiology. 2002 Mar;222(3):797-804
[
11867804.001
]
[Cites]
Curr Probl Surg. 2002 May;39(5):449-571
[
12019420.001
]
[Cites]
Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56
[
12098606.001
]
[Cites]
Lasers Surg Med. 2002;31(3):158-63
[
12224088.001
]
[Cites]
J Urol. 2003 Jan;169(1):338-46
[
12478186.001
]
[Cites]
J Pharmacol Exp Ther. 2003 Feb;304(2):845-54
[
12538842.001
]
[Cites]
J Thorac Cardiovasc Surg. 2003 Apr;125(4):929-37
[
12698158.001
]
[Cites]
Chemistry. 2003 Aug 18;9(16):3930-6
[
12916119.001
]
[Cites]
J Control Release. 2003 Aug 28;91(1-2):75-83
[
12932639.001
]
[Cites]
Pharm Res. 2003 Oct;20(10):1581-90
[
14620511.001
]
[Cites]
Radiology. 2004 Feb;230(2):450-8
[
14688400.001
]
[Cites]
J Vasc Interv Radiol. 2004 Mar;15(3):269-74
[
15028812.001
]
[Cites]
Radiologe. 2004 Apr;44(4):301-9
[
15042293.001
]
[Cites]
Annu Rev Biochem. 1986;55:1151-91
[
2427013.001
]
[Cites]
New Biol. 1991 Nov;3(11):1106-20
[
1777484.001
]
[Cites]
Bioconjug Chem. 1996 Mar-Apr;7(2):209-16
[
8983343.001
]
[Cites]
Nihon Rinsho. 1996 Jul;54(7):1949-54
[
8741693.001
]
[Cites]
Radiology. 1997 Jan;202(1):205-10
[
8988212.001
]
[Cites]
J Vasc Interv Radiol. 1998 Jan-Feb;9(1 Pt 1):101-11
[
9468403.001
]
[Cites]
Prostate. 1998 Feb 15;34(3):195-202
[
9492848.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3513-8
[
9520397.001
]
[Cites]
AJR Am J Roentgenol. 1998 Apr;170(4):1015-22
[
9530052.001
]
[Cites]
Ann Surg. 1998 Apr;227(4):559-65
[
9563546.001
]
[Cites]
Hum Cell. 1998 Sep;11(3):167-74
[
10086278.001
]
[Cites]
FEBS Lett. 1999 Mar 5;446(1):194-8
[
10100641.001
]
[Cites]
Radiology. 1999 Aug;212(2):459-66
[
10429704.001
]
[Cites]
FEBS Lett. 1999 Aug 6;456(2):339-42
[
10456335.001
]
[Cites]
Pharm Res. 1999 Sep;16(9):1373-9
[
10496652.001
]
[Cites]
Biochemistry. 2005 Mar 15;44(10):4042-54
[
15751981.001
]
[Cites]
J Control Release. 2005 Aug 18;106(1-2):188-97
[
15951044.001
]
[Cites]
FEBS J. 2005 Dec;272(23):6077-86
[
16302971.001
]
[Cites]
Invest Radiol. 2006 Apr;41(4):422-7
[
16523026.001
]
[Cites]
Mol Ther. 2006 Apr;13(4):804-13
[
16199206.001
]
[Cites]
Paediatr Anaesth. 2006 Aug;16(8):890-1
[
16884475.001
]
[Cites]
Invest Radiol. 2006 Dec;41(12):890-7
[
17099428.001
]
[Cites]
J Surg Res. 2007 May 15;139(2):176-81
[
17336331.001
]
[Cites]
J Natl Compr Canc Netw. 2007 Mar;5(3):339-44
[
17439762.001
]
[Cites]
Exp Biol Med (Maywood). 2007 Jul;232(7):950-7
[
17609512.001
]
[Cites]
Clin Oncol (R Coll Radiol). 2007 Aug;19(6):418-26
[
17493790.001
]
[Cites]
Abdom Imaging. 2007 May-Jun;32(3):332-8
[
16933116.001
]
[Cites]
J Mol Cell Cardiol. 2007 Nov;43(5):616-26
[
17884089.001
]
[Cites]
Cell Biochem Funct. 2007 Nov-Dec;25(6):669-72
[
16933368.001
]
[Cites]
Clin Oncol (R Coll Radiol). 2007 Dec;19(10):805-6
[
17892927.001
]
[Cites]
Radiology. 2008 Mar;246(3):796-803
[
18309015.001
]
[Cites]
J Colloid Interface Sci. 2008 Jun 1;322(1):263-73
[
18377918.001
]
[Cites]
Cancer. 2000 Jun 1;88(11):2452-63
[
10861420.001
]
(PMID = 18997100.001).
[ISSN]
1535-3702
[Journal-full-title]
Experimental biology and medicine (Maywood, N.J.)
[ISO-abbreviation]
Exp. Biol. Med. (Maywood)
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA136857; United States / NCI NIH HHS / CA / R01 CA136857-01; United States / NCI NIH HHS / CA / R01CA1118399
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / pluronic L61; 106392-12-5 / Poloxamer; 8L70Q75FXE / Adenosine Triphosphate; 9003-11-6 / Poloxalene
[Other-IDs]
NLM/ NIHMS359379; NLM/ PMC3293626
67.
Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, von Schulthess GK, Hany TF:
Fluorocholine PET/CT in patients with prostate cancer: initial experience.
Radiology
; 2005 May;235(2):623-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Fluorocholine PET/CT in patients with
prostate
cancer
: initial experience.
Patients with newly diagnosed
prostate
cancer
and patients suspected of having recurrent
prostate
cancer
were prospectively evaluated with fluorine 18 fluorocholine (FCH) combined in-line positron emission tomography (PET) and computed tomography (CT).
In nine patients evaluated at initial staging, histologic findings of the resected
prostate
were compared to FCH uptake.
Differentiation of benign hyperplasia from cancerous
prostate
lesions was not possible with FCH PET/CT.
However, in patients with recurrent
prostate
cancer
, FCH PET/CT is a promising imaging modality for detecting local recurrence and lymph node metastases.
[MeSH-major]
Adenocarcinoma
/
diagnosis
. Fluorine Radioisotopes. Image Enhancement. Image Interpretation, Computer-Assisted. Neoplasm Recurrence, Local /
diagnosis
. Positron-Emission Tomography.
Prostatic
Neoplasms /
diagnosis
. Quaternary Ammonium Compounds. Tomography, X-Ray Computed
[MeSH-minor]
Aged. Aged, 80 and over. Bone Neoplasms /
diagnosis
. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Humans. Male. Middle Aged. Neoplasm Staging. Pelvic Neoplasms /
diagnosis
. Pelvic Neoplasms / pathology. Pelvic Neoplasms / secondary.
Prostate
/ pathology. Sensitivity and Specificity. Tissue Distribution
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - CT Scans
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) RSNA, 2005.
(PMID = 15858102.001).
[ISSN]
0033-8419
[Journal-full-title]
Radiology
[ISO-abbreviation]
Radiology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Fluorine Radioisotopes; 0 / Quaternary Ammonium Compounds; 0 / fluoromethyl dimethyl-2-hydroxyethylammonium
68.
Canene-Adams K, Lindshield BL, Wang S, Jeffery EH, Clinton SK, Erdman JW Jr:
Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas.
Cancer Res
; 2007 Jan 15;67(2):836-43
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h
prostate
adenocarcinomas.
The consumption of diets containing 5 to 10 servings of fruits and vegetables daily is the foundation of public health recommendations for
cancer
prevention, yet this concept has not been tested in experimental models
of prostate
cancer
.
We evaluated combinations of tomato and broccoli in the Dunning R3327-H
prostate adenocarcinoma
model.
Castration reduced
prostate
weights, tumor areas, and tumor weight (62%, P<0.001), whereas finasteride reduced
prostate
weights (P<0.0001), but had no effect on tumor area or weight.
[MeSH-major]
Adenocarcinoma
/ prevention & control. Brassica. Diet. Lycopersicon esculentum.
Prostatic
Neoplasms / prevention & control
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17213256.001).
[ISSN]
0008-5472
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
36-88-4 / Carotenoids; SB0N2N0WV6 / lycopene
69.
Rozková D, Tiserová H, Fucíková J, Last'ovicka J, Podrazil M, Ulcová H, Budínský V, Prausová J, Linke Z, Minárik I, Sedivá A, Spísek R, Bartůnková J:
FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
Clin Immunol
; 2009 Apr;131(1):1-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic
prostate
cancer
.
Immunotherapy has emerged as another treatment modality in
cancer
.
The goal of immunotherapy in advanced
cancer
patients does not have to be the complete eradication of tumor cells but rather the restoration of a dynamic balance between tumor cells and the immune response.
We review experimental basis and key concepts of combined chemo-immunotherapy and document its principles in the case report of patient with hormone refractory metastatic
prostate
cancer
with sinister prognosis.
More than four hundred
prostate
cancer
patients have been treated with DC-based immunotherapy and tumor-specific immune responses have been reported in two-thirds of them.
Prostate
cancer
patients have elevated numbers of circulating and tumor infiltrating Tregs and there is evidence that Tregs increase tumor growth in vivo.
After obtaining IRB approval, we started regular vaccinations with dendritic cells (DCs) loaded with killed
prostate
cancer
cells.
DC-based vaccination induced
prostate
cancer
cell-specific immune response.
Combined chemo-immunotherapy consisting of alternate courses of chemotherapy and vaccination with mature DCs pulsed with LNCap
prostate
cancer
cell line led to the marked improvement in the clinical and laboratory presentation and to the decrease of PSA levels by more than 90%.
[MeSH-major]
Adenocarcinoma
/ therapy. Antineoplastic Agents / therapeutic use. Immunotherapy / methods.
Prostatic
Neoplasms / therapy
Genetic Alliance.
consumer health - Prostate cancer
.
Genetic Alliance.
consumer health - Metastatic cancer
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19201656.001).
[ISSN]
1521-7035
[Journal-full-title]
Clinical immunology (Orlando, Fla.)
[ISO-abbreviation]
Clin. Immunol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
[Number-of-references]
38
70.
Ozawa MG, Yao VJ, Chanthery YH, Troncoso P, Uemura A, Varner AS, Kasman IM, Pasqualini R, Arap W, McDonald DM:
Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma.
Cancer
; 2005 Nov 15;104(10):2104-15
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Angiogenesis with pericyte abnormalities in a transgenic model
of prostate
carcinoma.
BACKGROUND: Previous studies of the TRansgenic
Adenocarcinoma of
the Mouse
Prostate
(TRAMP) model vasculature suggest that, as tumors develop, vessels invade the glandular epithelium.
METHODS: Eighty-micron cryostat sections of normal
prostate
and three histopathologic stages of TRAMP tumor sections, classified by epithelial cell E-cadherin immunoreactivity, were immunostained with vascular endothelial cell and pericyte receptor antibodies and evaluated by confocal microscopy.
RESULTS: In the normal mouse
prostate
, capillaries were most abundant in the fibromuscular tunica between the epithelium and smooth muscle of the ductules.
In
the prostatic
intraepithelial neoplasia (PIN) stage, vessels accompanied epithelial cell protrusions into the ductule lumen but remained in the connective tissue at the basal side of the epithelium.
Angiogenesis and loss of vascular hierarchy were also found in human
prostate
carcinoma.
CONCLUSIONS: Vascular abnormalities, which begin at the PIN stage and intensify in well differentiated and poorly differentiated tumors, may be useful readouts for early detection and treatment assessment in
prostate
carcinoma.
[MeSH-major]
Adenocarcinoma
/ blood supply. Neovascularization, Pathologic. Pericytes / pathology.
Prostatic
Intraepithelial Neoplasia / blood supply.
Prostatic
Neoplasms / blood supply
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2005 American Cancer Society
(PMID = 16208706.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Grant]
United States / NHLBI NIH HHS / HL / P01 HL024136; United States / NHLBI NIH HHS / HL / HL-59157; United States / NHLBI NIH HHS / HL / HL-24136; United States / NCI NIH HHS / CA / P50 CA90270
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cadherins
71.
Bittner N, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Brammer SG, Moyad M:
Primary causes of death after permanent prostate brachytherapy.
Int J Radiat Oncol Biol Phys
; 2008 Oct 1;72(2):433-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary causes of death after permanent
prostate
brachytherapy.
PURPOSE: To evaluate the primary causes of death in low-risk (low-risk), intermediate-risk (intermediate-risk), and high-risk (high-risk) patients undergoing permanent
prostate
brachytherapy with or without supplemental therapies.
METHODS AND MATERIALS: From April 1995 through November 2004, a total of 1,354 consecutive patients underwent
prostate
brachytherapy.
The death rate from second malignancies (nonprostate
cancer
) was 7.2% and was not substantially different when stratified by risk group.
In multivariate analysis, death from
prostate
cancer
was best predicted by Gleason score and risk group, whereas death from cardiovascular disease, nonprostate
cancer
, and all other causes were most closely related to patient age and tobacco use.
CONCLUSIONS: Although cardiovascular mortality was the predominant cause of death,
prostate
cancer
was responsible for approximately 10% of all deaths.
Although high-risk patients were most likely to die
of prostate
cancer
, the divergence in overall survival between high-risk and lower-risk patients primarily resulted from an excess of cardiovascular deaths.
Changes in lifestyle to improve cardiovascular health may improve overall survival in patients with clinically localized
prostate
cancer
.
[MeSH-major]
Brachytherapy.
Prostatic
Neoplasms / mortality.
Prostatic
Neoplasms / radiotherapy
[MeSH-minor]
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ radiotherapy. Age Factors. Aged. Analysis of Variance. Androgen Antagonists / therapeutic use. Cardiovascular Diseases / mortality. Cause of Death. Comorbidity. Disease-Free Survival. Follow-Up Studies. Humans. Male. Neoplasms, Second Primary / mortality.
Prostate
-Specific Antigen / blood. Risk. Smoking / mortality
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18448268.001).
[ISSN]
0360-3016
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Androgen Antagonists; EC 3.4.21.77 / Prostate-Specific Antigen
72.
Alvarez-Múgica M, Fernández Gómez JM, Escaf Barmadah S, Jalón Monzón A, González Alvarez RC, Regadera Sejas FJ:
[Changes in the presentation pattern of the prostate cancer in Oviedo in the last 10 years: diagnostic and treatment (part II)].
Actas Urol Esp
; 2006 Nov-Dec;30(10):980-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Changes in the presentation pattern of the
prostate
cancer
in Oviedo in the last 10 years: diagnostic and treatment (part II)].
[Transliterated title]
Cambio en el patrón
de
presentación del cáncer
de
próstata en Oviedo en los últimos 10 aõs: diagnóstico y tratamiento (parte II).
OBJECTIVES: To describe and compare the diagnostic and treatment factors
of prostate
adenocarcinomas diagnosed in our department in the years 1995 and 2004.
CONCLUSIONS: The evolution held in treatment therapies for
prostate
adenocarcinomas, made this disease in terms of treatment a multidisciplinary disease obtaining better results.
[MeSH-major]
Adenocarcinoma
/
diagnosis
.
Adenocarcinoma
/ therapy.
Prostatic
Neoplasms /
diagnosis
.
Prostatic
Neoplasms / therapy
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17253065.001).
[ISSN]
0210-4806
[Journal-full-title]
Actas urologicas españolas
[ISO-abbreviation]
Actas Urol Esp
[Language]
spa
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Spain
73.
Hamstra DA, Michalski JM, Roach M, Sandler HM:
Do not count out external-beam radiation therapy for high-risk prostate cancer.
J Clin Oncol
; 2010 Oct 1;28(28):e518-9; author reply e521-e522
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Do not count out external-beam radiation therapy for high-risk
prostate
cancer
.
[MeSH-major]
Adenocarcinoma
/ radiotherapy.
Prostatic
Neoplasms / radiotherapy
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
J Clin Oncol. 2010 Mar 20;28(9):1508-13
[
20159826.001
]
(PMID = 20660824.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Comment; Letter
[Publication-country]
United States
74.
Delouya G, Carrier JF, Béliveau-Nadeau D, Donath D, Taussky D:
Migration of intraprostatic fiducial markers and its influence on the matching quality in external beam radiation therapy for prostate cancer.
Radiother Oncol
; 2010 Jul;96(1):43-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Migration of intraprostatic fiducial markers and its influence on the matching quality in external beam radiation therapy for
prostate
cancer
.
PURPOSE: To assess the influence of fiducial marker (FM) migration on the matching quality in external beam radiation therapy (EBRT) for
prostate
cancer
.
MATERIALS AND METHODS: The position of FMs were identified using on-board kV imaging (OBI) and their 3-D position established using an in-house reconstruction algorithm for 31 patients with
prostate adenocarcinoma
.
[MeSH-major]
Adenocarcinoma
/ radiotherapy. Foreign-Body Migration / etiology. Gold Radioisotopes / adverse effects.
Prostatic
Neoplasms / radiotherapy. Radiotherapy, High-Energy / methods
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
(PMID = 20378191.001).
[ISSN]
1879-0887
[Journal-full-title]
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
[ISO-abbreviation]
Radiother Oncol
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Gold Radioisotopes
75.
Wohlmuth H, Deseo MA, Brushett DJ, Thompson DR, Macfarlane G, Stevenson LM, Leach DN:
Diarylheptanoid from Pleuranthodium racemigerum with in vitro prostaglandin E(2) inhibitory and cytotoxic activity.
J Nat Prod
; 2010 Apr 23;73(4):743-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The compound also demonstrated cytotoxic activity against the P388D1 murine lymphoblast cell line (IC(50) = 117.0 microM) and four human cell lines: Caco-2 colonic
adenocarcinoma
(IC(50) = 44.8 microM), PC3
prostate adenocarcinoma
(IC(50) = 23.6 microM), HepG2 hepatocyte carcinoma (IC(50) = 40.6 microM), and MCF7 mammary
adenocarcinoma
(IC(50) = 56.9 microM).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20297825.001).
[ISSN]
1520-6025
[Journal-full-title]
Journal of natural products
[ISO-abbreviation]
J. Nat. Prod.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Diarylheptanoids; K7Q1JQR04M / Dinoprostone
76.
Touijer K, Kuroiwa K, Eastham JA, Vickers A, Reuter VE, Scardino PT, Guillonneau B:
Risk-adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy.
Eur Urol
; 2007 Oct;52(4):1090-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Between 1 January 2003 and 30 June 2005, 1177 consecutive men with clinically localized
adenocarcinoma of
the
prostate
underwent radical prostatectomy at the same institution: 485 laparoscopically and 692 through a retropubic approach.
CONCLUSIONS: In our institution, laparoscopic and retropubic radical prostatectomy provide comparable PSM rates for patients with clinically localized
prostate
cancer
.
[MeSH-major]
Adenocarcinoma
/ surgery. Laparoscopy / methods. Prostatectomy / methods.
Prostatic
Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17188801.001).
[ISSN]
0302-2838
[Journal-full-title]
European urology
[ISO-abbreviation]
Eur. Urol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA92629
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
Switzerland
77.
Pearson HB, Phesse TJ, Clarke AR:
K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse.
Cancer Res
; 2009 Jan 01;69(1):94-101
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
K-ras and Wnt signaling synergize to accelerate
prostate
tumorigenesis in the mouse.
Aberrant Ras and Wnt signaling are emerging as key events in the multistep nature
of prostate
tumorigenesis and progression.
Here, we report the generation of a compound model
of prostate
cancer
to define the synergism of activated K-ras (K-ras(+/V12)) and dominant stabilized beta-catenin (Catnb(+/lox(ex3))) in the murine
prostate
.
Concomitant with elevated mitogen-activated protein kinase (MAPK) signaling, PBCre(+)K-ras(+/V12) mice developed AH at 100 days (100% incidence) and low-grade
prostate
intraepithelial neoplasia and
adenocarcinoma
(60% and 7% incidence) by 500 days.
PBCre(+)Catnb(+/lox(ex3)) mice showed reduced longevity (average 428 days) and were predisposed to PIN-like keratinized squamous metaplasia at 100 days (100% incidence) and
adenocarcinoma
(100% incidence) at end-point.
Notably, expression of the basal cell marker p63 negatively correlated with tumor grade, resembling human
prostate adenocarcinoma
.
Taken together, our data show that combinatorial oncogenic mutations of K-ras and beta-catenin drive rapid progression
of prostate
tumorigenesis to invasive carcinoma, characterized by the synergistic elevation of androgen receptor, cyclooxygenase-2, and c-Myc.
[MeSH-major]
Cell Transformation, Neoplastic / metabolism.
Prostatic
Neoplasms / metabolism. Wnt Proteins / metabolism. ras Proteins / metabolism
[MeSH-minor]
Adenocarcinoma
/ genetics.
Adenocarcinoma
/ metabolism. Animals. Cyclooxygenase 2 / metabolism. Female. Genes, ras. Inbreeding. MAP Kinase Signaling System. Male. Metaplasia. Mice. Mice, Transgenic. Proto-Oncogene Proteins c-myc / metabolism. Receptors, Androgen / metabolism. Signal Transduction. Urogenital System / pathology. beta Catenin / metabolism
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19117991.001).
[ISSN]
1538-7445
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / G0301154
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / CTNNB1 protein, mouse; 0 / Myc protein, mouse; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptors, Androgen; 0 / Wnt Proteins; 0 / beta Catenin; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.6.5.2 / ras Proteins
78.
Weizer AZ, Shah RB, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP Jr:
Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy.
Urol Oncol
; 2007 Nov-Dec;25(6):460-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Evaluation of the
prostate
peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with
prostate
capsule sparing cystectomy.
OBJECTIVES:
Prostate
capsule sparing cystectomy has been performed in conjunction with orthotopic diversion to preserve sexual function and improve urinary control.
Because concerns remain regarding incomplete surgical resection, we evaluated the risk of urothelial and
prostate
cancer
in a series of patients undergoing radical cystoprostatectomy.
METHODS: A total of 35 men undergoing radical cystoprostatectomy (August 2003-August 2005) had separate submission of the
prostate
peripheral zone/capsule from the
prostate
adenoma and bladder after surgery.
These specimens were evaluated for bladder and
prostate
cancer
grade, stage, and largest diameter
of prostate
cancer
.
Clinical variables were compared between patients with and without carcinoma involving the
prostate
using standard statistical software.
RESULTS: Of patients, 57% had
cancer
involving the
prostate
at radical cystoprostatectomy.
There were 9 patients (26%) who had urothelial carcinoma involving the
prostate
; only
prostatic
urethral biopsy identified these patients before radical cystoprostatectomy.
Prostate adenocarcinoma
was evident in 16 of 35 (47%) patients, with a majority involving the
prostate
peripheral zone/capsule (43%).
There were 4 patients (11%) who had clinically significant
prostate
cancer
(Gleason sum >6 or tumor volume >0.5 cm(3)).
Patients with
prostate
cancer
were significantly older than patients without
prostate
cancer
(P = 0.01).
CONCLUSIONS: No clinical variable can confidently predict patients with
prostate
cancer
involving the
prostate
.
Because a majority of patients undergoing radical cystoprostatectomy have
cancer
involving their
prostate
, preoperative evaluation with
prostatic
urethral and
prostate
biopsy may be useful to guide patient selection for
prostate
capsule sparing cystectomy.
[MeSH-major]
Cystectomy / methods.
Prostate
/ pathology. Prostatectomy / methods.
Prostatic
Neoplasms / surgery. Urinary Bladder Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Bladder Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18047952.001).
[ISSN]
1078-1439
[Journal-full-title]
Urologic oncology
[ISO-abbreviation]
Urol. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
79.
Stathopoulos GP, Koutantos J, Vaslamatzis MM, Athanasiadis A, Papadopoulos G, Labrodimou G, Stathopoulos J, Rigatos S:
Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
Oncol Rep
; 2009 Aug;22(2):345-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant
prostate
cancer
: a phase II study.
In the past, it was believed that when advanced-stage
prostate
cancer
became resistant to hormonal management, no chemotherapy should be administered, as survival was not prolonged.
Sixty-five patients with advanced
prostate
cancer
were included.
The inclusion criteria involved histological confirmation
of adenocarcinoma
and resistance to hormonal therapy.
The hormone treatment preceded the cytotoxic administration and no amelioration in the patients nor
prostate
serum antigen (PSA) reduction was observed.
Patients with hormone-resistant advanced
prostate
cancer
do have good prospects for receiving substantial benefit with the addition of chemotherapy, as observed in the present trial.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Prostatic
Neoplasms / drug therapy
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19578775.001).
[ISSN]
1021-335X
[Journal-full-title]
Oncology reports
[ISO-abbreviation]
Oncol. Rep.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article
[Publication-country]
Greece
80.
Hakkarainen T, Rajecki M, Sarparanta M, Tenhunen M, Airaksinen AJ, Desmond RA, Kairemo K, Hemminki A:
Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.
Clin Cancer Res
; 2009 Sep 1;15(17):5396-403
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Targeted radiotherapy for
prostate
cancer
with an oncolytic adenovirus coding for human sodium iodide symporter.
PURPOSE: Oncolytic adenoviruses are promising tools for
cancer
therapy.
RESULTS: Ad5/3-Delta24-hNIS replication effectively killed
prostate
cancer
cells in vitro and in vivo.
Also, the virus-mediated radioiodide uptake into
prostate
cancer
cells in vitro and into tumors in vivo.
Furthermore, Ad5/3-Delta24-hNIS with radioiodide was significantly more effective than virus alone in mice with
prostate
cancer
xenografts.
[MeSH-major]
Adenocarcinoma
/ therapy. Lung Neoplasms / therapy. Oncolytic Virotherapy.
Prostatic
Neoplasms / therapy. Symporters / genetics
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19706820.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Iodine Isotopes; 0 / Symporters; 0 / sodium-iodide symporter
81.
Alberts SR, Novotny PJ, Sloan JA, Danella J, Bostwick DG, Sebo TJ, Blute ML, Fitch TR, Levitt R, Lieberman R, Loprinzi CL:
Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.
Am J Ther
; 2006 Jul-Aug;13(4):291-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Flutamide in men with
prostatic
intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.
High-grade
prostatic
intraepithelial neoplasia (HGPIN) has been identified as a premalignant change in the
prostate
that indicates increased risk of the subsequent development
of prostate adenocarcinoma
.
We therefore conducted a chemoprevention trial assessing the efficacy of flutamide in reducing the rate
of prostate adenocarcinoma
development in men with HGPIN.
Men with biopsyproven HGPIN but no evidence
of prostate adenocarcinoma
were randomized in a double-blind manner to either flutamide 250 mg/d or a placebo.
At 1 year, 14% of men receiving flutamide and 10% of men receiving placebo had developed
prostate adenocarcinoma
.
[MeSH-major]
Antineoplastic Agents, Hormonal / therapeutic use. Flutamide / therapeutic use.
Prostatic
Intraepithelial Neoplasia / drug therapy.
Prostatic
Neoplasms / prevention & control
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16858161.001).
[ISSN]
1075-2765
[Journal-full-title]
American journal of therapeutics
[ISO-abbreviation]
Am J Ther
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-60276
[Publication-type]
Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Hormonal; 76W6J0943E / Flutamide
82.
Huncharek M, Haddock KS, Reid R, Kupelnick B:
Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies.
Am J Public Health
; 2010 Apr;100(4):693-701
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Smoking as a risk factor for
prostate
cancer
: a meta-analysis of 24 prospective cohort studies.
OBJECTIVES: We evaluated the relationship between smoking and
adenocarcinoma of
the
prostate
.
METHODS: We pooled data from 24 cohort studies enrolling 21 579
prostate
cancer
case participants for a general variance-based meta-analysis.
RESULTS: In the pooled data, current smokers had no increased risk of incident
prostate
cancer
(RR = 1.04; 95% CI = 0.87, 1.24), but in data stratified by amount smoked they had statistically significant elevated risk (cigarettes per day or years: RR = 1.22; 95% CI = 1.01, 1.46; pack years of smoking: RR = 1.11; 95% CI = 1.01, 1.22).
Current smokers had an increased risk of fatal
prostate
cancer
(RR = 1.14; 95% CI = 1.06, 1.19).
The heaviest smokers had a 24% to 30% greater risk of death from
prostate
cancer
than did nonsmokers.
CONCLUSIONS: Observational cohort studies show an association of smoking with
prostate
cancer
incidence and mortality.
[MeSH-major]
Adenocarcinoma
/ etiology.
Prostatic
Neoplasms / etiology. Smoking / adverse effects
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
MedlinePlus Health Information.
consumer health - Smoking
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Cancer. 2000 Apr;82(7):1358-63
[
10755415.001
]
[Cites]
Epidemiol Rev. 2001;23(1):115-25
[
11588835.001
]
[Cites]
Ann Epidemiol. 2000 Aug;10(6):361-9
[
10964002.001
]
[Cites]
J Am Med Assoc. 1958 March 15;166(11):1294-308
[
12308037.001
]
[Cites]
Natl Cancer Inst Monogr. 1966 Jan;19:127-204
[
5905667.001
]
[Cites]
J Natl Cancer Inst. 1968 Jan;40(1):43-68
[
5635018.001
]
[Cites]
Cancer. 1970 Jan;25(1):105-12
[
5410301.001
]
[Cites]
Natl Cancer Inst Monogr. 1979 Nov;(53):149-55
[
537622.001
]
[Cites]
Public Health Rep. 1980 May-Jun;95(3):213-22
[
7384406.001
]
[Cites]
Cancer Lett. 1981 Sep;13(4):303-8
[
6171336.001
]
[Cites]
J Epidemiol Community Health. 1987 Jun;41(2):166-72
[
3655638.001
]
[Cites]
Epidemiol Rev. 1987;9:1-30
[
3678409.001
]
[Cites]
Am J Epidemiol. 1988 Oct;128(4):796-805
[
3421245.001
]
[Cites]
Am J Epidemiol. 1989 Mar;129(3):511-7
[
2916544.001
]
[Cites]
Cancer Res. 1989 Apr 1;49(7):1857-60
[
2924323.001
]
[Cites]
Cancer. 1989 Aug 1;64(3):598-604
[
2743254.001
]
[Cites]
Cancer Res. 1990 Nov 1;50(21):6836-40
[
2208150.001
]
[Cites]
Environ Health Perspect. 1990 Jul;87:19-26
[
2269225.001
]
[Cites]
Am J Epidemiol. 1991 Mar 1;133(5):437-41
[
2000853.001
]
[Cites]
J Urol. 1993 Jan;149(1):68-72
[
7678042.001
]
[Cites]
Ann Intern Med. 1993 May 15;118(10):793-803
[
8470854.001
]
[Cites]
J Clin Epidemiol. 1993 May;46(5):475-87
[
8501474.001
]
[Cites]
Cancer Causes Control. 1993 Jul;4(4):313-21
[
8347780.001
]
[Cites]
Cancer Causes Control. 1994 Jan;5(1):66-72
[
7510134.001
]
[Cites]
Epidemiology. 1994 May;5(3):276-82
[
8038241.001
]
[Cites]
Am J Epidemiol. 1996 May 15;143(10):1002-6
[
8629606.001
]
[Cites]
Int J Cancer. 1996 Sep 17;67(6):764-8
[
8824546.001
]
[Cites]
Cancer Causes Control. 1996 Sep;7(5):497-506
[
8877046.001
]
[Cites]
Cancer Causes Control. 1996 Sep;7(5):560-2
[
8877055.001
]
[Cites]
Am J Epidemiol. 1997 Mar 1;145(5):466-75
[
9048521.001
]
[Cites]
Cancer Causes Control. 1997 Mar;8(2):229-38
[
9134247.001
]
[Cites]
Int J Cancer. 1997 Nov 27;73(5):634-8
[
9398038.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):627-30
[
9681532.001
]
[Cites]
Prostate. 1999 Feb 15;38(3):189-98
[
10068343.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 1):277-82
[
10207628.001
]
[Cites]
J Urol. 2004 Nov;172(5 Pt 2):S13-6; discussion S17
[
15535436.001
]
[Cites]
Cancer Causes Control. 2004 Nov;15(9):911-20
[
15577293.001
]
[Cites]
Swiss Med Wkly. 2005 Jan 8;135(1-2):27-33
[
15662577.001
]
[Cites]
Br J Cancer. 2005 Feb 14;92(3):426-9
[
15668706.001
]
[Cites]
Public Health. 2005 Aug;119(8):686-93
[
15949522.001
]
[Cites]
Int J Cancer. 2006 Dec 15;119(12):2943-7
[
17019717.001
]
[Cites]
Urology. 2007 Apr;69(4):721-5
[
17445658.001
]
[Cites]
Int J Cancer. 2007 Oct 1;121(7):1571-8
[
17450530.001
]
[Cites]
Int J Cancer. 2000 Jul 1;87(1):141-4
[
10861465.001
]
(PMID = 19608952.001).
[ISSN]
1541-0048
[Journal-full-title]
American journal of public health
[ISO-abbreviation]
Am J Public Health
[Language]
eng
[Publication-type]
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2836346
83.
Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ:
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Cancer
; 2007 Aug 1;110(3):556-63
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory
prostate
cancer
patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
BACKGROUND: This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second-line chemotherapy for taxane-refractory, hormone-refractory,
prostate
cancer
(HRPC).
Prostate
-specific antigen (PSA) declines of >or=50% were observed in 17% of ixabepilone (95% CI, 7-32) and 20% of second-line MP patients (95% CI, 9-35).
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Neoplasms, Hormone-Dependent / drug therapy.
Prostatic
Neoplasms / drug therapy
[MeSH-minor]
Adenocarcinoma
/ drug therapy.
Adenocarcinoma
/ secondary. Aged. Aged, 80 and over. Cross-Over Studies. Epothilones / administration & dosage. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisone / administration & dosage.
Prostate
-Specific Antigen / blood. Salvage Therapy. Survival Rate. Taxoids / therapeutic use. Treatment Outcome
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DOCETAXEL
.
Hazardous Substances Data Bank.
Ixabepilone
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2007 American Cancer Society.
(PMID = 17577218.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Epothilones; 0 / Taxoids; 15H5577CQD / docetaxel; BZ114NVM5P / Mitoxantrone; EC 3.4.21.77 / Prostate-Specific Antigen; K27005NP0A / ixabepilone; VB0R961HZT / Prednisone
84.
Vollmer RT:
Predictive probability of serum prostate-specific antigen for prostate cancer: an approach using Bayes rule.
Am J Clin Pathol
; 2006 Mar;125(3):336-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Predictive probability of serum
prostate
-specific antigen for
prostate
cancer
: an approach using Bayes rule.
This article introduces the use of Bayes probability rule to calculate age and serum
prostate
-specific antigen (PSA)-specific positive predictive values (PPVs) for
prostate
cancer
.
The PPV is the conditional probability of having
prostate
cancer
, given a value of PSA and a particular age group.
The formulation uses values of sensitivity obtained from previously reported studies of more than 2,700 men with
prostate
cancer
, and it uses values of specificity obtained from previously reported studies of more than 99,000 men without
prostate
cancer
.
The formulation also introduces the use of a population-based and age-specific probability
of prostate
cancer
, and for this it relies on the National
Cancer
Institute-sponsored Surveillance, Epidemiology and End Results data.
[MeSH-major]
Adenocarcinoma
/
diagnosis
. Bayes Theorem.
Prostate
-Specific Antigen / blood.
Prostatic
Neoplasms /
diagnosis
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer Screening
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Am J Clin Pathol. 2006 Mar;125(3):331-3
[
16613335.001
]
(PMID = 16613336.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
EC 3.4.21.77 / Prostate-Specific Antigen
85.
Song Y, Washington MK, Crawford HC:
Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer.
Cancer Res
; 2010 Mar 1;70(5):2115-25
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic
cancer
.
Here, we identified FOXA1 and FOXA2 as important antagonists of the epithelial-to-mesenchymal transition (EMT) in pancreatic ductal
adenocarcinoma
(PDA) through their positive regulation of E-cadherin and maintenance of the epithelial phenotype.
In human PDA samples, FOXA1/2 are expressed in all epithelia from normal to well-differentiated
cancer
cells, but are lost in undifferentiated
cancer
cells.
Genetic Alliance.
consumer health - Pancreatic cancer
.
Genetic Alliance.
consumer health - Pancreatic cancer 2
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
Gene Ontology.
gene/protein/disease-specific - Gene Ontology annotations from this paper
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Cell Biol. 2000 Feb;2(2):76-83
[
10655586.001
]
[Cites]
Science. 1998 Jul 31;281(5377):692-5
[
9685261.001
]
[Cites]
Cancer Res. 2000 Apr 1;60(7):1835-9
[
10766168.001
]
[Cites]
Genes Dev. 1999 Feb 15;13(4):495-504
[
10049364.001
]
[Cites]
Cell. 1999 Mar 19;96(6):857-68
[
10102273.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10152-7
[
10468578.001
]
[Cites]
Gene Expr Patterns. 2004 Dec;5(2):193-208
[
15567715.001
]
[Cites]
Dev Biol. 2005 Feb 15;278(2):484-95
[
15680365.001
]
[Cites]
Nature. 2005 Jun 16;435(7044):944-7
[
15959514.001
]
[Cites]
Cell. 2005 Jul 15;122(1):33-43
[
16009131.001
]
[Cites]
Development. 2005 Aug;132(15):3431-43
[
15987773.001
]
[Cites]
J Biol Chem. 2005 Nov 25;280(47):38914-22
[
16166088.001
]
[Cites]
Oncogene. 2005 Dec 15;24(56):8277-90
[
16116478.001
]
[Cites]
Br J Cancer. 2006 Mar 13;94(5):661-71
[
16495925.001
]
[Cites]
Nat Rev Genet. 2006 Jun;7(6):415-26
[
16708070.001
]
[Cites]
Prostate. 2006 Jul 1;66(10):1013-28
[
16001449.001
]
[Cites]
Carcinogenesis. 2006 Jun;27(6):1160-8
[
16537562.001
]
[Cites]
Cell Mol Life Sci. 2006 Oct;63(19-20):2317-28
[
16909212.001
]
[Cites]
Int J Cancer. 2007 Mar 1;120(5):1013-22
[
17163418.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10069-74
[
17537911.001
]
[Cites]
J Cell Biochem. 2007 Nov 1;102(4):829-39
[
17914743.001
]
[Cites]
Clin Cancer Res. 2008 Jan 15;14(2):412-8
[
18223216.001
]
[Cites]
J Clin Pathol. 2008 Mar;61(3):327-32
[
18037662.001
]
[Cites]
J Biol Chem. 2009 Jan 2;284(1):245-53
[
19010789.001
]
[Cites]
Cancer Res. 2001 May 15;61(10):4222-8
[
11358848.001
]
[Cites]
Mol Cell. 2001 Jun;7(6):1267-78
[
11430829.001
]
[Cites]
Mol Cell. 2002 Feb;9(2):279-89
[
11864602.001
]
[Cites]
Mol Cell Biol. 2002 May;22(9):3157-73
[
11940673.001
]
[Cites]
Nat Rev Cancer. 2002 Jun;2(6):442-54
[
12189386.001
]
[Cites]
Cancer Res. 2002 Sep 15;62(18):5273-9
[
12234996.001
]
[Cites]
Virchows Arch. 2003 May;442(5):444-52
[
12692724.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11624-9
[
14500912.001
]
[Cites]
Development. 2004 Feb;131(4):953-64
[
14757645.001
]
[Cites]
Cell. 2004 Jun 25;117(7):927-39
[
15210113.001
]
[Cites]
Carcinogenesis. 1993 Feb;14(2):259-64
[
8382114.001
]
[Cites]
Science. 1994 May 6;264(5160):835-9
[
7513443.001
]
[Cites]
Cell. 1994 Aug 26;78(4):561-74
[
8069909.001
]
[Cites]
Cell. 1994 Aug 26;78(4):575-88
[
8069910.001
]
[Cites]
Mol Cell Biol. 1997 Oct;17(10):6002-13
[
9315659.001
]
[Cites]
Nat Cell Biol. 2000 Feb;2(2):84-9
[
10655587.001
]
(PMID = 20160041.001).
[ISSN]
1538-7445
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA100126-05; United States / NCI NIH HHS / CA / P50CA095103; United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / R01CA100126; United States / NCI NIH HHS / CA / R01 CA100126; United States / NCI NIH HHS / CA / R01 CA100126-05
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cadherins; 0 / FOXA1 protein, human; 0 / FOXA2 protein, human; 0 / Hepatocyte Nuclear Factor 3-alpha; 0 / RNA, Small Interfering; 135845-92-0 / Hepatocyte Nuclear Factor 3-beta
[Other-IDs]
NLM/ NIHMS170218; NLM/ PMC2831111
86.
Sciarra A, Cardi A, Dattilo C, Mariotti G, Di Monaco F, Di Silverio F:
New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Int J Clin Pract
; 2006 Apr;60(4):462-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
New perspective in the management of neuroendocrine differentiation in
prostate adenocarcinoma
.
In this review, we will present some of the information that is known about neuroendocrine (NE) cells and differentiation in the
prostate
.
We will then speculate on the potential role that NE differentiation in
prostate
carcinoma may play and how this differentiation may be clinically analysed and treated.
The androgen-independent growth
of prostate
cancer
can be caused by different mechanisms; one of these is receptor-specific paracrine or autocrine growth modulation of human
prostatic cancer
cells by neuropeptides secreted by NE cells.
Our results affirm that different methods of androgen deprivation can influence the serum chromogranin A (CgA) levels to different extents in
prostate
cancer
.
In the light of other evidence that supports a significant relationship between serum CgA levels, tissue CgA expression and NE activity, we hypothesise that bicalutamide may reduce the risk of NE cell hyperactivation in
prostate
cancer
.
It is important to determine whether increases in CgA levels and NE cell activation are associated with progression towards hormone-independent
prostate
cancer
.
We recently proposed as therapy of NE activation in hormone-independent
prostate
cancer
, a combination of oestrogens and somatostatin analogues.
This combination therapy also sustains the novel concept in
cancer
treatment in which therapies may target not only
cancer
cells but also its microenvironment in combination, which can confer protection from apoptosis.
[MeSH-major]
Adenocarcinoma
/ pathology. Neuroendocrine Tumors / pathology.
Prostatic
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
Hazardous Substances Data Bank.
BICALUTAMIDE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16620361.001).
[ISSN]
1368-5031
[Journal-full-title]
International journal of clinical practice
[ISO-abbreviation]
Int. J. Clin. Pract.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide
[Number-of-references]
44
87.
Maingon P, Bolla M, Truc G, Bosset M, Peignaux K, Ammor A:
[Conformal radiation therapy with or without intensity modulation in the treatment of localized prostate cancer].
Cancer Radiother
; 2005 Nov;9(6-7):382-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Conformal radiation therapy with or without intensity modulation in the treatment of localized
prostate
cancer
].
[Transliterated title]
La
radiothérapie
de
conformation avec et sans modulation d'intensité dans le traitement du
cancer
localisé
de la
prostate
.
Conformal radiation therapy has now to be considered as a standard treatment of localized
prostatic
adenocarcinomas.
[MeSH-major]
Adenocarcinoma
/ radiotherapy.
Prostatic
Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16095944.001).
[ISSN]
1278-3218
[Journal-full-title]
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
[ISO-abbreviation]
Cancer Radiother
[Language]
fre
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
France
[Number-of-references]
31
88.
Veltri RW, Miller MC, Isharwal S, Marlow C, Makarov DV, Partin AW:
Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
Cancer Epidemiol Biomarkers Prev
; 2008 Jan;17(1):102-10
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prediction
of prostate
-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
We evaluated the use of a patient-specific quantitative nuclear grade (QNG) alone and in combination with routine pathologic features to predict biochemical [
prostate
-specific antigen (PSA)] recurrence-free survival in patients with
prostate
cancer
.
METHODS: The National
Cancer
Institute Cooperative
Prostate
Cancer
Tissue Resource (NCI-CPCTR) tissue microarray was prepared from radical prostatectomy cases treated in 1991 to 1992.
[MeSH-major]
Adenocarcinoma
/ pathology. DNA, Neoplasm / analysis. Neoplasm Recurrence, Local /
diagnosis
.
Prostate
-Specific Antigen / blood. Prostatectomy.
Prostatic
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer Screening
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18199716.001).
[ISSN]
1055-9965
[Journal-full-title]
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
[ISO-abbreviation]
Cancer Epidemiol. Biomarkers Prev.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 3.4.21.77 / Prostate-Specific Antigen
89.
Takamatsu H, Zawlodzka S:
Contribution of extracellular ice formation and the solution effects to the freezing injury of PC-3 cells suspended in NaCl solutions.
Cryobiology
; 2006 Aug;53(1):1-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The mechanism of cell injury during slow freezing was examined using PC-3 human
prostate adenocarcinoma
cells suspended in NaCl solutions.
[MeSH-minor]
Adenocarcinoma
. Cell Survival / drug effects. Cold Temperature. Humans. Male. Osmotic Pressure. Propidium / metabolism.
Prostatic
Neoplasms. Sodium Chloride / pharmacology. Solutions
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
SODIUM CHLORIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16626679.001).
[ISSN]
0011-2240
[Journal-full-title]
Cryobiology
[ISO-abbreviation]
Cryobiology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Solutions; 36015-30-2 / Propidium; 451W47IQ8X / Sodium Chloride
90.
Weinmann S, Richert-Boe KE, Van Den Eeden SK, Enger SM, Rybicki BA, Shapiro JA, Weiss NS:
Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: a case-control study.
Epidemiology
; 2005 May;16(3):367-76
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Screening by
prostate
-specific antigen and digital rectal examination in relation to
prostate
cancer
mortality: a case-control study.
BACKGROUND: The potential role
of prostate
cancer
screening in reducing mortality is uncertain.
To examine whether screening with the
prostate
-specific antigen (PSA) test or digital rectal examination is associated with reduced
prostate
cancer
mortality, we conducted a population-based case-control study in 4 health maintenance organizations.
METHODS: Cases were 769 health plan members who died because
of prostate adenocarcinoma
during the years 1997-2001.
Medical records were used to document all screening tests in the 10 years before and including the date on which
prostate
cancer
was first suspected.
Most screening tests were digital rectal examinations; therefore, in the subgroup with no history of PSA screening, the association between digital rectal screening and
prostate
cancer
mortality was similar to the overall association (0.65 [0.48-0.88] among whites; 0.86 [0.53-1.4] among blacks).
CONCLUSIONS: Digital rectal screening was associated with a reduced risk of death due to
prostate
cancer
in our population.
[MeSH-major]
Adenocarcinoma
/
diagnosis
. Mass Screening / methods. Palpation / methods.
Prostate
-Specific Antigen.
Prostatic
Neoplasms /
diagnosis
Genetic Alliance.
consumer health - Rectal Cancer
.
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer Screening
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Epidemiology. 2005 Jul;16(4):515
(PMID = 15824554.001).
[ISSN]
1044-3983
[Journal-full-title]
Epidemiology (Cambridge, Mass.)
[ISO-abbreviation]
Epidemiology
[Language]
eng
[Publication-type]
Journal Article; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
EC 3.4.21.77 / Prostate-Specific Antigen
91.
Song JJ, An JY, Kwon YT, Lee YJ:
Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL.
J Biol Chem
; 2007 Jan 5;282(1):319-28
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Using human
prostate adenocarcinoma
DU-145 and human pancreatic carcinoma MiaPaCa-2 cells as a model, we now demonstrate for the first time that two states of acquired TRAIL resistance can be developed after TRAIL treatment.
[MeSH-minor]
Apoptosis. Cell Line, Tumor. Cell Survival. Gossypol / pharmacology. Humans. Male. Pancreatic Neoplasms / metabolism.
Prostatic
Neoplasms / metabolism. Protein Binding. Transfection
Hazardous Substances Data Bank.
Gossypol
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17110373.001).
[ISSN]
0021-9258
[Journal-full-title]
The Journal of biological chemistry
[ISO-abbreviation]
J. Biol. Chem.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA121395; United States / NCI NIH HHS / CA / CA95191; United States / NCI NIH HHS / CA / CA96989
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / BAD protein, human; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / bcl-Associated Death Protein; 0 / bcl-X Protein; KAV15B369O / Gossypol
92.
Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A:
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Expert Opin Investig Drugs
; 2006 Jul;15(7):795-804
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory
prostate
cancer
patients with bone involvement: a bench to bedside approach.
The development of resistance to anticancer therapies is a major hurdle in preventing long-lasting clinical responses to conventional therapies in hormone-refractory
prostate
cancer
.
Herein, the molecular evidence documenting that bone metastasis microenvironment survival factors (mainly the paracrine growth hormone-independent, urokinase-type plasminogen activator-mediated increase of IGF-1 and the endocrine production of growth hormone-dependent IGF-1, mainly liver-derived IGF-1 production) produce an epigenetic form
of prostate
cancer
cells that are resistant to proapoptotic therapies is reviewed.
Consequently, the authors present the conceptual framework of a novel antibone microenvironment survival factor, mainly an anti-IGF-1 hormonal manipulation for androgen ablation refractory
prostate
cancer
(a combination of conventional androgen ablation therapy [luteinising hormone-releasing hormone agonist-A or orchiectomy]) with dexamethasone plus somatostatin analogue, which yielded durable objective responses and major improvement of bone pain and performance status in stage D3
prostate
cancer
patients.
[MeSH-major]
Adenocarcinoma
/ secondary. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary.
Prostatic
Neoplasms / drug therapy
Genetic Alliance.
consumer health - Bone Cancer
.
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
Hazardous Substances Data Bank.
LEUPROLIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16787142.001).
[ISSN]
1744-7658
[Journal-full-title]
Expert opinion on investigational drugs
[ISO-abbreviation]
Expert Opin Investig Drugs
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Androgen Antagonists; 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 0 / Growth Substances; 0 / Neoplasm Proteins; 0 / Peptides, Cyclic; 0 / Receptors, Androgen; 118992-92-0 / lanreotide; 33515-09-2 / Gonadotropin-Releasing Hormone; 35LT29625A / Estramustine; 51110-01-1 / Somatostatin; 57773-63-4 / Triptorelin Pamoate; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EFY6W0M8TG / Leuprolide
[Number-of-references]
79
93.
Uetsuki H, Tsunemori H, Taoka R, Haba R, Ishikawa M, Kakehi Y:
Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.
J Urol
; 2005 Aug;174(2):514-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the
prostate
.
PURPOSE: EPCA, a nuclear matrix protein, has been identified as a novel
prostate
cancer
marker through protein profiling analyses comparing
prostate
cancer
and its normal counterpart.
A recent study
of prostate
biopsy specimens revealed that EPCA stained positive in
the cancer
negative biopsy cores of individuals with
cancer
at later biopsy.
MATERIALS AND METHODS:
Prostate
tissue specimens were obtained from 50 patients with localized
prostate
cancer
and 10 with invasive bladder
cancer
.
Anti-P504S/anti-p63/anti-34betaE12 monoclonal antibodies were used for adjunct
diagnosis
for
prostatic
intraepithelial neoplasia.
RESULTS: EPCA staining was positive in the
prostate
samples of 94% of patients with
prostate
cancer
but it was completely negative in samples from patients with bladder
cancer
.
In noncancerous tissues adjacent to major
cancer
foci EPCA was positive in 86%
of prostate
cancers.
Most EPCA positive glands adjacent to
cancer
consisted of
prostatic
intraepithelial neoplasia and proliferative inflammatory atrophy.
CONCLUSIONS: EPCA seems to reflect nuclear matrix alterations that occur in the earlier stage
of prostate
carcinogenesis.
Individuals in whom the
prostate
is influenced by this field effect may be detected with this new biomarker.
[MeSH-major]
Adenocarcinoma
/ metabolism. Biomarkers, Tumor / metabolism. Nuclear Matrix-Associated Proteins / metabolism. Precancerous Conditions / metabolism.
Prostate
/ metabolism.
Prostatic
Intraepithelial Neoplasia / metabolism.
Prostatic
Neoplasms / metabolism
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16006883.001).
[ISSN]
0022-5347
[Journal-full-title]
The Journal of urology
[ISO-abbreviation]
J. Urol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Nuclear Matrix-Associated Proteins
94.
Tardy I, Pochon S, Theraulaz M, Emmel P, Passantino L, Tranquart F, Schneider M:
Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.
Invest Radiol
; 2010 Oct;45(10):573-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Ultrasound molecular imaging of VEGFR2 in a rat
prostate
tumor model using BR55.
OBJECTIVES: To evaluate BR55, a new VEGFR2-specific ultrasound contrast agent, for imaging
prostate
tumors in an orthotopic model in the rat.
MATERIALS AND METHODS: Rat
prostate adenocarcinoma
were established by injection of G Dunning R-3327 tumor cells in one lobe of the
prostate of
Copenhagen rats.
Contrast enhancement in the tumor and healthy
prostate
was followed over time by intermittent imaging at low acoustic power.
Immunohistochemistry was performed on the
prostate
and tumor specimen to determine the expression of VEGFR2.
Then, once unbound microbubbles had cleared from the circulation, a strong enhancement of the tumor was obtained with BR55, whereas no significant microbubble accumulation was detected in the healthy
prostate
tissue.
The tumor to
prostate
ratio calculated after signal quantification was about 20 for the 3 doses of BR55 tested.
CONCLUSIONS: This study showed that BR55 binding to
prostate
tumors resulted in a strong enhancement of the lesions as early as a few minutes after contrast injection, whereas minimal nonspecific accumulation occurred in the healthy part of
the gland
.
The late phase enhancement of the tumor should be particularly valuable for
prostate
cancer
detection and for biopsy guidance.
[MeSH-major]
Adenocarcinoma
/ radionuclide imaging. Molecular Imaging / methods.
Prostate
/ radionuclide imaging.
Prostatic
Neoplasms / radionuclide imaging. Vascular Endothelial Growth Factor Receptor-2 / drug effects
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
Hazardous Substances Data Bank.
SULFUR HEXAFLUORIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20808233.001).
[ISSN]
1536-0210
[Journal-full-title]
Investigative radiology
[ISO-abbreviation]
Invest Radiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; WS7LR3I1D6 / Sulfur Hexafluoride
95.
Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, Wagner JP, Hay MH, Beckendorf V, Suchaud JP, Pabot du Chatelard PM, Bernier V, Voirin N, Perol D, Carrie C:
Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.
J Clin Oncol
; 2007 Dec 1;25(34):5366-73
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Is there a role for pelvic irradiation in localized
prostate adenocarcinoma
? Preliminary results of GETUG-01.
PURPOSE: To assess the benefit and toxicity and quality-of-life (QOL) outcomes of pelvic nodes irradiation in nonmetastatic
prostate
carcinoma patients.
PATIENTS AND METHODS: Between December 1998 and June 2004, 444 patients with T1b-T3, N0 pNx, M0
prostate
carcinoma were randomly assigned to either pelvic and
prostate
radiotherapy or
prostate
radiotherapy only.
The total dose recommended to the
prostate
was changed during the course of the study from 66 Gy to 70 Gy.
Criteria for progression-free survival (PFS) included biologic
prostate
-specific antigen recurrences or a local or metastatic evolution.
The QOL outcome was recorded with the European Organisation for Research and Treatment of
Cancer
Quality of Life Questionnaire C30, the International
Prostatic
Symptom Score, and the Sexual Function Index scales.
[MeSH-major]
Adenocarcinoma
/ radiotherapy.
Prostatic
Neoplasms / radiotherapy
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Clin Oncol. 2008 Apr 20;26(12):2055-6; author reply 2056-7
[
18421061.001
]
(PMID = 18048817.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
United States
96.
Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, Rice GE:
Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma.
Br J Cancer
; 2005 Jan 17;92(1):113-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Previous studies have demonstrated the expression of PPARgamma in several tumours including colon, breast, bladder,
prostate
, lung and stomach.
[MeSH-minor]
Adenocarcinoma
, Clear Cell / metabolism. Blotting, Western. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Female. Humans. Immunohistochemistry. Ovary / metabolism
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Cancer. 2003 Sep 20;106(5):752-7
[
12866036.001
]
[Cites]
Oncogene. 2003 Jun 19;22(25):3888-900
[
12813462.001
]
[Cites]
Mol Cell Biol. 2003 Sep;23(17):6159-73
[
12917338.001
]
[Cites]
Oncogene. 2003 Aug 21;22(35):5446-50
[
12934104.001
]
[Cites]
Arch Pathol Lab Med. 2003 Sep;127(9):1121-3
[
12946234.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5
[
12970322.001
]
[Cites]
Clin Cancer Res. 2003 Oct 1;9(12):4627-35
[
14555539.001
]
[Cites]
Minerva Ginecol. 2003 Aug;55(4):297-314
[
14581855.001
]
[Cites]
Nat Immunol. 2004 Jan;5(1):104-12
[
14691478.001
]
[Cites]
Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E201-7
[
14701665.001
]
[Cites]
Biochem Biophys Res Commun. 2004 Mar 5;315(2):497-501
[
14766236.001
]
[Cites]
Cancer Res. 2004 Feb 1;64(3):1181-9
[
14871855.001
]
[Cites]
Gut. 2004 Mar;53(3):331-8
[
14960510.001
]
[Cites]
Mol Cell Proteomics. 2004 Apr;3(4):355-66
[
14764655.001
]
[Cites]
Mol Cell Biol. 2004 Apr;24(8):3430-44
[
15060163.001
]
[Cites]
Clin Cancer Res. 2004 Apr 1;10(7):2415-20
[
15073119.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7355-9
[
8041794.001
]
[Cites]
Eur J Biochem. 1996 Jul 1;239(1):1-7
[
8706692.001
]
[Cites]
Curr Opin Cell Biol. 1998 Jun;10(3):384-91
[
9640540.001
]
[Cites]
Nat Med. 1998 Sep;4(9):1053-7
[
9734399.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6
[
10097144.001
]
[Cites]
Cancer Res. 1999 Apr 15;59(8):2011-7
[
10213514.001
]
[Cites]
Int J Gynecol Pathol. 2000 Jan;19(1):7-15
[
10638449.001
]
[Cites]
Cell. 2000 Jan 7;100(1):57-70
[
10647931.001
]
[Cites]
Mutat Res. 2000 Mar 17;448(2):139-51
[
10725468.001
]
[Cites]
Nature. 2000 May 25;405(6785):421-4
[
10839530.001
]
[Cites]
Clin Cancer Res. 2000 Aug;6(8):3241-8
[
10955810.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5
[
10984506.001
]
[Cites]
Cancer Res. 2000 Oct 1;60(19):5494-8
[
11034093.001
]
[Cites]
Br J Cancer. 2000 Nov;83(10):1394-400
[
11044367.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13275-80
[
11087869.001
]
[Cites]
Toxicol Lett. 2000 Dec 20;118(1-2):79-86
[
11137312.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2598-603
[
11226285.001
]
[Cites]
Neoplasia. 2000 Nov-Dec;2(6):483-90
[
11228540.001
]
[Cites]
Cancer Res. 2001 Jul 1;61(13):5307-10
[
11431375.001
]
[Cites]
Arch Otolaryngol Head Neck Surg. 2001 Oct;127(10):1253-9
[
11587608.001
]
[Cites]
Annu Rev Med. 2002;53:409-35
[
11818483.001
]
[Cites]
J Biol Chem. 2002 May 17;277(20):17830-5
[
11884400.001
]
[Cites]
Lung Cancer. 2002 Jun;36(3):249-55
[
12009233.001
]
[Cites]
Mol Hum Reprod. 2002 Jun;8(6):574-9
[
12029076.001
]
[Cites]
Invest New Drugs. 2002 May;20(2):195-200
[
12099579.001
]
[Cites]
Jpn J Clin Oncol. 2002 Jul;32(7):238-43
[
12324573.001
]
[Cites]
Int J Cancer. 2003 May 1;104(5):597-602
[
12594814.001
]
[Cites]
J Biol Chem. 2003 Apr 4;278(14):11945-53
[
12551936.001
]
[Cites]
Clin Cancer Res. 2003 Aug 1;9(8):3198-203
[
12912973.001
]
(PMID = 15583697.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / PPAR gamma
[Other-IDs]
NLM/ PMC2361744
97.
Biade S, Marinucci M, Schick J, Roberts D, Workman G, Sage EH, O'Dwyer PJ, Livolsi VA, Johnson SW:
Gene expression profiling of human ovarian tumours.
Br J Cancer
; 2006 Oct 23;95(8):1092-100
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
There is currently a lack of reliable diagnostic and prognostic markers for ovarian
cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Biotechniques. 2000 Sep;29(3):548-50, 552-4, 556 passim
[
10997270.001
]
[Cites]
Cancer Res. 1998 Feb 15;58(4):626-9
[
9485012.001
]
[Cites]
Int J Oncol. 2001 Mar;18(3):521-6
[
11179481.001
]
[Cites]
Anticancer Res. 2001 Jan-Feb;21(1A):65-70
[
11299791.001
]
[Cites]
Eur J Cancer. 2001 Jun;37(9):1158-65
[
11378347.001
]
[Cites]
Int J Gynecol Cancer. 2001 Nov-Dec;11(6):454-61
[
11906548.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72
[
12011421.001
]
[Cites]
Gynecol Oncol. 2002 Jul;86(1):34-7
[
12079297.001
]
[Cites]
Cancer Res. 2002 Aug 15;62(16):4722-9
[
12183431.001
]
[Cites]
Am J Pathol. 2002 Oct;161(4):1215-21
[
12368195.001
]
[Cites]
Int J Cancer. 2003 Apr 10;104(3):289-302
[
12569552.001
]
[Cites]
Leuk Lymphoma. 2003 Mar;44(3):439-44
[
12688312.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5778-82
[
12732717.001
]
[Cites]
Int J Gynecol Pathol. 2003 Jul;22(3):240-7
[
12819390.001
]
[Cites]
Hematol Oncol Clin North Am. 2003 Aug;17(4):909-25, vii
[
12959182.001
]
[Cites]
Clin Cancer Res. 2003 Oct 15;9(13):4906-13
[
14581365.001
]
[Cites]
Br J Cancer. 2003 Nov 3;89(9):1599-604
[
14583755.001
]
[Cites]
Mol Biol Cell. 2003 Nov;14(11):4376-86
[
12960427.001
]
[Cites]
J Exp Ther Oncol. 2003 Nov-Dec;3(6):297-304
[
14678518.001
]
[Cites]
Prostate. 2004 Feb 1;58(2):183-92
[
14716744.001
]
[Cites]
Semin Oncol. 1998 Jun;25(3):305-14
[
9633842.001
]
[Cites]
Semin Oncol. 1998 Jun;25(3):372-80
[
9633850.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
[
9843981.001
]
[Cites]
Br J Cancer. 2004 Feb 9;90(3):686-92
[
14760385.001
]
[Cites]
Cancer. 2004 Mar 1;100(5):1045-52
[
14983501.001
]
[Cites]
J Natl Cancer Inst. 2004 Mar 3;96(5):364-75
[
14996858.001
]
[Cites]
Br J Cancer. 2004 Apr 19;90(8):1620-6
[
15083195.001
]
[Cites]
Am J Pathol. 2004 May;164(5):1511-8
[
15111296.001
]
[Cites]
J Histochem Cytochem. 2004 Jun;52(6):735-48
[
15150282.001
]
[Cites]
Proc Natl Acad Sci U S A. 1990 Mar;87(5):1663-7
[
1689846.001
]
[Cites]
Cancer. 1993 Mar 1;71(5):1810-20
[
8383580.001
]
[Cites]
Gynecol Oncol. 1994 Feb;52(2):247-52
[
8314147.001
]
[Cites]
Science. 1995 Oct 20;270(5235):467-70
[
7569999.001
]
[Cites]
J Cell Biol. 1997 May 19;137(4):899-908
[
9151692.001
]
[Cites]
Nature. 2000 Feb 3;403(6769):503-11
[
10676951.001
]
[Cites]
Br J Cancer. 2000 Mar;82(6):1123-30
[
10735494.001
]
[Cites]
Br J Cancer. 2000 May;82(9):1535-8
[
10789720.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81
[
11158614.001
]
(PMID = 16969345.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
ENG
[Grant]
United States / NIGMS NIH HHS / GM / R01 GM040711; United States / NIGMS NIH HHS / GM / GM40711; United States / NCI NIH HHS / CA / U01-CA85059
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD24; 0 / Calcium-Binding Proteins; 0 / Extracellular Matrix Proteins; 0 / SPARCL1 protein, human
[Other-IDs]
NLM/ PMC2360705
98.
Henderson A, Andreyev HJ, Stephens R, Dearnaley D:
Patient and physician reporting of symptoms and health-related quality of life in trials of treatment for early prostate cancer: considerations for future studies.
Clin Oncol (R Coll Radiol)
; 2006 Dec;18(10):735-43
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Patient and physician reporting of symptoms and health-related quality of life in trials of treatment for early
prostate
cancer
: considerations for future studies.
AIMS: Clinical trials in early
prostate
cancer
(EPC) have used a variety of outcome measures, including patient-reported outcomes (PROs) and physician-reported data.
MATERIALS AND METHODS: A literature search combining the terms 'quality of life' or 'symptoms' and '
prostate
cancer
' or '
prostate adenocarcinoma
' was carried out.
[MeSH-major]
Clinical Trials as Topic / methods.
Prostatic
Neoplasms / psychology.
Prostatic
Neoplasms / therapy. Quality of Life. Research Design. Surveys and Questionnaires
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Clinical Trials
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17168208.001).
[ISSN]
0936-6555
[Journal-full-title]
Clinical oncology (Royal College of Radiologists (Great Britain))
[ISO-abbreviation]
Clin Oncol (R Coll Radiol)
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / G0501019
[Publication-type]
Journal Article
[Publication-country]
England
99.
Culhaci N, Sagol O, Karademir S, Astarcioglu H, Astarcioglu I, Soyturk M, Oztop I, Obuz F:
Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cell-cycle-associated proteins and clinicopathologic characteristics.
BMC Cancer
; 2005;5:98
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: We examined TGF-beta1 and p27 expression immunohistochemically in 63 cases of invasive ductal
adenocarcinoma of
the pancreas.
But it is not associated with cell cycle proteins. p27 expression is reduce